


# **Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma (Review)**

Ducharme FM, Lasserson TJ, Cates CJ



**THE COCHRANE  
COLLABORATION®**

This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in *The Cochrane Library* 2011, Issue 8

<http://www.thecochranelibrary.com>



---

**Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma (Review)**  
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

## TABLE OF CONTENTS

HEADER . . . . .	1
ABSTRACT . . . . .	1
PLAIN LANGUAGE SUMMARY . . . . .	2
BACKGROUND . . . . .	2
OBJECTIVES . . . . .	3
METHODS . . . . .	3
RESULTS . . . . .	5
Figure 1. . . . .	6
Figure 2. . . . .	9
Figure 3. . . . .	11
Figure 4. . . . .	12
Figure 5. . . . .	13
Figure 6. . . . .	16
DISCUSSION . . . . .	17
AUTHORS' CONCLUSIONS . . . . .	19
ACKNOWLEDGEMENTS . . . . .	19
REFERENCES . . . . .	20
CHARACTERISTICS OF STUDIES . . . . .	32
DATA AND ANALYSES . . . . .	77
Analysis 1.1. Comparison 1 Long-acting $\beta$ 2-agonists + ICS versus leukotriene receptor antagonists + ICS, Outcome 1 Participants with one or more exacerbations requiring systemic corticosteroids. . . . .	83
Analysis 1.2. Comparison 1 Long-acting $\beta$ 2-agonists + ICS versus leukotriene receptor antagonists + ICS, Outcome 2 Morning PEF: L/min change from baseline. . . . .	84
Analysis 1.3. Comparison 1 Long-acting $\beta$ 2-agonists + ICS versus leukotriene receptor antagonists + ICS, Outcome 3 Evening PEF: L/min change from baseline. . . . .	85
Analysis 1.4. Comparison 1 Long-acting $\beta$ 2-agonists + ICS versus leukotriene receptor antagonists + ICS, Outcome 4 FEV1: L change from baseline. . . . .	86
Analysis 1.5. Comparison 1 Long-acting $\beta$ 2-agonists + ICS versus leukotriene receptor antagonists + ICS, Outcome 5 FEV1: L % change from baseline. . . . .	87
Analysis 1.6. Comparison 1 Long-acting $\beta$ 2-agonists + ICS versus leukotriene receptor antagonists + ICS, Outcome 6 FEV1: % predicted end of treatment. . . . .	87
Analysis 1.7. Comparison 1 Long-acting $\beta$ 2-agonists + ICS versus leukotriene receptor antagonists + ICS, Outcome 7 % fall in FEV1 POST-EXERCISE. . . . .	88
Analysis 1.8. Comparison 1 Long-acting $\beta$ 2-agonists + ICS versus leukotriene receptor antagonists + ICS, Outcome 8 Rescue-free days: % change from baseline. . . . .	88
Analysis 1.9. Comparison 1 Long-acting $\beta$ 2-agonists + ICS versus leukotriene receptor antagonists + ICS, Outcome 9 Rescue medication use: puffs/day change from baseline. . . . .	89
Analysis 1.10. Comparison 1 Long-acting $\beta$ 2-agonists + ICS versus leukotriene receptor antagonists + ICS, Outcome 10 Change in Global asthma QoL AQLQ Score (higher is better) - change from baseline. . . . .	91
Analysis 1.11. Comparison 1 Long-acting $\beta$ 2-agonists + ICS versus leukotriene receptor antagonists + ICS, Outcome 11 Symptom free days: % change from baseline. . . . .	92
Analysis 1.12. Comparison 1 Long-acting $\beta$ 2-agonists + ICS versus leukotriene receptor antagonists + ICS, Outcome 12 Day-time symptom scores (high is worse) - change from baseline. . . . .	93
Analysis 1.13. Comparison 1 Long-acting $\beta$ 2-agonists + ICS versus leukotriene receptor antagonists + ICS, Outcome 13 Morning symptoms - change from baseline. . . . .	94
Analysis 1.14. Comparison 1 Long-acting $\beta$ 2-agonists + ICS versus leukotriene receptor antagonists + ICS, Outcome 14 Night-time symptom score (5pt scale, higher score is worse) - change from baseline. . . . .	94
Analysis 1.15. Comparison 1 Long-acting $\beta$ 2-agonists + ICS versus leukotriene receptor antagonists + ICS, Outcome 15 Change in number of night awakenings per week - change from baseline. . . . .	95
Analysis 1.16. Comparison 1 Long-acting $\beta$ 2-agonists + ICS versus leukotriene receptor antagonists + ICS, Outcome 16 Change in % of nights with no awakenings per week - change from baseline. . . . .	96

Analysis 1.17. Comparison 1 Long-acting $\beta$ 2-agonists + ICS versus leukotriene receptor antagonists + ICS, Outcome 17 Rescue-free nights (%) - change from baseline. . . . .	97
Analysis 1.18. Comparison 1 Long-acting $\beta$ 2-agonists + ICS versus leukotriene receptor antagonists + ICS, Outcome 18 Withdrawals for any reason. . . . .	97
Analysis 1.19. Comparison 1 Long-acting $\beta$ 2-agonists + ICS versus leukotriene receptor antagonists + ICS, Outcome 19 Withdrawals due to adverse events. . . . .	99
Analysis 1.20. Comparison 1 Long-acting $\beta$ 2-agonists + ICS versus leukotriene receptor antagonists + ICS, Outcome 20 Withdrawals due to poor asthma control/asthma exacerbation. . . . .	100
Analysis 1.21. Comparison 1 Long-acting $\beta$ 2-agonists + ICS versus leukotriene receptor antagonists + ICS, Outcome 21 Patients with one or more exacerbations requiring hospital admission. . . . .	101
Analysis 1.22. Comparison 1 Long-acting $\beta$ 2-agonists + ICS versus leukotriene receptor antagonists + ICS, Outcome 22 Serious Adverse events. . . . .	102
Analysis 1.23. Comparison 1 Long-acting $\beta$ 2-agonists + ICS versus leukotriene receptor antagonists + ICS, Outcome 23 Death. . . . .	103
Analysis 1.24. Comparison 1 Long-acting $\beta$ 2-agonists + ICS versus leukotriene receptor antagonists + ICS, Outcome 24 Headache. . . . .	103
Analysis 1.25. Comparison 1 Long-acting $\beta$ 2-agonists + ICS versus leukotriene receptor antagonists + ICS, Outcome 25 Cardiovascular events. . . . .	105
Analysis 1.26. Comparison 1 Long-acting $\beta$ 2-agonists + ICS versus leukotriene receptor antagonists + ICS, Outcome 26 Oral moniliasis. . . . .	106
Analysis 1.27. Comparison 1 Long-acting $\beta$ 2-agonists + ICS versus leukotriene receptor antagonists + ICS, Outcome 27 Osteopenia/osteoporosis. . . . .	107
Analysis 1.28. Comparison 1 Long-acting $\beta$ 2-agonists + ICS versus leukotriene receptor antagonists + ICS, Outcome 28 Elevated liver enzymes. . . . .	107
Analysis 1.29. Comparison 1 Long-acting $\beta$ 2-agonists + ICS versus leukotriene receptor antagonists + ICS, Outcome 29 Overall adverse events. . . . .	108
Analysis 1.30. Comparison 1 Long-acting $\beta$ 2-agonists + ICS versus leukotriene receptor antagonists + ICS, Outcome 30 Patient treatment satisfaction. . . . .	109
Analysis 1.31. Comparison 1 Long-acting $\beta$ 2-agonists + ICS versus leukotriene receptor antagonists + ICS, Outcome 31 Change from baseline in serum eosinophils (x 10e9/L). . . . .	110
Analysis 2.1. Comparison 2 Subgroup and sensitivity analyses, Outcome 1 Participants with one or more exacerbations requiring systemic corticosteroids: number of inhaler devices. . . . .	111
Analysis 2.2. Comparison 2 Subgroup and sensitivity analyses, Outcome 2 Participants with one or more exacerbations requiring systemic corticosteroids: dose of ICS. . . . .	112
Analysis 2.3. Comparison 2 Subgroup and sensitivity analyses, Outcome 3 Participants with one or more exacerbations requiring systemic corticosteroids: study duration. . . . .	113
Analysis 2.4. Comparison 2 Subgroup and sensitivity analyses, Outcome 4 Serious adverse effects stratified by number of inhaler devices used for LABA + ICS. . . . .	114
Analysis 3.1. Comparison 3 MD archive from previous review version, Outcome 1 Morning PEF (L/min) - change from baseline. . . . .	115
Analysis 3.2. Comparison 3 MD archive from previous review version, Outcome 2 Evening PEF (L/min) - change from baseline. . . . .	116
Analysis 3.3. Comparison 3 MD archive from previous review version, Outcome 3 FEV1 (L) - change from baseline. . . . .	117
Analysis 3.4. Comparison 3 MD archive from previous review version, Outcome 4 Symptom free days (%) - change from baseline. . . . .	118
ADDITIONAL TABLES . . . . .	118
APPENDICES . . . . .	120
WHAT'S NEW . . . . .	120
HISTORY . . . . .	120
CONTRIBUTIONS OF AUTHORS . . . . .	121
DECLARATIONS OF INTEREST . . . . .	121
SOURCES OF SUPPORT . . . . .	121
DIFFERENCES BETWEEN PROTOCOL AND REVIEW . . . . .	122

INDEX TERMS . . . . . 122

[Intervention Review]

## Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma

Francine M Ducharme<sup>1</sup>, Toby J Lasserson<sup>2</sup>, Christopher J Cates<sup>3</sup>

<sup>1</sup>Research Centre, CHU Sainte-Justine and the Department of Pediatrics, University of Montreal, Montreal, Canada. <sup>2</sup>Cochrane Editorial Unit, The Cochrane Collaboration, London, UK. <sup>3</sup>Population Health Sciences and Education, St George's, University of London, London, UK

Contact address: Francine M Ducharme, Research Centre, CHU Sainte-Justine and the Department of Pediatrics, University of Montreal, Room number 7939, 3175 Cote Sainte-Catherine, Montreal, Québec, H3T 1C5, Canada. [francine.m.ducharme@umontreal.ca](mailto:francine.m.ducharme@umontreal.ca).

**Editorial group:** Cochrane Airways Group.

**Publication status and date:** Edited (no change to conclusions), published in Issue 8, 2011.

**Review content assessed as up-to-date:** 16 March 2010.

**Citation:** Ducharme FM, Lasserson TJ, Cates CJ. Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma. *Cochrane Database of Systematic Reviews* 2011, Issue 5. Art. No.: CD003137. DOI: 10.1002/14651858.CD003137.pub4.

Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

### ABSTRACT

#### Background

Asthma patients who continue to experience symptoms despite being on regular inhaled corticosteroids (ICS) represent a management challenge. Long-acting beta<sub>2</sub>-agonists (LABA) or anti-leukotrienes (LTRA) are two treatment options that could be considered as add-on therapy to ICS.

#### Objectives

We compared the efficacy and safety profile of adding either daily LABA or LTRA in adults and children with asthma who remain symptomatic on ICS.

#### Search methods

We searched the Cochrane Airways Group Specialised Register (up to and including March 2010). We consulted reference lists of all included studies and contacted authors and pharmaceutical manufacturers for other published or unpublished studies.

#### Selection criteria

We included randomised controlled trials (RCTs) conducted in adults or children with recurrent asthma that was treated with ICS and where a fixed dose of a long-acting beta<sub>2</sub>-agonist or leukotriene agent was added for a minimum of 28 days.

#### Data collection and analysis

Two authors independently assessed the risk of bias of included studies and extracted data. We sought unpublished data and further details of study design, where necessary.

#### Main results

We included 17 RCTs (7032 participants), of which 16 recruited adults and adolescents (6850) and one recruited children aged 6 to 17 years (182). Participants demonstrated substantial reversibility to short-acting beta-agonist at baseline. The studies were at a low risk of bias. The risk of exacerbations requiring systemic corticosteroids was lower with the combination of LABA and ICS compared

---

**Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma (Review)**

Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

1

with LTRA and ICS, from 11% to 9% (RR 0.83, 95% CI 0.71 to 0.97; six studies, 5571 adults). The number needed to treat (NNT) with LABA compared to LTRA to prevent one exacerbation over 48 weeks was 38 (95% CI 22 to 244). The choice of LTRA did not significantly affect the results. The effect appeared stronger in the trials using a single device to administer ICS and LABA compared to those using two devices. In the absence of data from the paediatric trial and the clinical homogeneity of studies, we could not perform subgroup analyses on age or asthma severity. The addition to ICS of LABA compared to LTRA was associated with a statistically greater improvement from baseline in several of the secondary outcomes, including lung function, functional status measures and quality of life. Serious adverse events were more common with LABA than LTRA, although the estimate was imprecise (RR 1.35, 95% CI 1.00 to 1.82), and the NNT to harm for one additional patient to suffer a serious adverse event on LABA over 48 weeks was 78 (95% CI 33 to infinity). The risk of withdrawal for any reason in adults was significantly lower with LABA and ICS compared to LTRA and ICS (RR 0.84, 95% CI 0.74 to 0.96).

### Authors' conclusions

In adults with asthma that is inadequately controlled on low doses of inhaled steroids and showing significant reversibility with beta<sub>2</sub>-agonists, LABA is superior to LTRA in reducing oral steroid treated exacerbations. Differences favouring LABA in lung function, functional status and quality of life scores are generally modest. There is some evidence of increased risk of SAEs with LABA. The findings support the use of a single inhaler for the delivery of LABA and inhaled corticosteroids. We are unable to draw conclusions about which treatment is better as add-on therapy for children.

## PLAIN LANGUAGE SUMMARY

### What are the effects of long-acting beta<sub>2</sub>-agonists compared with anti-leukotrienes when added to inhaled steroids?

People who continue to experience asthma symptoms despite regularly taking inhaled corticosteroids are a challenge for management. It is not clear whether the addition of a long-acting beta<sub>2</sub>-agonist (LABA) such as formoterol or salmeterol would provide more benefit in comparison with an oral anti-leukotriene agent (LTRA), for example zafirlukast or montelukast.

Seventeen trials (16 in adults and one in children) were included in this review and were of good quality. We found that the addition of a LABA provides significantly greater protection against exacerbations requiring oral steroids when compared with a LTRA for adults. Based on the results of our analyses, approximately 38 adults (with a range of between 22 and 244) would need to be treated with a LABA rather than a LTRA for 48 weeks to prevent one experiencing an exacerbation needing a course of oral steroids. The trial on children did not contribute data on the main outcome and therefore we could not draw any conclusions for children.

LABAs also led to a greater improvement in lung function, improvement in symptoms, use of rescue medication, quality of life and symptoms compared to the use of LTRAs. The magnitude of the improvements was modest. Serious adverse events were more frequent with LABA than with LTRAs although this result was imprecise. Based on our analyses, around 78 people would need to be treated for 48 weeks with a LABA rather than a LTRA for one of them to experience a serious adverse event. However, due to the lack of precision around our result, the true number could be between 33 and infinity. There are currently insufficient data to draw any conclusions about the effects of these drugs in children.

## BACKGROUND

Leukotrienes are inflammatory molecules and are one of several substances released by mast cells during the immediate response to an inhaled allergen. They are derived from arachidonic acid, the precursor of prostaglandins (Wasserman 1988; Wenzel 1997). There are two families of leukotrienes. Leukotriene B<sub>4</sub> acts primarily in conditions in which inflammation is dependent on neutrophils, such as cystic fibrosis, inflammatory bowel dis-

ease, and psoriasis. The second group (C<sub>4</sub>, D<sub>4</sub>, E<sub>4</sub>), called cysteinyl-leukotrienes, bind to highly selective receptors to induce eosinophil- and mast cell-induced bronchoconstriction and inflammation associated with asthma (Davis 1997). Drugs that can interfere with the production (leukotriene synthesis inhibitors) and activity (leukotriene receptor antagonists) of leukotrienes have been designed. Leukotriene synthesis inhibitors (for example zileu-

ton) inhibit the enzyme 5-lipoxygenase thus blocking the production of many leukotrienes (for example B<sub>4</sub>, C<sub>4</sub>, D<sub>4</sub>, and E<sub>4</sub>) (Georgitis 1999). Leukotriene (cysteinyl) receptor antagonists (for example montelukast, zafirlukast, pranlukast) block leukotriene D<sub>4</sub> (LTD<sub>4</sub>) receptors (Georgitis 1999). Both types of leukotriene modifiers are administered orally as tablets.

Two Cochrane reviews have concluded that leukotriene receptor antagonists (LTRA) are mild anti-inflammatory agents when used as monotherapy (Ducharme 2004b) and bring modest benefit as add-on therapy to inhaled steroids (Ducharme 2004a). Long-acting beta<sub>2</sub> (β<sub>2</sub>)-agonists (LABA) have a similar mode of action to that of short-acting β<sub>2</sub>-agonists. Some LABAs may have a slightly slower onset of action than short-acting β<sub>2</sub>-agonists (SABA, Lotvall 1996) but display prolonged activation of β<sub>2</sub>-receptors (Johnson 1995) in bronchial smooth muscle resulting in prolonged duration of action, for up to 12 hours (Rees 1995). LABA are recommended solely as add-on therapy to inhaled corticosteroids (ICS) in patients with moderate to severe asthma who remain symptomatic despite anti-inflammatory therapy (BTS 2009; GINA; Loughheed 2010). A number of concerns have been raised about the safety of LABA, predominantly when used without concomitant ICS (Cates 2008a; Cates 2008b; Salpeter 2006; Walters 2007). Due to evidence of increased risk of severe exacerbations and death, there has been a recent call for the withdrawal of inhalation devices containing only LABA. The combination of LABA with ICS has been carefully examined and is superior to placebo when introduced as a second-line therapy in adults treated with ICS (Ducharme 2010; Ernst 2006). In children already taking ICS and in steroid-naïve patients, there remains some uncertainty as to whether additive LABA confers any meaningful benefit (Ni Chroinin 2009a; Ni Chroinin 2009b). Despite non-statistically significant results for outcomes relating to serious adverse events, the data do not prove conclusively that the risk of serious adverse events is abolished by the presence of ICS (Cates 2009a; Cates 2009b).

People with asthma who continue to experience symptoms with ongoing airway obstruction despite taking regular ICS represent a management challenge. Both leukotriene receptor antagonists (LTRAs) and LABA agents may be considered as add-on therapy to ICS (Adams 2007). There are several reasons to support the synergistic effect of either combination at the cellular or pathophysiology level. LABAs reduce airway hyper-responsiveness by means of functional antagonism (Lipworth 2002) while corticosteroids increase the expression of β<sub>2</sub>-adrenergic receptors (Baraniuk 1997), which is a good combination for synergy. LTRAs inhibit the production of cysteinyl leukotrienes, important pro-inflammatory mediators in asthma that are unaffected by steroid treatment. LTRAs are particularly effective in allergen-, exercise-, and aspirin-induced asthma (Krawiec 2002). Thus, both the addition of LTRAs or LABA could potentiate the anti-inflammatory effect of inhaled corticosteroids and lead to better asthma control. The

current review compares the relative benefits and safety profile of adding either an LTRA or a LABA to the treatment of patients with asthma who are inadequately controlled by ICS and updates a previous Cochrane review (Ducharme 2006).

## OBJECTIVES

To compare the safety and efficacy of adding LABA versus LTRA in children and adults with asthma who remain symptomatic in spite of regular treatment with ICS. We specifically wished to examine the relative impact of the two agents on asthma exacerbations, lung function, symptoms, quality of life, adverse health events, and withdrawals.

## METHODS

### Criteria for considering studies for this review

#### Types of studies

We included randomised controlled trials (RCT) conducted in adults or children in whom a long-acting β<sub>2</sub>-agonist (LABA) or leukotriene receptor antagonist (LTRA) were added, as a fixed-dose combination, to ICS.

#### Types of participants

Children or adults with recurrent or persistent asthma treated with inhaled steroids (ICS) as the only asthma control medication prior to study entry.

#### Types of interventions

Interventions included LABA (for example salmeterol or formoterol) or LTRA (for example montelukast, pranlukast, zafirlukast, or zileuton). Participants were required to be on a stable dose of ICS throughout the treatment period. The intervention must have been administered for a minimum of 28 days. Inhaled short-acting β<sub>2</sub>-agonists and short courses of oral steroids were permitted as rescue interventions.

#### Types of outcome measures

##### Primary outcomes

Number of patients with asthma exacerbations requiring a rescue short course of systemic corticosteroids.

## Secondary outcomes

1. Other measures of severity of exacerbations, such as hospital admissions.
2. Measures reflecting chronic asthma control such as pulmonary function tests; symptom scores; days or nights without symptoms, or both; quality of life; use of rescue fast-acting  $\beta_2$ -agonists; and patient satisfaction.
3. Measures of inflammation such as eosinophilia, serum eosinophil cationic protein, and sputum eosinophils.
4. Adverse effects including rates of clinical and biochemical adverse effects.
5. Withdrawal.

## Search methods for identification of studies

### Electronic searches

Trials were identified using the Cochrane Airways Group Specialised Register of trials (searched up to March 2010), which is derived from systematic searches of bibliographic databases including the Cochrane Central Register of Controlled Trials (CENTRAL) (*The Cochrane Library*), MEDLINE, EMBASE, and CINAHL; and handsearching of respiratory journals and meeting abstracts (please see the [Airways Group search methods](#) for further details). All records in the Specialised Register coded as 'asthma' were searched using the following terms:

((beta\* AND agonist\*) AND (long-acting OR "long acting")) OR ((beta\* AND adrenergic\*) AND (long-acting OR "long acting")) OR (bronchodilat\* AND (long-acting OR "long acting")) OR (salmeterol OR formoterol OR eformoterol OR advair OR symbicort) AND (((steroid\* OR glucocorticoid\* OR corticosteroid\*) AND inhal\*) OR (budesonide OR beclomethasone OR fluticasone OR triamcinolone OR flunisolide)) AND (leucotrien\* OR leukotrien\* OR anti-leukotrien\* OR anti-leucotrien\* OR \*lukast). An additional search of CENTRAL was completed using the above search strategy.

### Searching other resources

We reviewed reference lists of all included studies and reviews to identify potentially relevant citations. We asked authors of included studies and pharmaceutical companies to identify other published or unpublished studies. We searched abstract books of the American Thoracic Society (ATS) and European Respiratory Society (ERS) (1998 to 2005) by hand. For the 2006 and 2010 updates, we accessed a register of study results posted by pharmaceutical manufacturers ([www.clinicalstudyresults.org](http://www.clinicalstudyresults.org)). This website lists study results from the manufacturers of LABAs (GSK, AstraZeneca) and LTRAs (Merck, AstraZeneca).

## Data collection and analysis

### Selection of studies

Two of us screened the title, abstract or descriptors and excluded all studies that were clearly not RCTs or that clearly did not fit the inclusion criteria. Two of us reviewed the full-text documents of the remaining trials, assessing for inclusion based on population, intervention, study design, and outcome. We searched the bibliographies of articles that we retrieved in full to identify any additional studies.

### Data extraction and management

Data for the trials were extracted by two authors and entered into [Review Manager 5](#). Where necessary, expansions of graphic reproductions and estimations from other data presented in the papers were performed.

We contacted primary study authors to confirm methodology and data extraction as well as to provide additional information and clarification, if needed.

### Assessment of risk of bias in included studies

We assessed the risk of bias for each study in terms of allocation generation and concealment, blinding, handling of withdrawals, and selective reporting bias (*see* Chapter 8 of the [Cochrane Handbook](#)) (Higgins 2008). This replaced the previous methodology for assessing study quality (*see* [Differences between protocol and review](#)).

We assessed the risk of bias of each study for the following six items.

1. Allocation generation.
2. Allocation concealment.
3. Blinding.
4. Incomplete data.
5. Selective reporting.
6. Other potential sources of bias.

Our judgments of high, low, and unclear risk of bias were corroborated by quotations from trial reports, correspondence, or summarized information from the relevant sections of the individual study reports.

### Assessment of heterogeneity

We measured heterogeneity of effect sizes between studies with the  $I^2$  statistic (Higgins 2003). If heterogeneity was suggested by  $I^2 > 25\%$ , a random-effects model was applied to the summary estimates and was reported in the results.

Subgroup analyses were planned to explore possible effect modifications associated with a priori identified variables or to explore the cause of heterogeneity of study results, if any, for the main



outcome. Differences in the magnitude of effect attributable to these subgroups were examined with the residual  $\text{Chi}^2$  test from the odds ratios (Deeks 2001).

### Data synthesis

All included trials were combined using Review Manager 5. For dichotomous variables, we combined data as a pooled fixed-effect model risk ratio (RR) with 95% confidence interval (95% CI). For continuous outcomes we combined data as a pooled fixed-effect model mean difference (MD) or standard mean difference (SMD) with 95% CI. We calculated the number needed to treat (NNT) for the primary outcome using Visual Rx, a web-based programme available via [www.nntonline.net](http://www.nntonline.net) (Cates 2002).

Odds ratios were used for NNT as the results are not affected by the selection of the reference treatment (LABA or LTRA). In view of the different duration of the trials, the pooled odds ratio was applied to the average exacerbation rate in the trials to give NNTs for 12 and 48 weeks of treatment.

### Subgroup analysis and investigation of heterogeneity

1. Number of inhaler devices used to deliver LABA and ICS therapy (added after publication of the protocol, *see Differences between protocol and review*)
2. Dose and type of long-acting  $\beta_2$ -agonist (salmeterol, formoterol)
3. Dose and type of anti-leukotriene (montelukast, pranlukast, zafirlukast, zileuton)
4. Dose and type of ICS (in beclomethasone-equivalents)
5. Children versus adults
6. Baseline severity of airway obstruction based on the per cent predicted forced expiratory volume in one second (FEV1), or peak expiratory flow (PEF): severe < 60%, moderate 61% to < 80%, mild  $\geq$  80% (GINA 2009)

### Sensitivity analysis

For the primary outcome, we planned to perform the following sensitivity analyses to investigate the potential effect of study duration ( $\leq$  12 weeks, > 12 weeks), publication bias, risk of bias, and funding source (trials funded by producers of LABA, studies funded by producers of LTRA, independently-funded studies) on the study results. Funnel plots were used to test for the presence of publication and other biases for trials contributing data to the main outcomes (Egger 1997).

## RESULTS


### Description of studies

See: [Characteristics of included studies](#); [Characteristics of excluded studies](#); [Characteristics of ongoing studies](#).

### Results of the search

See [Table 1](#) for details of the search history which formed the basis of the previous version of the review (all years to January 2006). Three studies from searches conducted between January 2006 and March 2010 met the eligibility criteria of the review (ELEVATE; Lemanske 2010; Pavord 2007). We re-assessed the eligibility of one previously included study and excluded it due to pre-trial exposure to combination therapy (Stelmach 2008). The addition of three new studies and the exclusion of Stelmach 2008 gave a total of 17 included studies reported in 45 publications (*see Figure 1*).

Figure 1. Literature flow diagram for studies included in 2010 update of the Cochrane review.



## Included studies

The studies were reported as 13 full-text journal publications (Bjerner 2003; Ceylan 2004; ELEVATE; Fish 2001; Green 2006; Grosclaude 2003; Ilowite 2004; Lemanske 2010; Nelson 2000; Nelson 2001; Pavord 2007; Ringdal 2003; Storms 2004), two unpublished full-text company reports (SAM40030; SD-004-0216) and two conference abstracts (Hendeles 2004; Nsouli 2001). The conference abstracts did not provide data in sufficient detail to contribute to the meta-analyses, and we have not been able to obtain data from the investigators through correspondence. We describe below the characteristics of the 15 included studies which contributed data to the review.

## Design

All but one trial employed a parallel-group design. Lemanske 2010 was a three-arm cross-over trial conducted in children. The authors declined our request for additional data to enable inclusion of any data from this study in the review.

## Participants

Fourteen trials focused on adults, with mean ages ranging from 35 to 44 years, with similar gender representation and mean asthma duration ranging from 10 to 26 years. One study recruited children aged between six and 17 years (Lemanske 2010). Most trials (Bjerner 2003; Ceylan 2004; Fish 2001; Grosclaude 2003; Ilowite 2004; Nelson 2000; Ringdal 2003; Storms 2004) allowed the inclusion of adolescents aged  $\geq 15$  years (or  $\geq 12$  years for SD-004-0216 and Nelson 2001) although the number of teenagers randomised, if any, was not reported. All but one trial clearly specified that participants could not be steroid naive at enrolment; the remaining study, which failed to specify whether this was a specific criterion for eligibility (Nelson 2001), was still included.

Participants were symptomatic at enrolment despite inhaled steroids at doses of 200 to 1000  $\mu\text{g}/\text{day}$  of chlorofluorocarbon (CFC)-propelled beclomethasone or equivalent (CFC-BDP), when ICS doses were reported. Severity of asthma as measured by degree of airway obstruction was available for one study. Based on categorisations outlined by GINA of: mild obstruction, FEV1 80% predicted or higher; moderate, FEV1 60% to 80% predicted; severe, less than 60% predicted, the mean FEV1 indicated that participants had mild airway obstruction in two trials (Lemanske 2010; Storms 2004) and moderate airway obstruction in 11 trials (Bjerner 2003; Ceylan 2004; Fish 2001; Green 2006; Ilowite 2004; Nelson 2000; Nelson 2001; Pavord 2007; Ringdal 2003;

SAM40030; SD-004-0216). We were not able to ascertain baseline FEV1 for two studies (ELEVATE; Grosclaude 2003).

Allergy status was reported in two studies (Bjerner 2003; Lemanske 2010) where 65% and 77% respectively of participants were affected at baseline. Three studies (Bjerner 2003; Ceylan 2004; Grosclaude 2003) reported that 60%, 65%, and 51% respectively of participants suffered from allergic rhinitis.

Withdrawal rates varied from 8% to 17% in the LTRA group and 5% to 27% in the LABA group.

## Intervention

During the intervention period, all participants remained on a stable dose of inhaled corticosteroids (ICS). For the purposes of this review, we considered low ICS doses to be 400  $\mu\text{g}/\text{day}$  or less (CFC-BDP equivalent), moderate doses to be 400 to 800  $\mu\text{g}/\text{day}$  (CFC-BDP equivalent) and high doses as 800  $\mu\text{g}/\text{day}$  (CFC-BDP equivalent) or higher. Based on these categorisations, most of the studies assessed the addition of LABAs or LTRAs to low and moderate doses of ICS (see Table 2). Two trials failed to report the dose of background ICS (ELEVATE; Nelson 2001).

The LTRAs and doses administered were: zafirlukast 20 mg twice daily (Nelson 2001; SD-004-0216) and montelukast 10 mg once daily (Bjerner 2003; Ceylan 2004; Fish 2001; Green 2006; Grosclaude 2003; Ilowite 2004; Lemanske 2010; Nelson 2000; Pavord 2007; Ringdal 2003; SAM40030; Storms 2004). ELEVATE was a pragmatic study in which study participants were allocated to either montelukast or zafirlukast.

The LABAs used were: salmeterol 50  $\mu\text{g}$  twice daily in seven trials (Bjerner 2003; Fish 2001; Grosclaude 2003; Ilowite 2004; Lemanske 2010; Nelson 2000; Nelson 2001; Pavord 2007; Ringdal 2003; SAM40030; Storms 2004) and formoterol 12  $\mu\text{g}$  twice daily in three trials (Ceylan 2004; Green 2006; SD-004-0216). ELEVATE was a pragmatic study in which study participants were allocated to either formoterol or salmeterol.

In seven studies, the combination therapy (Seretide®, Advair® or Symbicort®) was administered in a single device (Green 2006; Grosclaude 2003; Lemanske 2010; Nelson 2000; Pavord 2007; Ringdal 2003; SAM40030) and by separate inhaler devices in seven studies (Bjerner 2003; Ceylan 2004; Fish 2001; Ilowite 2004; Nelson 2001; SD-004-0216; Storms 2004). We were unable to determine the number of inhalers used to deliver therapy in ELEVATE.

The intervention period varied between four weeks (Nelson 2001; Storms 2004), six weeks (Green 2006), eight weeks (Ceylan 2004; SD-004-0216), 12 weeks (Fish 2001; Grosclaude 2003; Pavord 2007; Nelson 2000; Ringdal 2003; SAM40030), 16 weeks (Lemanske 2010), 48 weeks (Bjerner 2003; Ilowite 2004), and

two years (ELEVATE).

### Outcomes

The primary outcome (the number of participants with exacerbations requiring rescue systemic corticosteroids) was available for six trials contributing to the main outcome (Bjermer 2003; Fish 2001; Ilowite 2004; Nelson 2000; Nelson 2001; Ringdal 2003), representing 77% of the total number of participants (81% of adults and 0% children) randomised to trials included in this review. For four trials we could not satisfactorily identify the requirements for oral steroids as binary data (ELEVATE; Green 2006; Grosclaude 2003; Lemanske 2010). None of the studies identified since the first version of the review contributed additional data to our primary outcome.

Other measures of asthma control (for example pulmonary function tests, symptoms, use of rescue  $\beta$ 2-agonist, quality of life), withdrawals and adverse effects were reported by several included studies.

### Excluded studies

Of the 69 citations retrieved since the 2006 version of the review, we excluded 66 records because:

1. the study was a duplicate (i.e. identical citation of a trial report or a subsequent report of a trial), N = 29;
  2. the study was not randomised, N = 2;
  3. the study was ongoing, N = 5;
  4. the administration of either LTRA or LABA was not standardised across treatment groups, N = 3;
  5. there was no consistent co-treatment with inhaled glucocorticoids, N = 8;
  6. one of the tested interventions was not daily LTRA as add-on to inhaled glucocorticoids, N = 9;
  7. one of the tested interventions was not daily LABA as add-on to inhaled glucocorticoids, N = 2;
  8. the tested interventions were administered for less than four weeks, N = 1;
  9. the study used prohibited co-intervention, N = 3;
  10. the study did not recruit participants at the step 2\* level, i.e. the study recruited steroid-naïve participants or participants on combination therapy, N = 3
- \* Step 1, 2, and 3 refer to levels of asthma treatment (BTS 2003).

### Risk of bias in included studies

An overview of our judgments for the risk of bias of each study is provided in Figure 2.

**Figure 2. Risk of bias summary: review authors' judgements about each risk of bias item for each included study.**

	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding (performance bias and detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)	Other bias
Bjermer 2003	+	+	+	?	+	+
Ceylan 2004	?	?	-	?	?	+
ELEVATE	?	+	-	+	-	?
Fish 2001	+	+	+	+	+	+
Green 2006	+	+	+	-	+	+
Grosclaude 2003	+	+	-	?	+	+
Hendeles 2004	?	?	?	?	?	?
Ilowite 2004	+	+	+	?	+	+
Lemanske 2010	+	+	+	-	+	+
Nelson 2000	+	+	+	?	+	+
Nelson 2001	+	+	+	?	+	+
Nsouli 2001	?	?	?	?	?	?
Pavord 2007	+	+	+	?	+	+
Ringdal 2003	+	+	+	?	+	+
SAM40030	+	+	+	?	?	+
SD-004-0216	?	+	+	?	?	+
Storms 2004	+	?	+	+	+	+

### Allocation

Randomisation was clearly described and appropriate in all trials with the exception of three trials that contributed data to the review (Ceylan 2004; Grosclaude 2003; SD-004-0216) and the two abstracts not contributing data in sufficient detail to be meta-analysed (Hendeles 2004; Nsouli 2001). All the data included in the primary outcome were drawn from six studies with robust random sequence generation and allocation concealment.

### Blinding

Twelve trials reported double blinding with identical 'dummy' treatments, while three trials (Ceylan 2004; Grosclaude 2003; Nsouli 2001) had an open-label design. One trial failed to clearly report the means of blinding (Hendeles 2004).

The methodology was confirmed by the authors of all trials contributing data with the exception of three (Ceylan 2004; Grosclaude 2003; Storms 2004). No confirmation was obtained for two studies reported as abstracts (Hendeles 2004; Nsouli 2001).

The six trials contributing data to the primary outcome were double-blind, double-dummy studies.

### Incomplete outcome data

Withdrawal rates were described in all but one study (Nsouli 2001). Withdrawals were not reported in three trials by treatment group (Ceylan 2004; ELEVATE; Lemanske 2010).

The analyses within the studies were frequently described as being by intention to treat. However, further information as to how missing data were handled in the trials was limited. For one trial, data were from patients who completed the study (Nelson 2001).

### Selective reporting


The amount of data for the review primary outcome was high when considered as the proportion of the total participants randomised (77%). We were unable to use data from other studies due to their broader definition of exacerbations or inadequate reporting of outcome data (ELEVATE; Green 2006; Grosclaude 2003; Lemanske 2010). In one study, exacerbations were not measured (Pavord 2007) and in another there were no occurrences (Storms 2004). From the remaining five studies, we could not ascertain whether exacerbations were measured.

### Effects of interventions


#### Primary outcome: exacerbations requiring oral (systemic) corticosteroids

Six trials with 5571 adults (no children) contributed data to the primary outcome (Bjermer 2003; Fish 2001; Ilowite 2004; Nelson 2000; Nelson 2001; Ringdal 2003). The risk of having an exacerbation requiring systemic corticosteroids was statistically significantly lower with the use of LABA and ICS compared to LTRA and ICS (RR 0.83, 95% CI 0.71 to 0.97) (Figure 3). The addition of LABA lowered the risk of an exacerbation from 11% to 9%, a 2% (95% CI 0 to 3%) risk difference in exacerbations requiring systemic steroids over the use of LTRA. The number of patients who needed to be treated (NNT) with the combination of LABA and ICS instead of LTRA and ICS to prevent one exacerbation over 48 weeks was 38 (95% CI; 22 to 244), as shown in a Cates plot in Figure 4. For the shorter 12-week trials the NNT was 106 (95% CI 63 to 676).

**Figure 3. Forest plot of comparison: I Leukotriene receptor antagonists + ICS versus Long-acting  $\beta$ 2-agonists + ICS, outcome: I.1 Participants with one or more exacerbations requiring systemic corticosteroids.**




**Figure 4.** In the LRTA group 16 out of 100 had an exacerbation requiring oral corticosteroids over 48 weeks, compared to 14 (95% CI 12 to 16) for the LABA group. The NNT with LABA to prevent one patient having an exacerbation over 48 weeks is 38 (95% CI 22 to 244).



The results were homogeneous despite the different LABAs and LTRAs used ( $I^2 = 6\%$ ). Although the funnel plot intercept suggested no evidence of publication bias (-0.01, 95% CI -4.23 to 2.10) visual inspection of the funnel plot precludes firm reassurance (Figure 5). The number of unpublished studies with null results needed to overturn the current findings was nine.



**Figure 5. Funnel plot of comparison: I Leukotriene receptor antagonists + ICS versus Long-acting  $\beta$ 2-agonists + ICS, outcome: I.1 Participants with one or more exacerbations requiring systemic corticosteroids.**



Although there was no heterogeneity between trials, we had planned a priori to perform subgroup analyses on the following variables, to explore their possible influence on the magnitude of effect (effect modification). The subgroup comparison between single and combined inhalers was added after publication of the initial protocol as a result of work subsequently published on this topic (Nelson 2003).

### 1. Number of inhaler devices used to deliver LABA and ICS

Of the six studies contributing outcome data to the primary outcome, there were two studies (Nelson 2000; Ringdal 2003) where LABA and ICS were delivered in one inhaler device and four studies (Bjerner 2003; Fish 2001; Ilowite 2004; Nelson 2001) where separate inhalers were used. Use of a single inhaler provided significantly greater protection against exacerbations than use of separate inhalers (Analysis 2.1). We calculated the ratio of risk ratios (RRR) as 0.55 (95% CI 0.31 to 0.95;  $P = 0.04$ ) (Altman 2003). In other words, the protective effect seen with single inhaler devices that combined ICS and LABA on exacerbations requiring rescue oral corticosteroids was almost twice that of the separate inhaler devices as compared to ICA and LTRA. However, this indirect comparison is confounded by other differences between trials, including trial duration and ICS dose.

### 2. Dose and type of LABA

All included studies contributing data towards the meta-analysis used salmeterol as the LABA, preventing assessment of the within-class effect of LABA.

### 3. Dose and type of LTRA

The type of LTRA used in the included trials did not appear to make a difference on the primary outcome. The RR of exacerbations when LABA + ICS was compared to montelukast + ICS and zafirlukast + ICS was 0.83 (95% CI 0.71 to 0.97) and 0.86 (95% CI 0.29 to 2.52) respectively, with no statistical difference between the two subgroups (Analysis 1.1).

### 4. Dose and type of inhaled corticosteroids (in beclomethasone-equivalent doses)

All six studies included in the primary outcome were reported to have used similar doses of inhaled glucocorticoids, ranging from 200 to 282  $\mu$ g/day of HFA-BDP equivalents. There were no subgroup differences between those with low, moderate, mixed, or unclear ICS dose (Analysis 2.2). Fluticasone was used in four trials

(Bjermer 2003; Ilowite 2004; Nelson 2000; Ringdal 2003). One trial used a variety of ICSs as the authors kept patients on their usual ICS (Fish 2001); and we were unable to obtain details on the ICS used in Nelson 2001.

## 5. Children versus adults

Since the paediatric trial did not contribute any outcome data to this review, the effect on children versus adults could not be examined.

## 6. Baseline severity of airway obstruction

As the studies pertained to patients with moderate airway obstruction who were relatively homogeneous in the average baseline FEV1 (all within 66% to 76% of predicted value), subgroup analyses of baseline severity could not be performed.

## 7. Duration of trials

The two trials of 48 week duration showed a smaller difference in treatment effect (RR 0.88; 95% CI 0.74 to 1.04) than the other trials of 12 week duration or less (RR 0.65; 95% CI 0.45 to 0.96), although the confidence intervals were overlapping and the difference between the longer and shorter trials was not statistically significant ( $\text{Chi}^2 = 1.93$ ,  $\text{df} = 1$ ,  $P = 0.16$ , Analysis 2.3). However, the difference in trial durations could be a confounding factor when considering the subgroup difference between single and separate inhalers.

The studies contributing to the primary outcome were at a low risk of bias, funded by manufacturers of the study drugs, and were all published. The pooled result was not sensitive to bias from any of the sources we assessed and we could not ascertain whether funding source or publication status affected the estimated effect.

## Secondary outcomes

### Morning peak expiratory flow (PEF) (L/min change from baseline)

Eleven studies in 5723 adults contributed data to the morning PEF results. There was a greater improvement in morning PEF with LABA compared with LTRA (15.36 L/min, 95% CI 11.35 to 19.37) (Analysis 1.2).

### Evening PEF (L/min change from baseline)

Ten studies in 4012 adults contributed data to the meta-analysis of evening PEF. There was a significantly greater improvement in evening PEF with LABA compared with LTRA (12.64 L/min, 95% CI 10.11 to 15.17) (Analysis 1.3).

### Forced expiratory volume in one second (FEV1) (L/sec change from baseline)

Ten studies in 4538 adults contributed data to changes in FEV1. There was a greater improvement in FEV1 with LABA compared with LTRA (0.08 L/sec, 95% CI 0.06 to 0.10) (Analysis 1.4).

### FEV1 (L/sec, % change from baseline)

As only one adult trial contributed data to this outcome (Ceylan 2004), we were unable to pool data (Analysis 1.5).

### FEV1 (% predicted)

As one small adult study contributed data to this outcome, we were unable to pool data (Analysis 1.6).

### FEV1 (% fall post-exercise)

One small adult study contributed data to this outcome (Analysis 1.7).

### Rescue-free days (% change from baseline)

Five studies conducted in 2612 adults contributed data to change in per cent of rescue medication-free days. LABA + ICS showed an increase in the percentage of days with no rescue medication use compared to LTRAs + ICS (MD 9.18, 95% CI 5.39 to 12.98) (Analysis 1.8).

### Rescue medication use (puffs/day)

Seven studies in 4055 adults contributed data on rescue medication. The combined overall estimate showed a significant decrease in the use of rescue medication with LABA + ICS (MD -0.49 puffs/day, 95% CI -0.75 to -0.24) (Analysis 1.9).

### Change in global asthma quality of life score (higher score is better) - change from baseline

Three studies in 2893 adults reported asthma-specific quality of life using the Juniper's 24-point scale: Bjermer 2003; Ilowite 2004 using montelukast, and Nelson 2001 using zafirlukast. The overall estimate showed an improvement in global asthma quality of life with LABA + ICS that was significantly different to that of LTRA + ICS (MD 0.11, 95% CI 0.05 to 0.17) (Analysis 1.10).

### Symptom-free days (% change from baseline)

Six studies with 2692 adults reported symptom-free days (Fish 2001; Grosclaude 2003; Nelson 2000; Nelson 2001; Pavord 2007; Ringdal 2003). The pooled effect estimate showed that the addition of LABA (salmeterol was used in all of these trials) increased

the percentage of symptom-free days by 7.27% (95% CI 4.71 to 9.83) compared with LTRA ([Analysis 1.11](#)).

#### **Day-time symptom scores (high score is worse) - change from baseline**

Five studies with 3823 adults reported daytime symptom scores ([Fish 2001](#); [Ilowite 2004](#); [Nelson 2000](#); [Nelson 2001](#); [Ringdal 2003](#)). Four of the studies comparing LABA + ICS to montelukast + ICS showed improvement in day-time symptom score with LABA + ICS (SMD -0.18, 95% CI -0.25 to -0.12) ([Analysis 1.12](#)).

#### **Change in morning symptom scores**

As only one adult trial contributed data to this outcome ([Ceylan 2004](#)), we were unable to pool data ([Analysis 1.13](#)).

#### **Night-time symptom score (5-point scale, higher score is worse) - change from baseline**

As only one trial contributed data to this outcome ([Nelson 2001](#)), we were unable to pool data ([Analysis 1.14](#)).

#### **Change in number of night awakenings per week - change from baseline**

Four studies with 4214 adults reported night awakenings ([Bjerner 2003](#); [Fish 2001](#); [Ilowite 2004](#); [Nelson 2000](#)). The combined overall estimate showed that LABA + ICS led to fewer awakenings than LTRA + ICS (MD -0.12, 95% CI -0.19 to -0.06) ([Analysis 1.15](#)).

#### **Change in % of nights with no awakenings per week - change from baseline**

Two studies reported this outcome based on data from 673 adults ([Grosclaude 2003](#); [Nelson 2001](#)) and showed a greater percentage of awakening-free nights per week with LABA + ICS (MD 6.89%, 95% CI 2.87 to 10.91) ([Analysis 1.16](#)).

#### **Change in % rescue-free nights**

As only one trial contributed data to this outcome ([Grosclaude 2003](#)), we were unable to pool data ([Analysis 1.17](#)).

#### **Withdrawals for any reason**

Eleven studies involving 6291 adults reported withdrawals due to any reason. Overall, there was a significant reduction in the risk of withdrawal with LABA (12%) compared with LTRA (14%) when added to ICS (RR 0.84, 95% CI 0.74 to 0.96) ([Analysis 1.18](#)).

#### **Withdrawals due to adverse effects**

Eleven studies in 6291 adults reported withdrawals due to adverse effects. The overall estimate comparing LABA and ICS with LTRA and ICS did not show a significant difference between the groups (RR 1.01, 95% CI 0.79 to 1.29) ([Analysis 1.19](#)).

#### **Withdrawals due to poor asthma control (exacerbations)**

Eight studies in 5354 participants reported withdrawals due to exacerbations. There were no significant differences in the overall estimate (RR 0.87, 95% CI 0.49 to 1.56; random-effects model) ([Analysis 1.20](#)).


#### **Patients with one or more exacerbations requiring hospital admission**

Four studies in 3993 adults contributed data for this outcome ([Bjerner 2003](#); [Grosclaude 2003](#); [Ilowite 2004](#); [Ringdal 2003](#)). There was no significant difference between the two study groups (RR 1.31, 95% CI 0.58 to 2.98) ([Analysis 1.21](#)).

#### **Serious adverse events**

Seven studies in 5658 adults reported this outcome. The pooled result indicated that serious adverse events were significantly more likely to occur with LABAs (3.4%) than with LTRAs (2.5%) (RR 1.35, 95% CI 1.00 to 1.82;  $P = 0.05$ ) ([Analysis 1.22](#)). This is shown as a Cates plot in [Figure 6](#), and the number needed to treat to harm (NNTH) for one additional patient to suffer a serious adverse event on LABA over 48 weeks was 78 (95% CI 33 to infinity). The 12-week NNTH for serious adverse events was 236 (95% CI 100 to infinity).

**Figure 6.** In the LRTA group 4 people out of 100 had a serious adverse event over 48 weeks, compared to 5 (95% CI 4 to 7) out of 100 for the LABA group. The NNT(H) for one extra patient to suffer a serious adverse event over 48 weeks with LABA is 78 (95% CI 33 to infinity).



In view of the proposed reasons behind the increased risk of serious adverse events (SAEs) with LABAs (Cates 2008a; Cates 2008b; Cates 2009a; Cates 2009b), we undertook a post hoc subgroup analysis of the pooled estimate by exploring the relationship between the number of inhaler devices and the risk of SAEs. The risk ratio of serious adverse events was RR 0.72 (95% CI 0.26 to 1.99) in the three studies using a single inhaler to deliver both LABA and ICS, compared to LTRA and ICS, and RR 1.43 (95% CI 1.04 to 1.97) in the four studies in which LABA and ICS were delivered by separate inhalers (Analysis 2.4). The difference between the two subgroup estimates did not reach statistical significance, with a test for subgroup differences giving:  $\text{Chi}^2 = 1.61$ ,  $\text{df} = 1$  ( $P = 0.20$ );  $I^2 = 38.1\%$  (Figure 7).

### Deaths

One study reported deaths (Bjerner 2003) with no significant difference between the two study groups (one death occurred in the LABA group) (Analysis 1.23).

### Headache

Ten studies with 6187 adults reported headache as an adverse event. There was no significant difference in the overall result or when the two different types of LTRA were compared to LABA and ICS (RR 1.07, 95% CI 0.9 to 1.26) (Analysis 1.24).

### Cardiovascular events

Five studies with 5163 adults reported cardiovascular events (Bjerner 2003; Fish 2001; Ilowite 2004; Nelson 2000; Ringdal 2003). There was no significant difference when LABA and ICS was compared to LTRA and ICS (RR 1.09, 95% CI 0.77 to 1.53) (Analysis 1.25).

### Oral moniliasis

Six studies with 5203 adults reported the number of patients with oral moniliasis. The studies compared LABA and ICS to mon-teelukast and ICS, showing an overall significantly increased risk

of oral moniliasis with the addition of LABA compared to monelukast + ICS (RR 1.86, 95% CI 1.00 to 3.44) (Analysis 1.26). Yet, the occurrence rates were low and this represents an average risk of oral moniliasis of 1% for LABA and 0.5% for LTRA. The risk difference for this outcome was 0.01 (95% CI 0 to 0.01).

### **Osteopenia and osteoporosis**

Two studies on 2963 adults reported this outcome (Bjermer 2003; Ilowite 2004) with no significant difference between the study groups (RR 0.56, 95% CI 0.12 to 2.63) (Analysis 1.27).

### **Elevated liver enzymes**

As only one trial contributed data to this outcome (Bjermer 2003), we were unable to pool data (Analysis 1.28).

### **Overall adverse events**

Nine studies with 5977 adults reported adverse events, which did not show a significant difference when LABA and ICS was compared to LTRA and ICS. In fact, the absence of group difference (RR 1.03, 95% CI 0.99 to 1.07) (Analysis 1.29) met our a priori definition of equivalence.

### **Patient treatment satisfaction**

Three studies with 2020 adults (Fish 2001; Nelson 2001; Ringdal 2003) reported significantly higher patient satisfaction with LABA and ICS than with LTRA and ICS (RR 1.12, 95% CI 1.04 to 1.20) (Analysis 1.30). Random-effects modelling was used due to the high level of statistical heterogeneity ( $I^2 = 61.8\%$ ).

### **Change from baseline in serum eosinophils ( $\times 10^9/L$ )**

Two adult studies reported this outcome (Bjermer 2003; Ilowite 2004), which showed a statistically significant greater decrease in serum eosinophils with LTRA + ICS than with LABA + ICS (MD 0.04, 95% CI 0.02 to 0.05) (Analysis 1.31).

## **DISCUSSION**

### **Primary outcome**

Our review has shown that in adult patients who remain symptomatic on low or moderate doses of inhaled steroids, the addition of a LABA reduces the relative risk of exacerbations requiring oral steroids compared to the addition of a LTRA. The rate of exacerbations requiring oral steroids was 11% in those treated with a combination of LTRA and ICS compared to 9% with the use

of LABA; an absolute risk reduction of 2%. Thirty-eight patients need to be treated over 48 weeks with LABA and ICS instead of LTRA and ICS to avoid one patient from experiencing an exacerbation requiring rescue oral steroids. When assessed over 12 weeks this number is 106.

The results were homogeneous between the trials. The choice of LTRA did not appear to affect the magnitude of the benefit related to LABA. When compared to LTRA and ICS, a single inhaler containing both LABA and ICS was associated with a 50% reduction in the risk of exacerbations requiring systemic steroids while a 10% reduction was observed when the two drugs were delivered separately. This difference was statistically significant but should be interpreted cautiously because it is not based on a head-to-head comparison and may be confounded by other differences between the trials that used single or separate inhalers (such as trial duration and ICS dose used). However, the direction of effect is congruent with findings of head-to-head comparisons of single versus separate inhalers (Nelson 2003).

The other characteristics we wished to explore to better guide the selection of treatment for specific patients were similar between the studies, and thus could not be explored. These were age, dose of ICS, degree of airway obstruction, choice of LABA, and study quality. In particular, the absence of paediatric trials contributing data to this outcome prevented any conclusion with regards to the relative effect of LABA versus LTRA as add-on to ICS on the occurrence of exacerbations requiring rescue systemic steroids in children. Treatment duration did not notably affect the direction or magnitude of effect.

### **Secondary outcomes**

Statistically significant improvements were seen with LABA and ICS compared to LTRA and ICS for most secondary outcomes. The average difference in the improvement from baseline in FEV1 between LABA and LTRA was 80 mL (95% CI 60 to 100 mL), namely 215 mL with the addition of LABA to ICS compared to 134 mL with the addition of LTRA to ICS. A change of 200 mL or more in FEV1 is considered a clinically important difference as it exceeds normal intra-subject variation (ATS 1991). However, in the absence of a placebo group these changes from baseline may overestimate an expected improvement as both exceed the previously reported benefit for the additive effect of each drug in comparison with the use of ICS alone. Indeed, previous Cochrane reviews have quantified the magnitude of improvement in FEV1 attributable to each drug over that of ICS and placebo. The addition of LABA to ICS was associated with an increase of 110 to 120 mL (Ducharme 2010), while an increase of 60 mL was observed for the combination of LTRA and ICS over ICS alone (Ducharme 2004b). The clinical importance of the observed differences in favour of LABA over LTRA (80 mL in FEV1, 15 mL in morning PEF, and 12 mL in evening PEF) is debatable, particularly as LABA are specifically meant to achieve bronchodilation.



The outcome measures of rescue-free days, rescue medication use, asthma quality of life, symptom-free days, daytime symptom score, number and per cent of night awakenings, and patient satisfaction were also statistically significantly better with LABA. Moreover, significantly fewer patients allocated to the combination of LABA and ICS withdrew from the study for any reason. Yet, in most secondary outcomes (other than lung function) the magnitude of the observed difference appeared modest. No group difference was observed in the risk of withdrawals due to poor asthma control and hospitalisation.

Only two trials examined the impact of both strategies on inflammatory markers, namely serum eosinophils. The addition of a LTRA to ICS was associated with a greater (4%) reduction from baseline serum eosinophils when compared to LABA and ICS.

The risk of serious adverse events (SAEs) was higher with LABA than LTRA (3.4% with LABA versus 2.5% with LTRA, a risk difference of 1%) but at the limit of statistical significance since the lower limit of the 95% CI equalled the conventional threshold for statistical significance at the 5% level. The apparent increased risk of SAEs with LABA should be regarded as a provisional result. Although the number needed to treat with LABA over 48 weeks for one additional serious adverse event is 78 (95% CI 33 to infinity), the severity of the adverse effects raises concern. We thus performed a post-hoc analysis to explore whether the use of one or two devices for delivering LABA and ICS influenced the risk of severe adverse outcomes. The increased risk may be limited to the studies using two separate inhalers to deliver LABA and ICS. This is concordant with accumulating evidence of an increased risk of SAEs in patients using LABA without ICS and is possibly mediated by non-compliance with concurrent inhaled steroids (Perera 2003). The test for a difference in risk between single and separate inhalers did not show a significant difference between these subgroups (Figure 7).

There was no difference observed between treatments in the risk of cardiovascular events, headaches, and osteopenia or osteoporosis. Only the risk of oral moniliasis was significantly higher in the LABA group than the LTRA group, although the risk difference was clinically small (1% for LABA in comparison with 0.5% for LTRA). The risk of overall adverse effects was similar in both groups, meeting our a priori definition of equivalence and suggesting a similar overall safety profile of the two treatment options. There was no difference between LABA and LTRA in withdrawals due to adverse effects.

One of the entry criteria common to all included trials was the need to demonstrate significant reversibility in FEV1 ( $\geq 12\%$  improvement post-bronchodilation). It is possible that the requirement to demonstrate a significant reversibility with short-acting  $\beta_2$ -agonists resulted in the selection of patients who were more likely to show a response on lung function outcomes. This may explain the greater differences in favour of LABA that were observed with measures of lung function compared to other outcomes. Although reversibility to a bronchodilator is one of the standard di-

agnostic criteria of asthma (Boulet 2001; BTS 2003; GINA 2009; USA 2002) only a minority of asthmatic patients display significant reversibility at a given point in time (Storms 2003). It is quite possible that the selection of patients, with significant reversibility, has favoured the combination of LABA and ICS over LTRA and ICS.

The major limitation of the relevant studies in this area is the striking absence of large studies examining the best step three in children. There remains uncertainty as to whether LABAs are effective in reducing the requirement for oral steroids in children (Ni Chroinin 2009b) and a direct comparison of the role of these two drugs in children is urgently required. One well-designed cross-over paediatric trial met the eligibility criteria for inclusion in this review (Lemanske 2010). Unfortunately it reported rescue oral steroids in the context of a composite outcome which did not fit our outcome definition and the authors declined to provide the necessary additional data to allow inclusion of other outcomes in this review. Several other paediatric trials were excluded as they tested add-on therapy in children still on step one or in those already on step three (Stelmach 2007; Stelmach 2008). As wide variations in the definition of exacerbations have been identified as an important difficulty in comparing data across studies, the extraction of data restricted to the use of rescue oral steroids appeared important. Many asthma guidelines still recommend LABAs as an add-on therapy in children. In view of the potential harms associated with LABAs, it is particularly critical for future paediatric studies to carefully examine the best option as add-on therapy for those who remain partially controlled on ICS alone.

The relative homogeneity of adult trials limits the application of the results in children and patients older than 65 years old, smokers, and those with asthma with no significant reversibility to short-acting beta<sub>2</sub>-agonists. Moreover, how well these add-on therapies perform when added to doses of ICS outside the range of those we have reviewed remains uncertain. Inadequate documentation and reporting also limits generalisation of results to adolescents. We recommend that trialists including adolescents specify the number included and perform subgroup analyses on this age group to begin to address this considerable gap in knowledge. An individual data meta-analysis might provide critical information to determine if the presence of allergic rhinitis modifies the observed superiority of LABA over LTRA as add-on therapy to ICS.

With well-documented decreases in adherence over time (Storms 2003), one wonders whether an undocumented lack of compliance affected the results. Was there poor adherence to a twice daily regimen for LABA? With a flat dose-response curve to inhaled steroids (Powell 2003), one may even wonder whether similar improvement observed with LTRA and LABA is derived from enhanced compliance to inhaled steroids per se, as a result of study participation, rather than the selected add-on therapies. Is the greater improvement associated with concomitant rather than separate delivery of LABA and ICS mostly attributable to better lung deposi-

tion of and interaction between both drugs (Buhl 2003; Rosenhall 2003) or better adherence with ICS? In the absence of adherence measures, these questions remain unanswered. The perception of more rapid and greater benefit by the patients with LABA is often regarded by clinicians as justification for selecting LABA over LTRA as add-on therapy. In the two trials reporting satisfaction, significantly more patients were satisfied in the group receiving LABA + ICS (85%) than those treated with LTRA + ICS (76%). Although derived from close to 6000 patients in six trials, the results of the primary outcome could be reversed by nine additional trials of similar size to those included, showing no group difference. The direction of results may be influenced by patient selection. It is possible that a differential effect of add-on options may be influenced by age, airway reversibility, smoking status, severity of baseline airway obstruction, type of asthma (eosinophilic versus non-eosinophilic), triggers (such as allergic rhinitis), adherence, etc. Future studies should now focus on comparing these add-on strategies in selected groups of patients so that characteristics of responders to either option may be better delineated. Measures of adherence (before and after randomisation) should also be incorporated in to the design of future studies.

The results apply predominantly to adult asthmatics who remain symptomatic despite 200 to 1000 µg/day doses of CFC-BDP or equivalent, and who present with a moderate (baseline FEV1 of 65% to 75% predicted value) reversible airway obstruction. The results should not be regarded as applicable to children and adolescents, or patients over 65 years of age.

The extensive search strategy yielded the identification and voluntary disclosure of data from several relevant trials, including two high-quality unpublished reports, and reduced the risk of publication bias. This assessment is also supported by a negative test for funnel plot asymmetry, although one must acknowledge the low sensitivity of this test in the presence of few trials. The high methodological quality of all trials contributing data and the confirmation of methodology and extracted data by authors or the study sponsors for the studies contributing to the primary outcome strengthen our findings.

## **AUTHORS' CONCLUSIONS**

### **Implications for practice**

In asthmatic adults with mild or moderate airway obstruction who are on low doses of inhaled corticosteroids and who demonstrate significant reversibility to a short-acting bronchodilator, the risk of an exacerbation requiring oral corticosteroids over 12 to 48 weeks was 17% lower in participants treated LABA compared LTRA. This was compatible with a NNT over a 48 week period of 38. Compared to LTRAs, the addition of LABA to inhaled corticosteroids is associated with statistically significant improvements in lung function, symptom-free days, use of rescue  $\beta_2$ -agonists, symptoms, symptom-free days, night awakenings, and quality of

life, although the group differences are generally modest. There is evidence that LABAs increase the risk of serious adverse events when compared with LTRAs, from 2.5% to 3.4%. The findings support the use of a single inhaler for the delivery of LABA and inhaled corticosteroids. There are insufficient data to conclude which is the best add-on therapy for children unsatisfactorily controlled on ICS alone.

### **Implications for research**

Future trials should address the main gaps in knowledge, namely the generalisability of results to the following.

1. Children, adolescents, and elderly patients.
2. Patients with severe (or milder) airway obstruction.
3. Asthmatic patients with minimal or no (< 12%) airway reversibility to bronchodilators at time of enrolment but with positive provocation challenge or other convincing criteria of the diagnosis of asthma.
4. Patients with co-morbidities, such as allergic rhinitis, aspirin-induced asthma, smokers or having environmental exposure to cigarette smoke, etc.
5. Add-on therapy to higher dose of inhaled corticosteroids than 200 to 280 µg/day of HFA-BDP, or equivalent.
6. Monitoring of adherence to both combination therapies.
7. Use of single inhalers for delivery of LABA and ICS compared to LTRA and ICS
8. Comparison of LABA and LTRA versus LABA and ICS (in a single device).
9. Measuring and reporting the impact of each adjunct therapy on inflammatory markers (preferably using induced sputum) and airway hyper-responsiveness over time.
10. Careful monitoring and reporting of outcomes that are important to the patient, particularly exacerbations requiring systemic steroids or hospital admission, symptoms, symptom-free days, night awakenings, quality of life, satisfaction, and life-threatening asthma as defined by admission to ICU or requiring intubation or ventilation.

## **ACKNOWLEDGEMENTS**

We are indebted to Liz Arnold, Susan Hansen and Veronica Stewart from the Cochrane Airways Review Group editorial base for extensive ongoing support with identifying, retrieving and translating literature.

We acknowledge the contribution of Felix Ram to the first iteration of this review. We are indebted to the following individuals

who replied to our request for confirmation of methodology and data extraction, and graciously provided additional data whenever possible: Karen Richardson and Inge Vestbo from GlaxoSmithKline, UK; Ian Naya from AstraZeneca, Sweden; Nitesh Shah and Graham Debney from AstraZeneca, England; and Peter Polos and Steven Bird from Merck Frosst, USA.

## REFERENCES

### References to studies included in this review

#### Bjermer 2003 *{published and unpublished data}*

Bjermer L, Bisgaard H, Bousquet J, Fabbri LM, Greening A, Haahntela T, et al. Montelukast or salmeterol combined with an inhaled steroid in adult asthma: design and rationale of a randomized, double-blind comparative study (the IMPACT Investigation of Montelukast as a Partner Agent for Complementary Therapy-trial). *Respiratory Medicine* 2000;**94**:612–21.

\* Bjermer L, Bisgaard H, Bousquet J, Fabbri LM, Greening AP, Haahntela T, et al. A one-year double-blind randomised comparative trial of montelukast and fluticasone versus salmeterol and fluticasone in protecting against asthma exacerbation in adults. *BMJ* 2003;**327**:891–6.

Bjermer L, Kocevkar VS, Zhang Q, Yin DD, Polos PG. Health care resource utilization following addition of montelukast or salmeterol in fluticasone in patients with inadequately controlled asthma (IMPACT trial). *European Respiratory Journal* 2004;**24 Suppl 48**:127.

Bousquet J, Gauhris S, Kocevkar VS, Zhang Q, Yin DD, Polos PG, et al. Increased risk of asthma attacks and emergency visits among asthma patients with allergic rhinitis: A subgroup analysis of the improving asthma control trial. *Clinical and Experimental Allergy* 2005;**35**(6): 723–7.

Polos PG. Montelukast or salmeterol added to fluticasone in uncontrolled asthma: a subgroup analysis of the IMPACT study. *The Journal of Allergy and Clinical Immunology* 2003; **111 Suppl 2**:126.

#### Ceylan 2004 *{published data only}*

Ceylan E, Mehmet G, Sahin A. Addition of formoterol or montelukast to low-dose budesonide: An efficacy comparison in short- and long-term asthma control. *Respiration* 2004;**71**(6):594–601.

#### ELEVATE *{published data only}*

A pragmatic single-blind RCT and health economic evaluation of leukotriene receptor antagonists in primary care at steps two and three of the national asthma guidelines (ELEVATE). <http://www.hta.ac.uk/project/1204.asp> (accessed 24th September 2010).

Sims E, Freeman D, Kemp L, Musgrave S, Juniper L, Gilbert R, et al. Should guidelines be revised for add on therapy in asthma? A 2 year randomized pragmatic equivalence trial of leukotriene antagonist (LTRAs) and long acting beta agonists (LABAs) with inhaled corticosteroids (ICS)

in primary care [Abstract]. European Respiratory Society Annual Congress, Berlin, Germany, October 4-8. 2008: E233.

Sims E, Freeman D, Musgrave D, Kemp L, Ayres J. Do asthma guidelines need rewriting for add-on therapy in asthma - results of a 2 year randomised pragmatic equivalence trial of leukotriene antagonists (LTRAs) and long-acting beta agonists (LABAs) with inhaled corticosteroids (ICS) in primary care [Abstract]. *Primary Care Respiratory Journal* 2008;**17**(2):128.

\* Wilson E, Price D, Musgrave S, Sims E, Shepstone L, et al. The cost-effectiveness of leukotriene receptor antagonists versus long acting beta-2 agonists as add-on therapy to inhaled corticosteroids for asthma: a pragmatic trial. *Pharmacoeconomics* 2010;**28**(7):597–608.

#### Fish 2001 *{published and unpublished data}*

Fish J, Boone R, Emmett A, Yancey S, Knobil K, Rickard K. Salmeterol added to inhaled corticosteroids (ICS) provides greater asthma control compared to montelukast. *American Journal of Respiratory and Critical Care Medicine* 2000;**161 Suppl**(3):A203.

\* Fish JE, Israel E, Murray JJ, Emmett A, Boone R, Yancey SW, et al. Salmeterol powder provides significantly better benefit than montelukast in asthmatic patients receiving concomitant inhaled corticosteroid therapy. *Chest* 2001; **120**(2):423–30.

Knobil K, Dorinsky P, Yancey S, Emmett A, Rickard K. Salmeterol is superior to montelukast as add-on therapy to inhaled corticosteroids (ICS). *European Respiratory Journal* 2000;**16 Suppl 31**:457.

McCarthy TP, Boone R, Yancey S, Rickard K. Salmeterol compared to montelukast as adjunctive therapy to inhaled corticosteroids. *Thorax* 2000;**55 Suppl 3**:A63.

Nathan BA, Boone RI, Emmett AH, Knobil K, Yancey SW, Rickard KA. Salmeterol and inhaled corticosteroids provide greater asthma control than montelukast and inhaled corticosteroids. *Chest* 2000;**118 Suppl 4**:85.

#### Green 2006 *{published and unpublished data}*

\* Green RH, Brightling CE, McKenna S, Hargadon B, Neale N, Parker D, et al. Comparison of asthma treatment given in addition to inhaled corticosteroids on airway inflammation and responsiveness. *European Respiratory Journal* 2006;**27**(6):1144–51.

Green RH, Brightling CE, McKenna S, Hargadon B, Parker D, Pavord ID. A placebo controlled comparison of formoterol, montelukast or higher dose of inhaled



- budesonide in subjects with symptomatic asthma despite treatment with low dose inhaled budesonide [Abstract]. American Thoracic Society 99th International Conference. 2003:B036, Poster H82.
- Green RH, Brightling CE, McKenna S, Hargadon B, Parker D, Wardlaw AJ, et al. A placebo controlled comparison of formoterol montelukast or higher dose of inhaled corticosteroids in subjects with symptomatic asthma despite treatment with low dose inhaled corticosteroids. *Thorax* 2002;**57** Suppl 3:iii3.
- Grosclaude 2003** *{published and unpublished data}*
- \* Grosclaude M, Cerruti JL, Delannay B, Herent M, Spilthooren F, Desfougères JL. The fixed fluticasone/salmeterol gives better control of asthma than the association of beclomethasone dipropionate-montelukast [L'association fixe fluticasone/salmétérol permet un meilleur contrôle de l'asthme que l'association dipropionate de béclométasone-montelukast]. *Allergie et Immunologie* 2003; **35**(9):356–62.
- SFCF4007. Comparison of the efficacy and safety of Seretide and beclomethasone dipropionate plus montelukast in asthma. GlaxoSmithKline Clinical Trials Register (<http://ctr.gsk.co.uk>) 2005.
- Hendeles 2004** *{published data only}*
- Hendeles L, Erb TA, Bird S, Hustard CM, Edelman JM. Post-exercise response to albuterol after addition of montelukast or salmeterol to inhaled fluticasone [Abstract]. *The Journal of Allergy and Clinical Immunology* 2004;**113** Suppl(2):34.
- Ilowite 2004** *{published and unpublished data}*
- Ilowite J, Webb R, Friedman B, Kerwin E, Bird SR, Hustad CM, et al. Addition of montelukast or salmeterol to fluticasone for protection against asthma attacks: a randomized, double-blind, multicenter study. *Annals of Allergy, Asthma & Immunology* 2004;**92**(6):641–8.
- Lemanske 2010** *{published data only}*
- Supplementary appendix. <http://content.nejm.org/> 2010 (accessed 16th March 2010).
- Lemanske RF, Mauger DT, Sorkness CA, Jackson DJ, Boehmer SJ, Martinez FD. Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. *New England Journal of Medicine* 2010 [accessed 16th March 2010];**10.1056/nejmoa1001278**:1–11.
- Nelson 2000** *{published and unpublished data}*
- Bateman ED, Akveld M, Ho M. Greater responder rate to fluticasone propionate/salmeterol combination over montelukast plus fluticasone in asthma. American Thoracic Society 99th International Conference. 2003:B036, Poster H90.
- Kerwin E, Srebro S, Church N, Emmett A, Rickard K, Knobil K. Salmeterol added to low-dose fluticasone propionate (FP) improves pulmonary function and albuterol use more rapidly than adding montelukast. *Annals of Allergy, Asthma & Immunology* 2001;**86**:99.
- Leibman C, Pathak D, Bowers B, Dorinsky PM, Pepsin P, Kalberg C, et al. Cost effectiveness analysis of fluticasone propionate/salmeterol combination versus montelukast in the treatment of adults with asthma [Abstract]. *Journal of Allergy, Asthma and Immunology* 2002;**109** Suppl 1:Ab No: 549.
- Leibman CW, Stanford R, Emmett A, Dorinsky PM, Rickard KA. Cost-effectiveness of fluticasone propionate/salmeterol combination versus fluticasone + montelukast in the treatment of persistent asthma. *American Journal of Respiratory and Critical Care Medicine* 2002;**165** Suppl(8): B4.
- \* Nelson HS, Busse WW, Kerwin E, Church N, Emmett A, Rickard K, et al. Fluticasone propionate/salmeterol combination provides more effective asthma control than low dose inhaled corticosteroid plus montelukast. *The Journal of Allergy and Clinical Immunology* 2000;**106**: 1088–95.
- O'Connor RD, Nelson H, Borker R, Emmett A, Jhingran P, Rickard K, et al. Cost effectiveness of fluticasone propionate plus salmeterol versus fluticasone propionate plus montelukast in the treatment of persistent asthma. *Pharmacoeconomics* 2004;**22**(12):815–25.
- Nelson 2001** *{published and unpublished data}*
- Busse W, Nelson H, Wolfe J, Kalberg C, Yancey SW, Rickard KA. Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma. *Journal of Allergy and Clinical Immunology* 1999;**103**(6):1075–80.
- Kalberg CJ, Rickard KA. A comparison of salmeterol and zafirlukast in patients with persistent asthma. *Thorax* 1998; **53** Suppl 4:A17.
- \* Nelson HS, Nathan RA, Kalberg C, Yancey SW, Rickard KA. Comparison of inhaled salmeterol and oral zafirlukast in asthmatic patients using concomitant inhaled corticosteroids. *Medscape General Medicine* 2001;**3**(4):3.
- Rickard KA, Yancey S, Emmett AH, Kalberg CJ. Salmeterol compared to zafirlukast when added to inhaled corticosteroid therapy in patients with persistent asthma. European Respiratory Society, Madrid, Spain, October 9-13. 1999:P839.
- SAS40018. A multi-center, randomized, double-blind, double dummy, parallel-group, 12 week active control comparison of salmeterol/fluticasone propionate combination product (50/100mcg BID) via the DISKUS inhaler with fluticasone propionate (100mcg BID) via the DISKUS plus oral montelukast (10mg QD) in adults and adolescents with persistent asthma experiencing symptoms on inhaled corticosteroid therapy. GlaxoSmithKline Clinical Trials Register (<http://ctr.gsk.co.uk>) 2005. Accessed 7th March 2008.
- Nsouli 2001** *{published data only}*
- Nsouli SM, McNutt WJ. The additive effects of montelukast and salmeterol in moderate asthmatics who are uncontrolled on a low dose of inhaled corticosteroids. *Annals of Allergy, Asthma & Immunology* 2001;**86**:81.
- Pavord 2007** *{published data only}*
- \* Pavord I, Woodcock A, Parker D, Rice L. Salmeterol plus fluticasone propionate versus fluticasone propionate plus montelukast: a randomised controlled trial investigating

the effects on airway inflammation in asthma. *Respiratory Research* 2007 (accessed 16th March 2010);**8**(67):1–7.  
[DOI: 10.1186/1465-9921-8-67]

**Ringdal 2003** {published and unpublished data}

Bateman ED, Akveld M, Ho M. Greater responder rate to fluticasone propionate/salmeterol combination over montelukast plus fluticasone in asthma. American Thoracic Society 99th International Conference. 2003:B036, Poster H90.

Gold M, Jogi R, Mulder PGH, Akveld ML. Salmeterol/fluticasone propionate combination 50/100 ug bid is more effective than fluticasone propionate 100 ug bid plus montelukast 10 mg once daily in reducing exacerbations. *European Respiratory Journal* 2001;**18 Suppl 33**:262.

Pieters WR, Wilson KK, Smith HC, Tamminga JJ, Sondhi S. Salmeterol/fluticasone propionate versus fluticasone propionate plus montelukast: a cost-effective comparison for asthma. *Treatments in Respiratory Medicine* 2005;**4**(2): 129–38.

Pieters WR, Wilson KK, Smith HCE, Tamminga JJ. Cost-effectiveness of fluticasone propionate/salmeterol combination product and fluticasone propionate/montelukast in asthma. ATS 97th International Conference, May 18-23, San Francisco. 2001.

\* Ringdal N, Eliraz A, Pruzinec R, Weber HH, Mulder PG, Akveld M, et al. The salmeterol/fluticasone combination is more effective than fluticasone plus oral montelukast in asthma. *Respiratory Medicine* 2003;**97**(3):234–41.

Ringdal N, Weber HH, Eliraz A, Pruzinec P, Akveld MLM, Bateman E. The salmeterol/fluticasone propionate combination 50/100 MCG Bid is more effective than the combination of fluticasone propionate 100 MCG Bid plus montelukast 10 MG once daily. ATS 97th International Conference, May 18-23, San Francisco. 2001.

SAS40015. A multicentre, randomised, double-blind, double-dummy, parallel-group, 12-week, active control comparison of the salmeterol/fluticasone propionate combination product (50/100mcg strength) bd via the DISKUS/ACCUHALER inhaler with fluticasone propionate (100mcg strength) bd via the DISKUS/ACCUHALER inhaler plus oral montelukast 10mg od in adolescents and adults with reversible airways obstruction. www.ctr.gsk.co.uk 2005.

**SAM40030** {published and unpublished data}

McCarthy TP, Woodcock AA, Pavord ID, Allen DJ, Parker D, Rice L. A comparison of the anti-inflammatory and clinical effects of salmeterol 25 mcg/fluticasone propionate 50 mcg (SFC 50) with fluticasone propionate (FP) plus montelukast (M) in patients with mild to moderate asthma. *American Journal of Respiratory and Critical Care Medicine* 2003;**167**(7):A367.

\* SAM40030. A phase IV, multicentre, randomised, double-blind, single dummy, parallel group study to compare the anti-inflammatory action of Seretide 50/100 bd via MDI with Flixotide 100mcg bd via MDI plus montelukast 10mg OD for 12 weeks in adults with mild to moderate asthma who are currently taking inhaled corticosteroids but have a

requirement for further therapy. GlaxoSmithKline Clinical Trials Register (<http://ctr.gsk.co.uk>) 2005.

**SD-004-0216** {unpublished data only}

Hultquist C, Domeij W, Kasak V, Laitinen L, O'Neil S. Oxis turbuhaler (formoterol), Accolate (zafirlukast) or placebo as add-on treatment to Pulmicort turbuhaler (budesonide) in asthmatic patients on inhaled steroids. Astra Zeneca Report No: SD-4004CR-0216 2000.

**Storms 2004** {published data only}

Storms W, Chervinsky P, Ghannam AF, Bird S, Hustad CM, Edelman JM, et al. A comparison of the effects of oral montelukast and inhaled salmeterol on response to rescue bronchodilation after challenge. *Respiratory Medicine* 2004;**98**(11):1051–62.

**References to studies excluded from this review**

**Adinoff 1998** {published data only}

Adinoff AD, Schwartz HJ, Rickard KA, Yancey SW, Swearingen BE. Salmeterol compared with current therapies in chronic asthma. *Journal of Family Practice* 1998;**47**(4): 278–84.

**Anon 1999** {published data only}

Anonymous. Leukotriene antagonists: new drugs for asthma. *MEREC Bulletin* 1999;**10**(1):1–4.

**Anon 2000** {published data only}

Anonymous. Montelukast: No current use for asthma. *Canadian Family Physician* 2000;**46**:85–99.

**Anon 2001** {published data only}

Anonymous. Montelukast: oral alternative to inhaled therapy for persistent asthma. *Drugs and Therapy Perspectives* 2001;**17**(4):1–6.

**Barnes 1997** {published data only}

Barnes NC. Current therapy for asthma: time for a change? *Journal of Pharmacy and Pharmacology* 1997;**49 Suppl 3**: 13–6.

**Becker 2000** {published data only}

Becker A. Clinical evidence with montelukast in the management of chronic childhood asthma. *Drugs* 2000;**59 Suppl 1**:29–34.

**Bergmann 2004** {published data only}

Bergmann KC, Lindemann L, Braun R, Steinkamp G. Salmeterol/fluticasone propionate (50/250 mug) combination is superior to double dose fluticasone (500 mug) for the treatment of symptomatic moderate asthma: A prospective, double-blind trial. *Swiss Medical Weekly* 2004;**134**(3-4):50–8.

**Bleecker 2006** {published data only}

Bleecker ER, Yancey SW, Baitinger LA, Edwards LD, Klotsman M, Anderson WH, et al. Salmeterol response is not affected by beta2-adrenergic receptor genotype in subjects with persistent asthma. *The Journal of Allergy and Clinical Immunology* 2006;**118**(4):809–16.

**Borker 2005** {published data only}

Borker R, Emmett A, Jhingran P, Rickard K, Dorinsky P. Abstract determining economic feasibility of fluticasone

- propionate-salmeterol vs montelukast in the treatment of persistent asthma using a net benefit approach and cost-effectiveness acceptability curves. *Annals of Allergy, Asthma & Immunology* 2005;**95**(2):181–9.
- Brabson 2002** *{published data only}*  
Brabson JH, Clifford D, Kerwin E, Raphael G, Pepsin PJ, Edwards LD, et al. Efficacy and safety of low-dose fluticasone propionate compared with zafirlukast in patients with persistent asthma. *American Journal of Medicine* 2002;**113**(1):15–21.
- Buchvald 2003** *{published data only}*  
\* Buchvald F, Bisgaard H. Comparisons of the complementary effect on exhaled nitric oxide of salmeterol versus montelukast in asthmatic children taking regular inhaled budesonide. *Annals of Allergy, Asthma & Immunology* 2003;**91**(3):309–13.  
Buchvald FF, Bisgaard H. Comparison of add-on of leukotriene receptor antagonist versus long-acting beta 2-agonist of FeNO in asthmatic children on regular inhaled budesonide. *European Respiratory Journal* 2002;**20** Suppl 38:431.
- Caffey 2005** *{published data only}*  
Caffey LF, Raissy HH, Marshik P, Kelly HW. A crossover comparison of fluticasone propionate and montelukast on inflammatory indices in children with asthma. *Pediatric Asthma, Allergy & Immunology* 2005;**18**(3):123–30.
- Calhoun 2001** *{published data only}*  
Calhoun W, Sutton L, Emmett A, Dorinsky P. Asthma control with fluticasone propionate/salmeterol 100/50µg Diskus(r) versus montelukast in patients previously receiving short-acting beta2-agonists. *The Journal of Allergy and Clinical Immunology* 2004;**113** Suppl(2):117.  
\* Calhoun WJ, Nelson HS, Nathan RA, Pepsin PJ, Kalberg C, Emmett A, et al. Comparison of fluticasone propionate-salmeterol combination therapy and montelukast in patients who are symptomatic on short-acting beta(2)-agonists alone. *American Journal of Respiratory and Critical Care Medicine* 2001;**164**(5):759–63.
- Cash 2001** *{published data only}*  
Cash R, Blonski J. In patients with asthma that is not well controlled with inhaled steroids, does salmeterol (Serevent) or montelukast (Singulair) offer better symptom relief?. *Journal of Family Practice* 2001;**50**(9):802.
- Chopra 2005** *{published data only}*  
Chopra N, Williams M, Rimmer M, Kahl L, Jenkins M, (SMO30006 and SMO30007 International Study Teams). Salmeterol HFA is as effective as salmeterol CFC in children and adults with persistent asthma. *Respiratory Medicine* 2005;**99** Suppl 1:1.
- Chuchalin 2002** *{published data only}*  
Chuchalin AG, Ovcharenko SI, Goriachkina LA, Sidorenko IV, Tsoi AN. The safety and efficacy of formoterol (Oxis) turbuhaler plus budesonide (Pulmicort) turbuhaler in mild to moderate asthma: a comparison with budesonide Turbuhaler alone and current non-corticosteroid therapy in Russia. *International Journal of Clinical Practice* 2002;**56**(1):15–20.
- Currie 2002** *{published data only}*  
Currie GP. Are there additional anti-inflammatory effects of leukotriene receptor antagonists in persistent asthmatics receiving inhaled steroid alone and combined inhaled steroid/long acting B2-agonists? [N0405110243]. National Research Register 2002.
- Currie 2003a** *{published data only}*  
Currie GP, Lee DKC, Haggart K, Bates CE, Lipworth BJ. Effects of montelukast on surrogate inflammatory markers in corticosteroid-treated patients with asthma. *American Journal of Respiratory and Critical Care Medicine* 2003;**167**(9):1232–8.
- Currie 2003b** *{published data only}*  
Currie GP, Lee DK, Haggart K, Bates CE, Lipworth BJ. Montelukast confers complimentary non-steroid anti-inflammatory activity in asthmatics receiving fluticasone alone and fluticasone/salmeterol combination [Abstract]. *Journal of Allergy and Clinical Immunology* 2003;**111** Suppl 2:146.
- Currie 2003c** *{published data only}*  
Currie GP, Stenback S, Lipworth B J. Effects of fluticasone versus fluticasone/salmeterol on airway calibre and airway hyperresponsiveness in mild persistent asthma. *British Journal of Clinical Pharmacology* 2003;**56**(1):11–7.
- Davis 2001** *{published data only}*  
Davis EA, Bowers B, Pepsin P, Kalberg C, Dorinsky P. The impact of fluticasone propionate/salmeterol combination product compared to oral montelukast on asthma related quality of life. ATS 97th International Conference, May 18-23, San Francisco. 2001:B92, Poster 714.
- Dekhuijzen 2002** *{published data only}*  
Dekhuijzen PN, Koopmans PP. Pharmacokinetic profile of zafirlukast. *Clinical Pharmacokinetics* 2002;**41**(2):105–14. [ PMID: 11888331 ]
- Delaronde 2005** *{published data only}*  
Delaronde S, Peruccio DL, Bauer BJ. Improving asthma treatment in a managed care population. *American Journal of Managed Care* 2005;**11**(6):361–8.
- Dempsey 2000** *{published data only}*  
Dempsey OJ, Wilson AM, Sims EJ, Mistry C, Lipworth BJ. Additive bronchoprotective and bronchodilator effects with single doses of salmeterol and montelukast in asthmatic patients receiving inhaled corticosteroids. *Chest* 2000;**117**:950–3.
- Deykin 2007** *{published data only}*  
Deykin A, Wechsler ME, Boushey HA, Chinchilli VM, Kunselman SJ, Craig TJ, et al. Combination therapy with a long-acting beta-agonist and a leukotriene antagonist in moderate asthma. *American Journal of Respiratory and Critical Care Medicine* 2007;**175**(3):228–34.
- Dicpinigaitis 2002** *{published data only}*  
Dicpinigaitis PV, Dobkin JB, Reichel J. Antitussive effect of the leukotriene receptor antagonist zafirlukast in subjects

- with cough-variant asthma. *Journal of Asthma* 2002;**39**(4): 291–7.
- Donohue 2001** *{published data only}*  
Donohue JF, Ohar JA. New combination therapies for asthma. *Current Opinion in Pulmonary Medicine* 2001;**7**(2): 62–8.
- Dorinsky 2001** *{published data only}*  
Dorinsky PM, Kalberg C, Pepsin P, Emmett A, Rickard K. Greater onset of improvement in clinical efficacy measures with first line use of the fluticasone/salmeterol combination product compared to montelukast. ATS 2001 97th International Conference, May 18-23, San Francisco, CA. 2001:D31.
- Dorinsky 2002** *{published data only}*  
Dorinsky P, Jones S, Kalberg C, Emmett A, Rickard K. Sustained protection against activity-induced bronchospasm (AIB) during chronic treatment with the fluticasone propionate/salmeterol combination (FSC). *American Journal of Respiratory and Critical Care Medicine* 2002;**165** Suppl 8:A568.
- Dorinsky 2002a** *{published data only}*  
Dorinsky PM, Crim C, Yancey S, Edwards L, Rickard K. First line therapy with fluticasone propionate/salmeterol combination product provides superior asthma control versus montelukast or fluticasone propionate alone. *Journal of Allergy, Asthma and Immunology* 2002;**109** Suppl 1: Abstract No: 767.
- Dorinsky 2004** *{published data only}*  
\* Dorinsky PM, Stauffer J, Waitkus-Edwards K, Yancey S, Prillaman BA, Sutton L. “Stepping down” from fluticasone propionate/salmeterol 100/50mcg diskus(r) results in loss of asthma control: lack of effect of ethnic origin. *Chest* 2004;**126** Suppl(4):758.  
Keonig S, Waitkus-Edwards K, Yancey S, Prillman B, Dorinsky P. Loss of asthma control when patients receiving fluticasone propionate/salmeterol 100/50µg Diskus are “stepped-down” to fluticasone propionate, salmeterol or montelukast alone [Abstract]. *The Journal of Allergy and Clinical Immunology* 2004;**113** Suppl(2):94.
- Dunn 2001** *{published data only}*  
Dunn CJ, Goa KL. Zafirlukast - an update of its pharmacology and therapeutic efficacy in asthma. *Drugs* 2001;**61**(2):285–315.
- Edelman 2000** *{published data only}*  
Edelman JM, Turpin JA, Bronsky EA, Grossman J, Kemp JP, Ghannam AF, et al. Oral montelukast compared with inhaled salmeterol to prevent exercise-induced bronchoconstriction. A randomized, double-blind trial. Exercise Study Group. *Annals of Internal Medicine* 2000;**132**(2):97–104.
- Edin 2002** *{published data only}*  
Edin HM, Prillaman B, Baitinger LA, House KW, Shah TP. Improved ability to perform strenuous activities after treatment with fluticasone propionate-salmeterol combination. *American Journal of Respiratory and Critical Care Medicine* 2002;**165** Suppl 8:A112.
- Eliraz 2001** *{published data only}*  
Eliraz A, Ramirez-Rivera A, Ferranti P, Holzer R, Garcia JM, Turcotte C, et al. Similar efficacy following four weeks treatment of asthmatics with formoterol 12 micrograms b.d. delivered by two different dry powder inhalers: differences in inhaler handling. *International Journal of Clinical Practice* 2001;**55**(3):164–70.
- Eliraz 2002** *{published data only}*  
Eliraz A, Fritscher CC, Perez CMR, Boonsawat W, Nang AN, Bardin P, et al. Symbicort® (budesonide/formoterol) achieves more rapid control of asthma than fluticasone in patients with mild asthma. *American Journal of Respiratory and Critical Care Medicine* 2002;**165** Suppl 8:A567.
- Everden 2002** *{published data only}*  
\* Everden P, Lloyd A, Hutchinson J, Plumb J. Cost-effectiveness of formoterol Turbohaler versus salmeterol Accuhaler in children with symptomatic asthma. *Respiratory Medicine* 2002;**96**(4):250–8.
- Gabrijelcic 2004** *{published data only}*  
Gabrijelcic J, Casas A, Rabinovich RA, Roca J, Barbera JA, Chung KF, et al. Formoterol protects against platelet-activating factor-induced effects in asthma. *European Respiratory Journal* 2004;**23**(1):71–5.
- Giannini 2002** *{published data only}*  
Giannini D, Tonelli M, Di Franco A, Bacci E, Conti I, Dente FL, et al. Tolerance to the protective effect of salmeterol + fluticasone combination (50/250 µg) on allergen challenge in mild untreated asthmatics. *American Journal of Respiratory and Critical Care Medicine* 2002;**165** Suppl(8):A566.
- Grzelewska 2003** *{published data only}*  
Grzelewska-Rzymowska I, Malolepszy J, de Molina M, Sladek K, Zarkovic J, Siergiejko Z. Equivalent asthma control and systemic safety of inhaled budesonide delivered via HFA-134a or CFC propellant in a broad range of doses. *Respiratory Medicine* 2003;**97** Suppl D:10–9.
- Gupta 2007** *{published data only}*  
Gupta S, Kansal AP, Kishan J. Comparative efficacy of combination of fluticasone and salmeterol; fluticasone, salmeterol and montelukast; fluticasone, salmeterol, and levocetirizine in moderate persistent asthma: a study of 120 patients. *Chest* 2007;**132**(4):512a.
- Havlucu 2005** *{published data only}*  
Havlucu Y, Yilmaz G, Goktan C, Yorgancioglu A. Usefulness of HRCT determining the distal airway inflammation in asthma [Abstract]. *European Respiratory Journal* 2005;**26** Suppl 49:Abstract No. 2072.
- Horwitz 1998** *{published data only}*  
Horwitz RJ, McGill KA, Busse WM. The role of leukotriene modifiers in the treatment of asthma. *American Journal of Respiratory and Critical Care Medicine* 1998;**157**:1363–71.
- Houghton 2004** *{published data only}*  
Houghton CM, Langley SJ, Singh SD, Holden J, Monici Preti AP, Acerbi D, et al. Comparison of bronchoprotective and bronchodilator effects of a single dose of formoterol

- delivered by hydrofluoroalkane and chlorofluorocarbon aerosols and dry powder in a double blind, placebo-controlled, crossover study. *British Journal of Clinical Pharmacology* 2004;**58**(4):359–66.
- Inouhe 2007** *{published data only}*  
Inoue H, Komori M, Matsumoto T, Fukuyama S, Matsumura M, Nakano T, et al. Effects of salmeterol in patients with persistent asthma receiving inhaled corticosteroid plus theophylline. *Respiration* 2007;**74**(6): 611–6.
- Jarvis 1998** *{published data only}*  
Jarvis B, Adkins JC. Management of asthma - the potential role of zafirlukast. *Disease Management Health Outcomes* 1998;**4**(6):337–53.
- Jarvis 1999** *{published data only}*  
Jarvis B, Faulds D. Inhaled fluticasone propionate: a review of its therapeutic efficacy at dosages < or = 500 microg/day in adults and adolescents with mild to moderate asthma. *Drugs* 1999;**57**(5):769–803.
- Jenkins 2005** *{published data only}*  
\* Jenkins CR, Thien FCK, Wheatley JR, Reddel HK. Traditional and patient-centred outcomes with three classes of asthma medication. *European Respiratory Journal* 2005; **26**(1):36–44.  
Reddel HK, Salome CM, Desai M, Thien FK, Jenkins CR. Change in perception of airway obstruction is associated with change in FEV1 and airway hyper-responsiveness. *Respirology* 2004;**9** Suppl 2:A28.
- Jonsson 2004** *{published data only}*  
Jonsson B, Berggren F, Svensson K, O'Byrne PM. An economic evaluation of combination treatment with budesonide and formoterol in patients with mild-to-moderate persistent asthma. *Respiratory Medicine* 2004;**98** (11):1146–54.
- Kalberg 1999** *{published data only}*  
Kalberg CJ, Yancey S, Emmett AH, Rickard K. A comparison of salmeterol versus zafirlukast in patients using inhaled corticosteroids. *Journal of Allergy and Clinical Immunology* 1999;**103**(1 pt 2):S229.
- Kanniess 2002** *{published data only}*  
Kanniess F, Richter K, Ohme S, Jorres RA, Magnussen H. Montelukast versus fluticasone: effects on lung function, airway responsiveness and inflammation in moderate asthma. *European Respiratory Journal* 2002;**20**(4):853–8.
- Kanniess 2002b** *{published and unpublished data}*  
Kanniess F, Richter K, Janicki S, Schleiss MB, Jorres RA, Magnussen H. Dose reduction of inhaled corticosteroids under concomitant medication with montelukast in patients with asthma. *European Respiratory Journal* 2002;**20**:1080–7.
- Karaman 2007** *{published data only}*  
Karaman O, Arli O, Uzuner N, Islekel H, Babayigit A, Olmez D, et al. The effectiveness of asthma therapy alternatives and evaluating the effectivity of asthma therapy by interleukin-13 and interferon gamma levels in children. *Allergy and Asthma Proceedings* 2007;**28**(2):204–9.
- Kardos 2001** *{published data only}*  
Kardos P, Bruggenjurgen B, Martin A, Meyer-Sabellek W, Richter K, Vogelmeier C, et al. The treatment of asthma: A study (TACO asthma control plan) introducing a new adjustable combination-treatment plan. *Pneumologie* 2001; **55**(5):253–7.
- Keith 2009** *{published data only}*  
Keith PK, Koch C, Djandji M, Bouchard J, Psaradellis E, Sampalis JS, et al. Montelukast as add-on therapy with inhaled corticosteroids alone or inhaled corticosteroids and long-acting beta-2-agonists in the management of patients diagnosed with asthma and concurrent allergic rhinitis (the RADAR trial). *Canadian Respiratory Journal* 2009;**16** Suppl A:17–31.
- Kemp 1998** *{published data only}*  
Kemp JP. Antileukotriene drugs as oral controller therapy for asthma. *European Respiratory Review* 1998;**8**(54):190–3.
- Knorr 2001** *{published data only}*  
Knorr B, Franchi LM, Bisgaard H, Vermeulen JH, LeSouef P, Santanello N, et al. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. *Pediatrics* 2001;**108**(3):E48.
- Koenig 2008** *{published data only}*  
Koenig SM, Ostrom N, Pearlman D, Waitkus-Edwards K, Yancey S, Prillaman BA, et al. Deterioration in asthma control when subjects receiving fluticasone propionate/salmeterol 100/50 mcg Diskus are “stepped-down”. *The Journal of Asthma* 2008;**45**(8):681–7.
- Kohrogi 1999** *{published data only}*  
Kohrogi H, Iwagoe H, Fuji K, Hamamoto J, Fukuda K, Hirata N, et al. The role of cysteinyl leukotrienes in the pathogenesis of asthma: Clinical study of leukotriene antagonist pranlukast for 1 year in moderate and severe asthma. *Respirology* 1999;**4**:319–23.
- Laviolette 1999** *{published data only}*  
Laviolette M, Malmstrom K, Lu S, Chervinsky P, Pujet JC, Peszek I, et al. Montelukast Added to Inhaled Beclomethasone in Treatment of Asthma. *American Journal of Respiratory and Critical Medicine* 1999;**160**:1862–8.
- Lazarus 2001** *{published data only}*  
Lazarus SC, Boushey HA, Fahy JV, Chinchilli VM, Lemanske RF Jr, Sorkness CA, et al. Long-acting beta2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial. *JAMA* 2001;**285**(20): 2583–93.
- Lee 2004** *{published data only}*  
Lee DK, Haggart K, Currie GP, Bates CE, Lipworth BJ. Effects of hydrofluoroalkane formulations of ciclesonide 400 microg once daily versus fluticasone 250 microg twice daily on methacholine hyper-responsiveness in mild-to-moderate persistent asthma. *British Journal of Clinical Pharmacology* 2004;**58**(1):26–33.  
Lee DKC, Jackson CM, Bates CE, Lipworth BJ. Cross tolerance to salbutamol occurs independently of beta2

adrenoceptor genotype-16 in asthmatic patients receiving regular formoterol or salmeterol. *Thorax* 2004;**59**(8):662–7.

**Lee 2005** {published data only}

\* Lee DK, Fardon TC, Bates CE, Haggart K, McFarlane LC, Lipworth BJ. Airway and systemic effects of hydrofluoroalkane formulations of high-dose ciclesonide and fluticasone in moderate persistent asthma. *Chest* 2005; **127**(3):851–60.

Lee DKC, Lipworth BJ. Relative airway and systemic effects of high dose ciclesonide and fluticasone propionate in asthma. *Thorax* 2004;**59** Suppl II:11.

**Leflein 2002** {published data only}

Leflein JG, Szefer SJ, Murphy KR, Fitzpatrick S, Cruz-Rivera M, Miller CJ, et al. Nebulized budesonide inhalation suspension compared with cromolyn sodium nebulizer solution for asthma in young children: results of a randomized outcomes trial. *Pediatrics* 2002;**109**(5):866–72.

**Lipworth 2000** {published data only}

Lipworth BJ, Dempsey OJ, Aziz I, Wilson AM. Effects of adding a leukotriene antagonist or a long-acting beta2-agonist in asthmatic patients with the glycine-16 beta2-adrenoceptor genotype. *American Journal of Medicine* 2000; **109**:114–21.

**Liu 1996** {published data only}

Liu MC, Dube LM, Lancaster J, Zileuton Study Group. Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: A 6-month randomized multicenter trial. *The Journal of Allergy and Clinical Immunology* 1996;**98**:859–71.

**LOCCS** {published data only}

Peters SP, Anthonisen N, Castro M, Holbrook JT, Irvin CG, Smith LJ, et al. Randomized comparison of strategies for reducing treatment in mild persistent asthma. *New England Journal of Medicine* 2007;**356**(20):2027–39.

**Maspero 2008** {published data only}

Maspero J, Guerra F, Cuevas F, Gutierrez JP, Soto-Ramos M, Anderton S, et al. Efficacy and tolerability of salmeterol/fluticasone propionate versus montelukast in childhood asthma: A prospective, randomized, double-blind, double-dummy, parallel-group study. *Clinical Therapeutics* 2008;**30**(8):1492–504.

Maspero J, Guerra F, Orozco S, Soto M, Gutierrez-Schwanhauser J, Mechali DG, et al. The efficacy of inhaled salmeterol/fluticasone propionate diskus/accuhaler compared with oral montelukast in children with persistent asthma PEACE (PEdiatric Asthma Control Evaluation) [Abstract]. American Thoracic Society International Conference, May 16-21, 2008, Toronto. 2008:A709 [# K61].

Maspero J, Soto-Ramos M, Guerra F, Chan R, Sharma R, Pedersen S. Improved asthma control and fewer exacerbations with inhaled salmeterol/fluticasone propionate compared with oral montelukast in children with persistent asthma: PEACE (Pediatric Asthma Control Evaluation). *Chest* 2008;**134**(4):51001s.

**McCarthy 2002** {published data only}

McCarthy TP, Greeting AP, Holgate SK, Whitehead C, Rice L. Salmeterol/fluticasone propionate combination (SFC) is more effective than beclomethasone dipropionate (BDP) in patients not well controlled on bronchodilators alone. *American Journal of Respiratory and Critical Care Medicine* 2002; Vol. 165 Suppl 8:A566.

**Meltzer 2002** {published data only}

Meltzer EO, Lockey RF, Friedman BF, Kalberg C, Goode-Sellers S, Srebro S, et al. Efficacy and safety of low-dose fluticasone propionate compared with montelukast for maintenance treatment of persistent asthma. *Mayo Clinic Proceedings* 2002;**77**(5):437–45.

**Miraglia del Giudice 2007** {published data only}

Miraglia del Giudice M, Piacentini GL, Capasso M, Capristo C, Maiello N, Boner AL, et al. Formoterol, montelukast, and budesonide in asthmatic children: Effect on lung function and exhaled nitric oxide. *Respiratory Medicine* 2007;**101**(8):1809–13.

**Mitchell 2005** {published data only}

Mitchell EA, Didsbury PB, Kruithof N, Robinson E, Milmine M, Barry M, et al. A randomised controlled trial of an asthma clinical pathway for children in general practice. *Acta Paediatrica* 2005;**94**(2):226–33.

**Molitor 2005** {published data only}

Molitor S, Liefing E, Traytmann M. Asthma control with the salmeterol-fluticasone-combination disc compared to standard treatment. *Pneumologie* 2005;**59**(3):167–73.

**Naedele-Risha 2001** {published data only}

Naedele-Risha R, Dorinsky P, Craig TJ. Dual components of optimal asthma therapy: scientific and clinical rationale for the use of long-acting beta-agonists with inhaled corticosteroids. *Journal of the American Osteopathic Association* 2001;**101**(9):526–33.

**Nathan 2000** {published data only}

Nathan RA. Adjunctive therapy for asthma: treatment options. *American Journal of Managed Care* 2000;**6** Suppl: 368–76.

**Nathan 2001b** {published data only}

Nathan RA, Kemp JP. Efficacy of antileukotriene agents in asthma management. *Annals of Allergy Asthma & Immunology* 2001;**86**(6 Suppl 1):9–17.

**Nathan 2005** {published data only}

Nathan RA, Philpot E, Faris M, Prillaman B, Yancey S, Dorinsky P. In patients taking fluticasone propionate/salmeterol 100/50µg Diskus(r) for asthma, the addition of fluticasone propionate nasal spray 200µg QD to treat concomitant allergic rhinitis has a safety profile comparable to the addition of montelukast 10mg QD or placebo [Abstract]. *The Journal of Allergy and Clinical Immunology* 2004;**113** Suppl 2:202.

\* Nathan RA, Yancey SW, Waitkus-Edwards K, Prillaman BA, Stauffer JL, Philpot E. Fluticasone propionate nasal spray is superior to montelukast for allergic rhinitis while neither affects overall asthma control. *Chest* 2005;**128**(4): 1910–20.

**Nelson 2004** *{published data only}*

Nelson H, Stauffer J, Yancey S, Prillaman B, Sutton L, Dorinsky P. In patients with both uncontrolled asthma and allergic rhinitis, montelukast added to fluticasone propionate/salmeterol provides no additional clinical improvements in overall asthma control regardless of baseline asthma severity [Abstract]. American Thoracic Society 100th International Conference, May 21-26, 2004, Orlando. 2004:D36, Poster A49.

Nelson HS, Yancey S, Waitkus-Edwards K, Prillaman B, Philpot E, Dorinsky P. In patients taking fluticasone propionate/salmeterol 100/50µg Diskus(r) for asthma, fluticasone propionate nasal spray 200µg QD is superior to montelukast 10mg QD in the treatment of allergic rhinitis in patients with coexistent allergic rhinitis: implication for the one airway hypothesis [Abstract]. *The Journal of Allergy and Clinical Immunology* 2004;**113 Suppl 2**:200.

**O'Sullivan 2003** *{published data only}*

\* O'Sullivan S, Akveld M, Burke CM, Poulter LW. Effect of the addition of montelukast to inhaled fluticasone propionate on airway inflammation. *American Journal of Respiratory and Critical Care Medicine* 2003;**167**(5):745-50.

**Ohbayashi 2009** *{published data only}*

Ohbayashi H, Shibata N, Adachi M. The evaluation of the additional effect of pranlukast to salmeterol/fluticasone combination therapy using impulse oscillometry system in a randomized crossover study. American Thoracic Society International Conference, May 15-20, 2009, San Diego. 2009:A2764.

Ohbayashi H, Shibata N, Hirose T, Adachi M. Additional effects of pranlukast in salmeterol/fluticasone combination therapy for the asthmatic distal airway in a randomized crossover study. *Pulmonary Pharmacology & Therapeutics* 2009;**22**(6):574-9.

**Ollendorf 2000** *{published data only}*

Ollendorf DA, Pozniak AS, Bowers BW, Oster G. Economic impact of salmeterol versus leukotriene modifiers in patients with chronic asthma. *Chest* 2000;**118 Suppl**(4):185.

**Oppenheimer 2008** *{published data only}*

Oppenheimer J, Mosnaim G, Waitkus-Edwards K, Prillaman B, Ortega H. Fluticasone propionate/salmeterol via diskus is superior to montelukast in overall asthma control in subjects with both asthma and allergic rhinitis [Abstract]. *Chest* 2008;**134**(4):94002s.

**Ortega-Cisneros 1998** *{published data only}*

Ortega-Cisneros M, Maldonado-Alanis ML, Rosas-Vargas MA, Sienra-Monge JLL. Salmeterol and inhaled beclomethasone versus high dose inhaled beclomethasone in the control of pediatric patients with moderate asthma. *Annals of Allergy, Asthma & Immunology* 1998;**80**:131, P124.

**Paterson 1999** *{published data only}*

Paterson MC, Wilson AM, Dempsey OJ, Sims EJ, Lipworth BJ. The effect of combination therapy with salmeterol and montelukast in asthmatic patients receiving inhaled

corticosteroids. European Respiratory Society; 1999 Oct 9-13; Madrid, Spain. 1999:3490.

**Pearlman 2002** *{published data only}*

Pearlman DS, White MV, Lieberman AK, Pepsin PJ, Kalberg C, Emmett A, et al. Fluticasone propionate/salmeterol combination compared with montelukast for the treatment of persistent asthma. *Annals of Allergy, Asthma & Immunology* 2002;**88**(2):227-35.

**Perez 2000** *{published data only}*

Perez O. Treatment with montelukast in children with asthma [Tratamiento con montelukast en el niño con asma]. *Revista Alergia Mexico* 2000;**47**(1):30-2.

**Peroni 2002** *{published data only}*

Peroni DG, Piacentini GL, Pietrobelli A, Bodini A, Boner AL. Montelukast or formoterol as second-line therapy in asthmatic children exposed to allergens. *The Journal of Allergy and Clinical Immunology* 2002;**109 Suppl**(1):240 (Abs 730).

**Peroni 2005** *{published data only}*

Peroni DG, Piacentini GL, Bodini A, Ressa M, Costella S, Boner AL. Montelukast versus formoterol as second-line therapy in asthmatic children exposed to relevant allergens. *Allergy & Asthma Proceedings* 2005;**26**(4):283-6.

**Petermann 2004** *{published data only}*

Petermann W, Mutschler E. Fixed combination of inhaled steroids and long-acting beta2 agonists, an important option in the treatment of persisting asthma. *Deutsche Medizinische Wochenschrift* 2004;**129**(5):210-4.

**Plaza 2005** *{published data only}*

Plaza V, Cobos A, Ignacio-Garcia JM, Molina J, Bergonon S, Garcia-Alonso F, et al. Cost-effectiveness of an intervention based on the Global Initiative for Asthma (GINA) recommendations using a computerized clinical decision support system: A physicians randomized trial. *Medicina Clinica* 2005;**124**(6):201-6.

**Price 2003** *{published data only}*

Price D, Haughney J, Rosen JP, Morrison K. Switching to symbicort(r) from beclomethasone dipropionate (BDP) with or without salmeterol significantly improved symptom severity in patients with moderate asthma. American Thoracic Society 99th International Conference. 2003: D034, Poster C40.

**Riccioni 2002** *{published data only}*

Riccioni G, D'Orazio N, Di Ilio C, Della Vecchia R, De Lorenzo A. Effectiveness and safety of montelukast versus budesonide at different doses on bronchial reactivity in subjects with mild-persistent asthma [Efficacia e tollerabilità del montelukast verso budesonide a diverso dosaggio sulla reattività bronchiale in soggetti con asma di grado lieve-persistente]. *Clinica Terapeutica* 2002;**155**(317):321.

**Rickard 1998** *{published data only}*

Rickard K, Boone R, Yancey S, Emmett A. Salmeterol provides better improvement in pulmonary function than zafirlukast in patients with persistent asthma. *European Respiratory Journal* 1998;**Suppl 29**:19.

**Rosenhall 2003** {published data only}

\* Rosenhall L, Elvstrand A, Tilling B, Vinge I, Jemby P, Stahl E, et al. One-year safety and efficacy of budesonide/formoterol in a single inhaler (Symbicort Turbuhaler) for the treatment of asthma. *Respiratory Medicine* 2003;**97**(6): 702–8.

**SAS40036** {unpublished data only}

GlaxoSmithKline (SAS40036). A multicenter, randomized, double-blind, double-dummy, parallel group, 16-week comparison of asthma control in adolescents and adults receiving either fluticasone propionate/salmeterol DISKUS combination product 100/50mcg BID, fluticasone propionate DISKUS 100mcg BID, salmeterol xinafoate DISKUS 50mcg BID, or oral montelukast 10mg QD. GlaxoSmithKline Clinical Trial Register 2004:Accessed 7th March 2008.

**SAS40037** {unpublished data only}

GlaxoSmithKline (SAS40037). A multicenter, randomized, double-blind, double-dummy, parallel group, 16-week comparison of asthma control in adolescents and adults receiving either fluticasone propionate/salmeterol DISKUS combination product 100/50mcg BID, fluticasone propionate DISKUS 100mcg BID, salmeterol xinafoate DISKUS 50mcg BID, or oral montelukast 10mg QD. GlaxoSmithKline Clinical Trial Register 2004:Accessed: 7th March 2008.

**SAS40066** {unpublished data only}

GlaxoSmithKline (SAS40066). A randomised, open-label, crossover pilot study, assessing patient preference for ADVAIR DISKUS 100/50 BID (fluticasone propionate/salmeterol combination product 100/50mcg) versus Singulair QD (montelukast 10mg) in subjects  $\geq 15$  years of age with persistent asthma. GlaxoSmithKline Clinical Trial Register 2004:Accessed 7th March 2008.

**Serrier 2003** {published data only}

Serrier P, Roche N, Pello JY, Laruier JS, Mezzi K. Asthma control achieved with inhaled corticosteroids and long-acting beta2-agonists in a free or fixed combination: Results of the ALISE survey. *La Presse Medicale* 2003;**32**(11): 493–7.

**Sheth 2002** {published data only}

Sheth K, Borker R, Emmett A, Rickard K, Dorinsky P. Cost-effectiveness comparison of salmeterol/fluticasone propionate versus montelukast in the treatment of adults with persistent asthma. *Pharmacoeconomics* 2002;**20**(13): 909–18.

**Sims 2003** {published data only}

Sims EJ, Jackson CM, Lipworth BJ. Add-on therapy with montelukast or formoterol in patients with the glycine-16 beta2-receptor genotype. *British Journal of Clinical Pharmacology* 2003;**56**(1):104–11.

**Smith 1998** {published data only}

Smith LJ. The prospects for long-term intervention in asthma with antileukotrienes. *Clinical and Experimental Allergy* 1998;**28** Suppl 5:154–63.

**Sorkness 2007** {published data only}

Covar RA, Szeffer SJ, Zeiger RS, Sorkness CA, Moss M, Mauger DT, et al. Factors associated with asthma exacerbations during a long-term clinical trial of controller medications in children. *The Journal of Allergy and Clinical Immunology* 2008;**122**(4):741–7.

Larsen GL, Morgan W, Heldt GP, Mauger DT, Boehmer SJ, Chinchilli VM, Lemanske RF, et al. Impulse oscillometry versus spirometry in a long-term study of controller therapy for pediatric asthma. *The Journal of Allergy and Clinical Immunology* 2009;**123**(4):861–7.

Sorkness CA, Lemanske Jr RF, Mauger DT, Boehmer SJ, Chinchilli VM, Martinez FD, et al. Long-term comparison of 3 controller regimens for mild-moderate persistent childhood asthma: The Pediatric Asthma Controller Trial. *The Journal of Allergy and Clinical Immunology* 2007;**119**(1):64–72.

**Stanford 2003** {published data only}

Stanford R, Dorinsky P, Crim C, Yancey S, Edwards L, Rickard K. Reduction in asthma related exacerbations and exacerbation related costs during initial maintenance therapy with fluticasone propionate/salmeterol combination product versus montelukast or fluticasone propionate alone. *The Journal of Allergy and Clinical Immunology* 2003;**111** Suppl 2:143.

**Stelmach 2001** {published data only}

Stelmach I, Grzelewski T, Majak P, Majak J, Bobrowska M, Jerzynska J, et al. The effect of triamcinolone, montelukast and formoterol on serum levels of il-4, IgE and clinical parameters in children with asthma. *Polski Merkurusz Lekarski* 2001;**11**(63):247–51.

**Stelmach 2002** {published data only}

Stelmach I, Jerzynska J, Majak P, Grzelewski T, Gorski P, Stelmach W, et al. The effect of triamcinolone acetonide, montelukast, nedocromil sodium, formoterol on levels of sICAM-1, sIL-2R in serum and clinical course of asthma in children. *Polski Merkurusz Lekarski* 2002;**12**(68):99–103.

**Stelmach 2002a** {published data only}

Stelmach I, Jerzynska J, Kuna P. A randomized, double-blind trial of the effect of glucocorticoid, antileukotriene and [beta]-agonist treatment on IL-10 serum levels in children with asthma. *Clinical and Experimental Allergy* 2002;**32**(2):264–9.

**Stelmach 2007** {published data only}

Stelmach I, Grzelewski T, Bobrowska-Korzeniowska M, Stelmach P, Kuna P. A randomized, double-blind trial of the effect of anti-asthma treatment on lung function in children with asthma. *Pulmonary Pharmacology & Therapeutics* 2007;**20**(6):691–700.

**Stelmach 2008** {published data only (unpublished sought but not used)}

Stelmach I, Grzelewski T, Jerzynska J, Kuna P. A randomized, double-blind trial on the effect of treatment with montelukast, budesonide, montelukast with budesonide, formoterol with budesonide on lung function



- and clinical symptoms in children with asthma [Abstract]. *The Journal of Allergy and Clinical Immunology* 2005;**115** Suppl(2):151.
- Stelmach I, Grzelewski T, Majak P, Jerzynska J, Stelmach W, Kuna P. Effect of different antiasthmatic treatments on exercise-induced bronchoconstriction in children with asthma. *The Journal of Allergy and Clinical Immunology* 2008;**121**(2):383–9.
- Stempel 1998** *{published data only}*  
Stempel DA. Leukotriene modifiers in the treatment of asthma. *Respiratory Care* 1998;**43**(6):481–9.
- Stempel 2002** *{published data only}*  
Stempel DA, O'Donnell JC, Meyer JW. Inhaled corticosteroids plus salmeterol or montelukast: effects on resource utilization and costs. *The Journal of Allergy and Clinical Immunology* 2002;**109**(3):433–9.
- Stevenson 2005** *{published data only}*  
Stevenson DD, Mehra PK, White AA, Gupta S, Woessner KM, Simon RA. Failure of tacrolimus to prevent aspirin-induced respiratory reactions in patients with aspirin-exacerbated respiratory disease. *The Journal of Allergy and Clinical Immunology* 2005;**116**(4):755–60.
- Terzano 2001** *{published data only}*  
Terzano C, Allegra L, Barkai L, Cremonesi G. Beclomethasone dipropionate versus budesonide inhalation suspension in children with mild to moderate persistent asthma. *European Review for Medical and Pharmacological Sciences* 2001;**5**(1):17–24.
- Thien 2000** *{published data only}*  
Thien F. Leukotriene antagonists - do they offer new hope for asthmatics?. *Australian Family Physician* 2000;**29**(6):547–51.
- Tolley 2002** *{published data only}*  
Tolley K, Martin A, Rice L, McCarthy TP. Salmeterol/fluticasone propionate combination (SFC) demonstrates improved health outcomes and good cost effectiveness compared with beclomethasone dipropionate. *American Journal of Respiratory and Critical Care Medicine* 2002;**165** Suppl 8:A112.
- Vaquerizo 2003** *{published data only}*  
Vaquerizo MJ, Casan P, Castillo J, Perpina M, Sanchis J, Sobradillo V, et al. Effect of montelukast added to inhaled budesonide on control of mild to moderate asthma. *Thorax* 2003;**58**:204–11.
- Volovitz 1999** *{published data only}*  
Volovitz B, Tabachnik E, Nussinovitch M, Shtaf B, Blau H, Gil-Ad I, et al. Montelukast, a leukotriene receptor agonist, reduces the concentration of leukotrienes in the respiratory tract of children with persistent asthma. *The Journal of Allergy and Clinical Immunology* 1999;**104**:1162–7.
- Warner 2001** *{published data only}*  
Warner JO. The role of leukotriene receptor antagonists in the treatment of chronic asthma in childhood. *Allergy* 2001;**56** Suppl 66:22–9.
- Wilson 1999** *{published data only}*  
Wilson AM. A comparison of salmeterol and montelukast as second-line therapy in asthmatic patients not controlled on inhaled corticosteroids. *Thorax* 1999;**54** Suppl 3:A66, P189.
- Wilson 2001** *{published data only}*  
Wilson AM, Dempsey OJ, Sims EJ, Lipworth BJ. Evaluation of salmeterol or montelukast as second-line therapy for asthma not controlled with inhaled corticosteroids. *Chest* 2001;**119**(4):1021–6.
- Wytrychowski 2001** *{published data only}*  
Wytrychowski K, Patkowski J, Kuzniar T, Malolepszy J. Zafirlucast in corticosteroid sensitive and resistant bronchial asthma [Zafirlucast w leczeniu astmy oskrzelowej wzralowej i odpornej na kortykosteroidy – ocena stanu klinicznego i jakosci zycia]. *Advances in Clinical and Experimental Medicine* 2001;**10**(4):337–47.
- Yurdakul 2002** *{published data only}*  
Yurdakul AS, Calisir HC, Tunctan B, Ogretensoy M. Comparison of second controller medications in addition to inhaled corticosteroid in patients with moderate asthma. *Respiratory Medicine* 2002;**96**(5):322–9.
- Zarkovic 1998** *{published data only}*  
Zarkovic J, Gotz MH, Holgate ST, Taak NK. Effect of long-term regular salmeterol treatment in children with moderate asthma. *Clinical Drug Investigation* 1998;**15**(3):169–75.
- Zimmerman 2002** *{published data only}*  
Zimmerman B. Efficacy and tolerability of formoterol turbuhaler® compared with placebo in children (6–11 years) with asthma poorly controlled with inhaled corticosteroids. *American Journal of Respiratory and Critical Care Medicine* 2002;**165** Suppl 8:A746.

## References to ongoing studies

- Fardon 2002** *{published data only}*  
Ongoing study Starting date of trial not provided. Contact author for more information.
- Fardon 2004** *{published data only}*  
Ongoing study Starting date of trial not provided. Contact author for more information.
- Price 2001** *{published data only}*  
Ongoing study Starting date of trial not provided. Contact author for more information.
- Ruggins 2003** *{unpublished data only}*  
Ongoing study Starting date of trial not provided. Contact author for more information.

## Additional references

- Adams 2007**  
Adams N, Bestall JM, Lasserson TJ, Jones PW. Fluticasone versus beclomethasone or budesonide for chronic asthma in adults and children. *Cochrane Database of Systematic Reviews* 2007, Issue 4. [DOI: 10.1002/14651858.CD002310.pub4]

**Altman 2003**

Altman DG, Bland JM. Statistics Notes: Interaction revisited: the difference between two estimates. *BMJ* 2003; **326**(7382):219.

**ATS 1991**

American Thoracic Society. Lung function testing: Selection of reference values and interpretative strategies. *American Review of Respiratory Disease* 1991; **144**:1202–18.

**Baraniuk 1997**

Baraniuk JN, Ali M, Brody D, Maniscalco J, Gaumond E, Fitzgerald T, et al. Glucocorticoids induce beta2-adrenergic receptor function in human nasal mucosa. *American Journal of Respiratory and Critical Care Medicine* 1997; **155**(2): 704–10.

**Boulet 2001**

Boulet LP, Bai TR, Becker A, Berube D, Beveridge R, Bowie DM, et al. What is new since the last (1999) Canadian Asthma Consensus Guidelines?. *Canadian Respiratory Journal* 2001; **8 Suppl A**:5–27.

**BTS 2003**

British Thoracic Society. British guidelines on the management of asthma. *Thorax* 2003; **58 Suppl 1**:1–94.

**Buhl 2003**

Buhl R, Creemers JP, Vondra V, Martelli NA, Naya IP, Ekstrom T. Once-daily budesonide/formoterol in a single inhaler in adults with moderate persistent asthma. *Respiratory Medicine* 2003; **97**(4):323–30.

**Cates 2002**

Cates CJ. Simpson's paradox and calculation of number needed to treat from meta-analysis. *BMC Medical Research Methodology* 2002; **2**:1.

**Cates 2008a**

Cates CJ, Cates MJ, Lasserson TJ. Regular treatment with formoterol for chronic asthma: serious adverse events. Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2008, issue 4. [DOI: 10.1002/14651858.CD006923.pub2; : CD006923]

**Cates 2008b**

Cates CJ, Cates MJ. Regular treatment with salmeterol for chronic asthma: serious adverse events. Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2008, issue 3. [DOI: 10.1002/14651858.CD006363.pub2; : CD006363]

**Cates 2009a**

Cates CJ, Lasserson TJ, Jaeschke R. Regular treatment with formoterol and inhaled steroids for chronic asthma: serious adverse events. Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2009, issue 2. [DOI: 10.1002/14651858.CD006924.pub2; : CD006924]

**Cates 2009b**

Cates CJ, Lasserson TJ, Jaeschke R. Regular treatment with salmeterol and inhaled steroids for chronic asthma: serious adverse events. Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2009, issue 3. [DOI: 10.1002/14651858.CD006922.pub2; : CD006922]

**Davis 1997**

Davies RJ, Wang J, Abdelaziz MM, Calderon MA, Khair O, Devalia JL, et al. New insights into the understanding of asthma. *Chest* 1997; **111 Suppl**:2–10.

**Deeks 2001**

Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Egger M, Smith GD, Altman DG editor(s). *Systematic reviews in health care: meta-analysis in context*. London: BMJ Publishing, 2001:285–312.

**Ducharme 2004a**

Ducharme FM, Schwartz Z, Kakuma R. Addition of anti-leukotriene agents to inhaled corticosteroids for chronic asthma (Cochrane review). *Cochrane Database of Systematic Reviews* 2004, Issue 1. [DOI: 10.1002/14651858.CD003133.pub2]

**Ducharme 2004b**

Ducharme FM, Di Salvo F. Anti-leukotrienes compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma (Cochrane review). *Cochrane Database of Systematic Reviews* 2004, Issue 1. [DOI: 10.1002/14651858.CD002314.pub2]

**Ducharme 2010**

Ducharme FM, Ni Chroinin M, Greenstone I, Lasserson TJ. Addition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children. *Cochrane Database of Systematic Reviews* 2010, Issue 5. [DOI: 10.1002/14651858.CD005535.pub3]

**Egger 1997**

Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ* 1997; **315**:629–34.

**Ernst 2006**

Ernst P, McIvor A, Ducharme FM, Boulet LP, Fitzgerald M, Chapman KR, Bai T. Safety and effectiveness of long-acting inhaled beta-agonist bronchodilators when taken with inhaled corticosteroids. *Annals of Internal Medicine* 2006; **145**:692–4.

**Georgitis 1999**

Georgitis JW. The 1997 asthma management guidelines and therapeutic issues relating to the treatment of asthma. *Chest* 1999; **115**:210–7.

**GINA 2009**

Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention (updated December 2009). NIH Publication 02-3659. Bethesda, MD: National Heart, Lung and Blood Institute, 2009.

**Gold 2001**

Gold M, Jogi R, Mulder PGH, Akveld MLK. Salmeterol/fluticasone propionate combination 50/100mcg bid is more effective than fluticasone propionate 100mcg bid plus montelukast 10 mg once daily in reducing exacerbations. *European Respiratory Journal* 2001; **18 Suppl** 33:262.

**Higgins 2003**

Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ* 2003;**327**:557–60.

**Higgins 2008**

Higgins JPT, Green S, editors. *Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 [updated September 2008]*. The Cochrane Collaboration, Available from www.cochrane-handbook.org, 2008.

**Johnson 1995**

Johnson M. Pharmacology of long acting beta-agonists. *Annals of Allergy, Asthma & Immunology* 1995;**75**(2):177–9.

**Krawiec 2002**

Krawiec ME, Jarjour NJ. Leukotriene receptor antagonists. *Seminars in Respiratory and Critical Care Medicine* 2002;**23**(4):399–410.

**Lipworth 2002**

Lipworth BJ. Antagonism of long-acting beta2-adrenoceptor agonism. *British Journal of Clinical Pharmacology* 2002;**54**:231–45.

**Lotvall 1996**

Lotvall J, Lunde H, Svedmyr N. Onset of bronchodilation and finger tremor induced by salmeterol and salbutamol in asthmatic patients. *Journal of the American Board of Family Practice* 1996;**9**(3):182–90.

**Lougheed 2010**

Lougheed MD, Lemièrre C, Dell SD, Ducharme FM, Fitzgerald JM, Leigh R, et al. Canadian Thoracic Society Asthma Management Continuum - 2010 Consensus Summary for children six years of age and over, and adults. *Canadian Respiratory Journal* 2010;**17**(1):15–24.

**Nelson 2003**

Nelson HS, Chapman KR, Pyke SD, Johnson M, Pritchard JN. Enhanced synergy between fluticasone propionate and salmeterol inhaled from a single inhaler versus separate inhalers. *The Journal of Allergy and Clinical Immunology* 2003;**112**(1):29–36.

**Ni Chroinin 2009a**

Ni Chroinin M, Greenstone I, Lasserson TJ, Ducharme FM. Addition of long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naïve adults and children. *Cochrane Database of Systematic Reviews* 2009, Issue 4. [DOI: 10.1002/14651858.CD005307.pub2]

**Ni Chroinin 2009b**

Ni Chroinin M, Lasserson TJ, Greenstone I, Ducharme FM. Addition of long-acting beta-agonists to inhaled corticosteroids for chronic asthma in children. *Cochrane Database of Systematic Reviews* 2009, Issue 3. [DOI: 10.1002/14651858.CD005535.pub2]

**Perera 2003**

Perera BJ. Salmeterol multicentre asthma research trial (SMART): interim analysis shows increased risk of asthma related deaths. *Ceylon Medical Journal* 2003;**48**(3):99.

**Powell 2003**

Powell H, Gibson PG. Inhaled corticosteroid doses in asthma: an evidence-based approach [Review]. *Medical Journal of Australia* 2003;**178**(5):223–5.

**Rees 1995**

Rees J, Price J. ABC of Asthma: Treatment of chronic asthma. *BMJ* 1995;**310**:1459–63.

**Review Manager 5**

Copenhagen, The Nordic Cochrane Centre: The Cochrane Collaboration. Review Manager (RevMan) Version 5.0. Copenhagen, The Nordic Cochrane Centre: The Cochrane Collaboration, 2008.

**Salpeter 2006**

Salpeter SR, Buckley NS, Ormiston TM, Salpeter EE. Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths. *Annals of Internal Medicine* 2006;**144**(12):904–12.

**Storms 2003**

Storms W. Clinical trials: are these your patients?. *The Journal of Allergy and Clinical Immunology* 2003;**112** Suppl (5):107–11.

**USA 2002**

National Asthma Education and Prevention Program. NAEP Expert Panel Report Guidelines for the Diagnosis and Management of Asthma. NIH Publication 02-5075. National Heart, Lung and Blood Institute. Bethesda, MD: National Institute of Health, 2002:1–111.

**Walters 2007**

Walters EH, Gibson PG, Lasserson TJ, Walters JAE. Long-acting beta2-agonists for chronic asthma in adults and children where background therapy contains varied or no inhaled corticosteroid. *Cochrane Database of Systematic Reviews* 2007, Issue 1. [DOI: 10.1002/14651858.CD001385.pub2]

**Wasserman 1988**

Wasserman MA. Modulation of arachidonic acid metabolites as potential therapy of asthma. *Agents and Actions. Supplements* 1988;**23**:95–111.

**Wenzel 1997**

Wenzel SE. Arachidonic acid metabolites: mediators of inflammation in asthma. *Pharmacotherapy* 1997;**17**(1Pt 2):3S–12S.

**References to other published versions of this review****Ducharme 2006**

Ducharme FM, Lasserson TJ, Cates CJ. Long-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma. *Cochrane Database of Systematic Reviews* 2006, Issue 4. [DOI: 10.1002/14651858.CD003137]

**Ram 2005**

Ram FSE, Cates CJ, Ducharme FM. Long-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma. *Cochrane*

*Database of Systematic Reviews* 2005, Issue 1. [DOI:  
10.1002/14651858.CD003137]

\* *Indicates the major publication for the study*

## CHARACTERISTICS OF STUDIES

### Characteristics of included studies [ordered by study ID]

#### Bjermer 2003

Methods	Parallel-group, multicentre trial (148 centres in 37 countries)
Participants	<p>INADEQUATELY controlled participants on inhaled glucocorticoids at baseline</p> <p>BASELINE INHALED STEROID DOSAGE:  LTRA: 638±285 µg of beclomethasone-equivalent/day  LABA: 647±229 µg of beclomethasone-equivalent/day  RANDOMISED: 1490 (LTRA: 747; LABA: 743)</p> <p>WITHDRAWALS:  LTRA: 125 (17%)  LABA: 110 (15%)</p> <p>AGE in years: mean ± SD  LTRA: 41.2 ± 13.6  LABA: 41.0± 13.7</p> <p>GENDER (% male)  LTRA: 45.4%  LABA: 44.8%</p> <p>SEVERITY:  MODERATE asthma</p> <p>BASELINE % PRED FEV1  LTRA: 71.3 ± 13.2  LABA: 72.7 ± 13.9</p> <p>ALLERGIC RHINITIS:  LTRA: 61.7%  LABA: 60.4%</p> <p>ALLERGEN TRIGGERS:  Not reported</p> <p>ASTHMA DURATION in years: mean ± SD  LTRA: 16.3 ± 13.0  LABA: 16.2 ± 12.7</p> <p>ELIGIBILITY CRITERIA: age: 15-72 years; clear history of chronic asthma for at least 1 year; regular use of inhaled corticosteroids over 8 weeks prior to study entry; FEV1 values between 50% and 90% of predicted; ≥12% improvement in FEV1 or PEFR after β-agonists; minimum pre-determined level of daytime and night-time inhaled short-acting β-agonist use (≥ 1 puff/day); minimum asthma symptom score (biweekly score of ≥56 on a scale of 0 to 336); current treatment includes only short-acting beta2-agonists and inhaled corticosteroids (200-1000 µg/day or equivalent); women with negative urine pregnancy test at screening</p> <p>EXCLUSION CRITERIA: emergency treatment for asthma within 1 month of 1st visit; hospitalisation for asthma within 3 months; unresolved upper respiratory tract infection within 3 weeks; active sinus infection; received the following asthma medications: oral corticosteroids within 1 month, cromolyn, nedocromil, leukotriene-receptor antagonists, long-acting or oral β-agonists, inhaled anticholinergics within 2 weeks, theophylline, terfenadine, fexofenadine, loratadine, or cetirizine within 1 week</p>

Interventions	<p>LTRA + ICS versus LABA + ICS (stable dose of ICS)  DURATION:  Run-in period: 4 weeks  Intervention period: 48 weeks  INTERVENTION GROUP 1  LTRA: montelukast @ 10 mg/day p.o. + ICS (FP 100 µg bid, via discus)  INTERVENTION GROUP 2  LABA: salmeterol 50 ug bid, via MDI + ICS (FP 100 µg bid, via Discus)  2 inhalers used for combination therapy.  CO-TREATMENT: none</p>	
Outcomes	<p>INTENTION-TO-TREAT ANALYSES  Outcomes used at endpoint or 48 weeks  PULMONARY FUNCTION TESTS  Change from baseline FEV<sub>1</sub>; change from baseline in am PEFR  SYMPTOM SCORES  Change from baseline NIGHT-TIME awakenings  **EXACERBATIONS  Exacerbations requiring systemic steroids; exacerbations requiring hospital admission; exacerbations requiring unscheduled office visit; exacerbations requiring emergency room visit; time to first exacerbation  Definition: an asthma attack was defined by one or all of the following, hospitalisation; unscheduled office visit; ER visit; CS use (oral, IM, IV or rectal use)  FUNCTIONAL STATUS  Change in quality of life; change in night-time awakenings  INFLAMMATORY MARKERS  Change in serum eosinophils  ADVERSE EFFECTS  Elevated liver enzymes, headache, nausea, death, neutropenia, increased lymphocytes  WITHDRAWALS  Due to adverse effects; due to poor control; overall  (** denotes primary outcome)</p>	
Notes	<p>Full-text report; additional unpublished data provided by Peter Polos, June 2003  Funder: Merck Frost  Confirmation of methodology and data extraction: received (Peter Polos, June 2003)  User-defined number: 48 weeks</p>	
<b><i>Risk of bias</i></b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Random sequence generation (selection bias)	Low risk	Randomisation by computer generated random numbers
Allocation concealment (selection bias)	Low risk	Allocation occurred at pharmacy and not conducted by investigator

**Bjermer 2003** (Continued)

Blinding (performance bias and detection bias) All outcomes	Low risk	Number coded MDI/tablets supplied by pharmacy Tripple-blind (patient, assessor and treating physician); double-dummy (identical placebo)
Incomplete outcome data (attrition bias) Exacerbations	Unclear risk	Intention-to-treat analysis reported, but method not available
Selective reporting (reporting bias)	Low risk	Data obtained from investigators
Other bias	Low risk	

**Ceylan 2004**

Methods	Parallel-group; single centre study (Turkey)
Participants	<p>INADEQUATELY controlled participants on inhaled glucocorticoids and SABA prn            BASELINE INHALED STEROID DOSAGE            Not reported (400µg/d BUD given as standard during 4 week run-in period)            RANDOMISED            48. NB baseline data only reported for those who completed the study: LTRA: 20; LABA: 20            WITHDRAWALS:            Not stated by treatment group            AGE in years, mean:            LTRA: 33.2            LABA: 39.1            GENDER (% male):            LTRA: 55            LABA: 50            SEVERITY            Moderate persistent asthma            BASELINE % PRED FEV1 (L):            LTRA: 69.7            LABA: 71.2            ALLERGIC RHINITIS (%):            LTRA: 60            LABA: 70            ALLERGEN TRIGGERS            Not reported            ASTHMA DURATION in years: Mean ± SD:            LTRA: 8.1 ± 4            LABA: 9 ± 8.8            ELIGIBILITY CRITERIA: age 15-60 years; diagnosis of asthma (GINA); persistent asthma symptoms for at least 1 year; use of ICS for at least 6 months; post-run in period: FEV1 or PEF ≥60 and ≤80% predicted</p>

Ceylan 2004 (Continued)

	- ≥15% reversibility increase in FEV1; mean am PEF value ≤85% max after SABA; use of SABA ≥2 times per day or am/night symptom score ≥2 on 4 or less days per week EXCLUSION CRITERIA: smokers; pregnant or lactating women; life-threatening asthma; patients hospitalised due to asthma in last 3 months; upper/lower RTI	
Interventions	LTRA + ICS versus LABA + ICS (stable dose of ICS) DURATION: Run-in period: 4 weeks Intervention period: 8 weeks Outcomes at 4, 8, and 12 weeks INTERVENTION GROUP 1 -LTRA = montelukast @ 10 mg/day p.o.+ BUD 200 µg BID, unclear inhaler device INTERVENTION GROUP 2 -LABA = formoterol 12 µg bid,+ BUD 200 µg BID, unclear inhaler device CO-TREATMENT: -SABA prn	
Outcomes	PULMONARY FUNCTION TESTS Change in FEV1 % predicted; change in FEV1 (L); change in am PEF*; change in pm PEF SYMPTOM SCORES Morning symptom scores; night symptom scores EXACERBATIONS Not reported (participants who exacerbated were excluded from the study) FUNCTIONAL STATUS Rescue medication usage (puffs/d); % days without rescue medication usage INFLAMMATORY MARKERS Not reported EXACERBATIONS Need for a drug not included in the protocol ADVERSE EFFECTS Candidiasis; sore throat; voice problems; headache WITHDRAWALS Not clear -Due to ADVERSE EFFECTS Not reported -Due to poor control Not reported -Overall Stated * Main outcome	
Notes	Full-text report No funding body User-defined number: 8 weeks	
<b>Risk of bias</b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>



**Ceylan 2004** (Continued)

Random sequence generation (selection bias)	Unclear risk	Not reported
Allocation concealment (selection bias)	Unclear risk	Not reported
Blinding (performance bias and detection bias) All outcomes	High risk	Open-label study
Incomplete outcome data (attrition bias) Exacerbations	Unclear risk	Stated ITT for efficacy and safety, however baseline data are only presented for 40 participants who completed the study
Selective reporting (reporting bias)	Unclear risk	Unable to verify whether primary outcome measured in the review
Other bias	Low risk	

**ELEVATE**

Methods	Parallel group, pragmatic randomised controlled study in primary care population in the UK
Participants	<p>INADEQUATELY controlled participants on inhaled glucocorticoids at baseline</p> <p>BASELINE INHALED STEROID DOSAGE</p> <p>Not specified</p> <p>RANDOMISED:</p> <p>LTRA: 164</p> <p>LABA: 176</p> <p>WITHDRAWALS</p> <p>Not specified (12 participants withdrew from treatment)</p> <p>AGE in years: mean ± SD</p> <p>Not reported</p> <p>GENDER (% male)</p> <p>Not reported</p> <p>SEVERITY</p> <p>Not described</p> <p>BASELINE PEF (% predicted)</p> <p>LTRA: 89.2</p> <p>LABA: 87</p> <p>ALLERGEN TRIGGERS</p> <p>Not reported</p> <p>ALLERGIC RHINITIS</p> <p>Not reported</p> <p>ASTHMA DURATION in years</p> <p>Not reported</p> <p>ELIGIBILITY CRITERIA</p> <p>&gt;11 years; PEF predicted &gt;50%; inadequately controlled on inhaled corticosteroids</p>

**ELEVATE** (Continued)

	EXCLUSION CRITERIA Not listed SETTING: primary care
Interventions	DURATION: 2 years 1. LTRA (not specified from abstract) 2. LABA (not specified from abstract)
Outcomes	Asthma quality of life (AQLQ); exacerbations; asthma control questionnaire; PEF % predicted; symptoms; SABA usage; hospital admission; change in ICS (for participants at step 3)
Notes	TJL emailed for data: 22nd April, 2010.

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Pragmatic randomised controlled trial
Allocation concealment (selection bias)	Low risk	Centralised 'ring-in' centre for randomisation
Blinding (performance bias and detection bias) All outcomes	High risk	Single-blind (to study personnel)
Incomplete outcome data (attrition bias) Exacerbations	Low risk	Low withdrawal rates (12/352) unlikely to affect results
Selective reporting (reporting bias)	High risk	Study presented as conference abstract. Outcomes within it well reported, but no information presented on exacerbations and SAEs. Trial protocol indicates that exacerbations were measured
Other bias	Unclear risk	No full-text article presenting clinical endpoints available to determine this

**Fish 2001**

Methods	Parallel-group study, multicentre trial (71 centres in USA and Puerto Rico)
Participants	INADEQUATELY controlled participants on inhaled glucocorticoids at baseline BASELINE INHALED STEROID DOSAGE: 84-4000 µg of beclomethasone-equivalent/day RANDOMISED: 948

**Fish 2001** (Continued)

	<p>LTRA: 472  LABA: 476  WITHDRAWALS:  LTRA: 70 (15%)  LABA: 61 (13%)  AGE in years: mean ± SD  LTRA: 39.5 ± 14.0  LABA: 39.9 ± 13.5  GENDER (% male)  LTRA: 38%  LABA: 39%  SEVERITY:  Not described  BASELINE FEV1 (% pred)  LTRA: 68.6 (0.4) SE  LABA: 68.1 (0.4) SE  ALLERGEN TRIGGERS  Not reported  ASTHMA DURATION in years: %  Less than 10 years  LTRA: 26%  LABA: 24%  Over 10 years  LTRA: 74%  LABA: 76%  ELIGIBILITY CRITERIA: aged ≥15 years; male or non-pregnant, non-lactating female; asthma for ≥ 6months; symptomatic despite ICS for at least 6 weeks prior to screening; 50-80% predicted FEV1; ≥12% increase in FEV1 post-bronchodilator (200 µg albuterol)  In the 7 to 14 days prior to randomisation one or more of the following:  1. FEV1 of 50 to 80% of predicted  2. average of 4 or more puffs per day albuterol  3. symptom score of 2 or more for 3 or more days  4. 3 or more nights when patient woke at night due to asthma symptoms  EXCLUSION CRITERIA  Not described  SETTING: outpatients in private and university clinics</p>
Interventions	<p>LTRA + ICS versus LABA + ICS (stable dose of ICS)  DURATION:  Run-in period: 1-2 weeks  Intervention period: 12 weeks  INTERVENTION GROUP 1  LTRA: montelukast 10 mg qd + ICS: continued current medication (which included fluticasone, triamcinolone, BDP, BUD and flunisolide) Mean 565 µg in CFC BDP-equivalent)  INTERVENTION GROUP 2  LABA: salmeterol 50 µg bid, via Diskus + ICS: continued current medication  Mean 546 µg in CFC BDP-equivalent</p>

**Fish 2001** (Continued)

	2 inhalers used for combination therapy CO-TREATMENT: none permitted	
Outcomes	<p>INTENTION-TO-TREAT ANALYSES Outcomes used at endpoint PULMONARY FUNCTION TESTS **Change from baseline in AM PEFr; change from baseline in pm PEFr SYMPTOM SCORES Change from baseline overall symptom scores; change in symptom-free days; patient satisfaction EXACERBATIONS Definition: any worsening of asthma symptoms requiring treatment beyond the use of blinded study drug and/or supplemental albuterol. Patients who experienced an asthma exacerbation were withdrawn from the study FUNCTIONAL STATUS Change from baseline in mean overall use of B2-agonists (puffs/DAY); change from baseline in mean DAYTIME use of B2-agonists (puffs/DAY); change from baseline in mean NIGHT-TIME use of B2-agonists (puffs/DAY); change in rescue-free days; change in night-time awakenings INFLAMMATORY MARKERS Not reported ADVERSE EFFECTS Drug related and non-drug related WITHDRAWALS Due to adverse effects reported (** denotes primary outcome)</p>	
Notes	<p>Full-text report Received additional unpublished data provided by Karen Richardson, GSK, UK, August 2003 Funded by Glaxo Wellcome, studies SMS40003 &amp; SMS40004 Confirmation of methodology and data extraction received User-defined order: 12 weeks</p>	
<b>Risk of bias</b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Random sequence generation (selection bias)	Low risk	Methods of randomisation: by computer generated random number
Allocation concealment (selection bias)	Low risk	Means of assignment by number coded inhaler/pills supplied by pharmacy
Blinding (performance bias and detection bias) All outcomes	Low risk	Double-blind, double-dummy design

**Fish 2001** (Continued)

Incomplete outcome data (attrition bias) Exacerbations	Low risk	Received additional unpublished data provided by Karen Richardson, GSK, UK, August 2003
Selective reporting (reporting bias)	Low risk	Primary outcome data available for meta-analysis
Other bias	Low risk	

**Green 2006**

Methods	Crossover, single centre study in UK
Participants	<p>INADEQUATELY controlled participants on inhaled glucocorticoids at baseline            BASELINE INHALED STEROID DOSAGE:            ≤400 µg BDP equivalent            N RANDOMISED: 49            N COMPLETED: 39            M = 25            F = 24            MEAN AGE: 42            SEVERITY: not stated            BASELINE FEV1: 74.8%            ATOPIC: 93%</p> <p>INCLUSION CRITERIA: 18-75 yrs, diagnosed with asthma; receiving treatment with less than or equal to 400 µg/day CFC-BDP per day ; one or more of 1) &gt;15% increase in FEV1 post-SABA; 2) &gt;20% within-day variability in PEF assessed twice daily over a 2-week period; 3) provocative concentration of methacholine causing a 20% fall in FEV1 (PC20) &lt;8 mg/mL-1; following run-in on 200mcg day BUD, participants were eligible if they had recorded day- or night-time asthma symptoms on their diary cards on at least 4 days in the third or fourth baseline week</p> <p>EXCLUSION: current smokers or smoking history of &gt;10 pack-yrs, significant comorbidity, treated with oral corticosteroids, long-acting β2-agonists, leukotriene antagonists or theophylline; asthma exacerbation or lower respiratory tract infection within the 4 weeks prior to trial entry</p>
Interventions	<p>LTRA + ICS versus LABA + ICS (Stable low dose of ICS)</p> <p>INTERVENTION GROUP 1            LTRA: oral montelukast 10 mg qd + budesonide 100 mg BID</p> <p>INTERVENTION GROUP 2            LABA: formoterol 12 mg BID + budesonide 100 mg BID</p> <p>TREATMENT PERIOD: 6 weeks (wash-out period: 4 weeks)            RUN-IN PERIOD: 4 weeks            CO-TREATMENT: not reported</p>
Outcomes	<p>INTENTION-TO-TREAT ANALYSES: Crossover data analysed for completers</p> <p>PULMONARY FUNCTION TESTS:            FEV1, PEFR but only improvements when groups compared, no individual group results</p>

Green 2006 (Continued)

	<p>were presented</p> <p>SYMPTOM SCORES: VAS (individual group values not presented, but rather differences between groups)</p> <p>EXACERBATIONS Reported as events</p> <p>FUNCTIONAL STATUS Not stated</p> <p>INFLAMMATORY MARKERS Not stated</p> <p>ADVERSE EFFECTS Not stated</p> <p>WITHDRAWALS Not reported</p>	
Notes	<p>Funding source not disclosed</p> <p>Confirmation of methodology and data extraction received</p> <p>User-defined order: 4 weeks</p>	
<b>Risk of bias</b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Random sequence generation (selection bias)	Low risk	'I believe that this was generated using a computer statistical package generating a random sequence. I don't know the package that was used and unfortunately the individual has left our organisation but had extensive clinical trials expertise.'
Allocation concealment (selection bias)	Low risk	'...this was indeed generated by a third party, namely the pharmacist responsible for dispensing the double blind medication (...) None of the study investigators were aware of the randomisation schedule until the last patient had completed the cross-over study'
Blinding (performance bias and detection bias) All outcomes	Low risk	Double-dummy
Incomplete outcome data (attrition bias) Exacerbations	High risk	Completers used for analysis
Selective reporting (reporting bias)	Low risk	OCS-treated exacerbations reported. Data could not be extracted as only data on events and not number of participants were made available
Other bias	Low risk	

Grosclaude 2003

Methods	Parallel group, open-label study; multicentre study (115 centres in France)
Participants	<p>INADEQUATELY controlled participants on inhaled glucocorticoids at baseline</p> <p>BASELINE INHALED STEROID DOSAGE 1000 µg CFC Beclomethasone or equivalent daily.</p> <p>RANDOMISED = 253</p> <p>LTRA: 130 LABA: 123</p> <p>WITHDRAWALS LTRA: 16 (12%) LABA: 7 (6%)</p> <p>AGE in years: mean ± SD LTRA: 44.6 (18.2) LABA: 43.1 (17.8)</p> <p>GENDER (% male) LTRA: 39 LABA: 39</p> <p>SEVERITY Not described</p> <p>BASELINE % PRED FEV1 (L) Not reported</p> <p>BASELINE PEF (L/min): LTRA: 327 LABA: 344</p> <p>ALLERGIC RHINITIS (%): LTRA: 51% LABA: 52%</p> <p>ALLERGEN TRIGGERS Not reported</p> <p>ASTHMA DURATION in years: Mean ± SD Reported as % with asthma duration: &lt;1 year: 6; between 1 and 5 years: 17; between 5 and 10 years: 15; between 10 and 15 years: 19; more than 15 years: 43</p> <p>ELIGIBILITY CRITERIA: less than or equal to 15 years of age diagnosed asthma; treatment for at least four weeks with CFC BDP equivalent of ≥1000 µg/d and inhaled SABA prn; able to use Mini Wright PEF metre; able to fill in daily record card</p> <p>Over last seven days of run-in:</p> <ol style="list-style-type: none"> <li>1. mean am PEF between 60-80% predicted best (as obtained post-BD at visit 2)</li> <li>2. asthma symptoms on at least two days</li> <li>3. used SABA at least four times</li> </ol> <p>EXCLUSION CRITERIA: use of systemic CS, anti-leukotriene agent, LABA, lower RTI within previous four weeks; hospitalisation within previous 4 weeks; hypersensitivity to one of compound study drugs; serious uncontrolled concurrent disease; allergen specific immunotherapy in incremental phase; smoker or ex-smoker with 10 pack year; participation in clinical study in previous month</p>
Interventions	<p>LTRA + ICS versus LABA + ICS (stable dose of ICS)</p> <p>DURATION: Run-in period: 1-2 weeks Intervention period: 12 weeks</p>

	<p>INTERVENTION GROUP 1  LTRA: montelukast @ 10 mg/day p.o.+ CFC BDP 250 ug two puffs bid, via pMDI  INTERVENTION GROUP 2  LABA: salmeterol 50 ug bid, via MDI + FP 250 mcg one puff bid, via diskus (single combination inhaler)  CO-TREATMENT: SABA prn</p>
<p>Outcomes</p>	<p>INTENTION-TO-TREAT ANALYSES outcomes used at endpoint or 12 weeks  PULMONARY FUNCTION TESTS  **change from baseline in AM PEF; change from baseline in pm PEF  SYMPTOM SCORES  Change from baseline % nights with awakenings; change from baseline in % days with no symptoms; change from baseline in % nights with no symptoms  EXACERBATIONS  One or more of:  Mild: reduction in AM PEF of &gt;20% of baseline; increased bronchodilator usage; awakenings due to asthma on one or more consecutive nights  Moderate: reduction in AM PEF &gt;30% of baseline; change in maintenance therapy or premature termination of trial therapy; oral steroids  Severe: hospitalisation  FUNCTIONAL STATUS  Change from baseline in % nights without rescue medication usage; change from baseline in % days without rescue medication usage; % of patients with good asthma control 10 of 12 weeks as defined by presence of two of:  <ol style="list-style-type: none"> <li>1. PEF ≥80% predicted</li> <li>2. no more than four puffs of BD on no more than 2 days</li> <li>3. symptom free for at least two days;</li> <li>4. presence of all the following criteria on a weekly basis: no nocturnal awakening; no exacerbation; no unscheduled medical contact; no adverse effect of treatment leading to withdrawal)</li> </ol> INFLAMMATORY MARKERS  Not reported  ADVERSE EFFECTS  Headache; gastroenteritis; upper respiratory inflammation; pharyngitis; viral respiratory infections; malaise and fatigue; allergic rhinitis; diarrhoea; digestive discomfort &amp; pain; ENT symptoms; muscle cramps and spasms; regurgitation and reflux; nasal inflammation; vertigo; nausea and vomiting; cough; lower respiratory infections; dyspeptic symptoms  WITHDRAWALS  Due to poor completion of diary cards; due to adverse effects; due to poor control -overall (all reported)  (** denotes primary outcome)</p>
<p>Notes</p>	<p>Full-text report and unpublished trial report  Received additional unpublished data (SFCF4007) from GSK website  Funded by GSK  User-defined number: 12 weeks</p>

*Risk of bias*



**Grosclaude 2003** (Continued)

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	See <a href="#">Appendix 1</a>
Allocation concealment (selection bias)	Low risk	See <a href="#">Appendix 1</a>
Blinding (performance bias and detection bias) All outcomes	High risk	Open-label study
Incomplete outcome data (attrition bias) Exacerbations	Unclear risk	'The safety population included all subjects who received at least 1 dose of the study medication. The intent-to-treat population (ITT) included all randomised subjects who received at least one dose of the study medication, and from whom daily record card (DRC) data were available during the run-in period and the treatment period.'
Selective reporting (reporting bias)	Low risk	Data for exacerbations reported in pharmaceutical company download. The definition of exacerbation was not explicit and we could not use the outcome data for this study in the meta-analysis
Other bias	Low risk	

**Hendeles 2004**

Methods	Parallel groups; number of sites and countries unclear
Participants	<p>INADEQUATELY controlled participants on inhaled glucocorticoids and SABA prn with history of EIB at baseline</p> <p>BASELINE INHALED STEROID DOSAGE Not reported</p> <p>RANDOMISED = 91 (unclear allocation between groups)</p> <p>WITHDRAWALS Not reported</p> <p>AGE in years (range) 15-60</p> <p>GENDER (% male) Not reported</p> <p>SEVERITY Not described</p> <p>BASELINE % PRED FEV1 (L) LTRA: 81.3</p>

**Hendeles 2004** (Continued)

	<p>LABA: 78.9          ALLERGIC RHINITIS (%)          Not reported          ALLERGEN TRIGGERS          Not reported          ASTHMA DURATION in years: Mean ± SD          Not reported          ELIGIBILITY CRITERIA: participants with asthma who remained symptomatic on ICS; age 15-60 years; history of EIB          EXCLUSION CRITERIA: not reported</p>	
Interventions	<p>LTRA + ICS versus LABA + ICS (stable dose of ICS)          DURATION          Intervention period: 4 weeks          INTERVENTION GROUP 1          LTRA: montelukast @ 10 mg/day p.o.+ FP 125 µg one puff bid, via inhalation          INTERVENTION GROUP 2          LABA: salmeterol 50 µg bid, via MDI + montelukast placebo + ICS = FP 125 µg one puff bid, via inhalation (separate inhalers)          CO-TREATMENT          Not reported</p>	
Outcomes	<p>INTENTION-TO-TREAT ANALYSES: outcomes used at endpoint or 4 weeks          PULMONARY FUNCTION TESTS          Challenge FEV1 % predicted; change in FEV1 % predicted; rescue bronchodilation          SYMPTOM SCORES          Not reported          EXACERBATIONS          Not reported          FUNCTIONAL STATUS          Not reported          INFLAMMATORY MARKERS          Not reported          ADVERSE EFFECTS          Not reported          WITHDRAWALS          Due to adverse events: not reported          Due to poor control: not reported          Overall: reported          Primary outcome not identified</p>	
Notes	<p>Unpublished: conference abstract          Funded by Merck          User-defined number: 4 weeks          No data could be used for aggregation</p>	
<b><i>Risk of bias</i></b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>

**Hendeles 2004** (Continued)

Random sequence generation (selection bias)	Unclear risk	Described as randomised; other information not available
Allocation concealment (selection bias)	Unclear risk	Information not available
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Information not available
Incomplete outcome data (attrition bias) Exacerbations	Unclear risk	Information not available
Selective reporting (reporting bias)	Unclear risk	Unable to verify whether primary outcome measured in the review
Other bias	Unclear risk	Not enough details about the study could be ascertained from the abstract available

**Ilowite 2004**

Methods	Parallel-group study, multicentre trial (132 centres in USA for 48 weeks)
Participants	<p>INADEQUATELY controlled participants on inhaled glucocorticoids at baseline            BASELINE INHALED STEROID DOSAGE: 220 µg of ICS per day            RANDOMISED = 1473            LTRA: 743            LABA: 730            WITHDRAWALS:            LTRA: 128/743            LABA: 113/730            AGE in years: mean ± SD            LTRA: 39.0 (range 14-73)            LABA: 38.1 (range 15-70)            GENDER (% male)            LTRA: 41.2%            LABA: 37.5%            SEVERITY            Moderate-to-severe persistent asthma            BASELINE FEV1 (% pred)            LTRA: 74.3 ± (SD 11.5)            LABA: 74.3 ± (SD 11.7)            ALLERGEN TRIGGERS            Not reported            ALLERGIC RHINITIS            Not reported            ASTHMA DURATION in years            NS            ELIGIBILITY CRITERIA: age 15-65 years; asthma for ≥1 year; ICS use daily for at</p>

	<p>least 8 weeks prior to first visit; baseline FEV1 of 50 to 90% of predicted <math>\geq 12\%</math> change in FEV1 after albuterol, and, in the 14 days prior to randomisation one or more of the following:</p> <ol style="list-style-type: none"> <li>1. asthma symptom that required the use of <math>\beta_2</math>-agonist medication on average once per day</li> <li>2. minimum biweekly daytime symptom score of 56 for a 14-day period)</li> </ol> <p>EXCLUSION CRITERIA: emergency department visit in &lt; 1 month; admission for asthma in &lt; 3 months; upper respiratory infection in &lt; 3 weeks of 1st visit or during run-in; pregnant or lactating women; use of LABA within 1 month prior to visit 1; use &lt; 1 month of oral, intravenous, intramuscular, or intra-articular corticosteroids; use &lt; 2 weeks of leukotriene antagonist, cromolyn, or nedocromil, use of theophylline in &lt; 1 week, use in &lt; 2 weeks of oral or inhaled long-acting <math>\beta_2</math>-agonists or inhaled anticholinergics</p> <p>SETTING: not described</p>
Interventions	<p>LTRA + ICS versus LABA + ICS (stable dose of ICS)</p> <p>DURATION:</p> <p>Run-in period: 2 weeks</p> <p>Intervention period: 48 weeks</p> <p>INTERVENTION GROUP 1</p> <p>LTRA: montelukast 10 mg once daily + fluticasone 125 <math>\mu\text{g}</math> bid via MDI</p> <p>INTERVENTION GROUP 2</p> <p>LABA: salmeterol 50 <math>\mu\text{g}</math> bid, via MDI + fluticasone 125 <math>\mu\text{g}</math> bid via MDI</p> <p>2 inhalers used for combination therapy</p> <p>CO-TREATMENT: not specified</p>
Outcomes	<p>INTENTION-TO-TREAT ANALYSES for patients who received at least one dose of medication</p> <p>Outcomes used at endpoint</p> <p>PULMONARY FUNCTION TESTS:</p> <p>**Change from baseline in AM PEFr; change from baseline in PM PEFr; change from baseline in FEV1</p> <p>SYMPTOM SCORES:</p> <p>Change from baseline DAYTIME symptom scores; change from baseline NIGHTTIME symptom scores</p> <p>EXACERBATIONS</p> <p>Exacerbations requiring systemic steroids</p> <p>FUNCTIONAL STATUS</p> <p>Change from baseline in mean OVERALL use of beta<sub>2</sub>-agonists (puffs/DAY); change from baseline in mean DAYTIME use of beta<sub>2</sub>-agonists (puffs/DAY); change from baseline in mean NIGHT-TIME use of beta<sub>2</sub>-agonists (puffs/DAY); % night-time awakenings</p> <p>INFLAMMATORY MARKERS</p> <p>Not reported</p> <p>ADVERSE EFFECTS</p> <p>Drug related and non-drug related</p> <p>WITHDRAWALS</p> <p>Due to adverse effects reported</p> <p>(** denotes trials primary outcome)</p>

**Ilowite 2004** (Continued)

Notes	Unpublished data Received full disclosure of unpublished data provided by Peter Polos, March 2004 Funded by Merck & Co Confirmation with supportive documents received for methodology and data extraction User-defined number: 48 weeks	
<b>Risk of bias</b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Random sequence generation (selection bias)	Low risk	Randomisation was determined by computer generated allocation schedule (block size 4)
Allocation concealment (selection bias)	Low risk	Centralised, third party randomisation
Blinding (performance bias and detection bias) All outcomes	Low risk	Double-dummy
Incomplete outcome data (attrition bias) Exacerbations	Unclear risk	ITT
Selective reporting (reporting bias)	Low risk	Data available for meta-analysis of primary outcome
Other bias	Low risk	

**Lemanske 2010**

Methods	Crossover study, multicentre study in USA
Participants	INADEQUATELY controlled children on inhaled corticosteroids at baseline BASELINE INHALED STEROID DOSAGE: 100 µg FP ICS per day during run-in RANDOMISED: 182 WITHDRAWALS: 25 AGE in years: mean ± SD 11 ± 3 GENDER (% male) 68% SEVERITY: Mild-to-moderate asthma BASELINE FEV1 (% pred) 98% ALLERGEN TRIGGERS: +ve aeroallergen test 77% +ve perennial allergen test 70%

	<p>ALLERGIC RHINITIS Not reported</p> <p>ASTHMA DURATION 7 years</p> <p>ELIGIBILITY CRITERIA: age 6 to 17 years; physician diagnosed mild to moderate asthma, based on NAEPP criteria; FEV1 predicted &gt;60%; increase in FEV1 &gt;12% predicted or PC20 12.5mg/mL or less</p> <p>During run-in children had to exhibit uncontrolled asthma, defined as one or more of:</p> <ol style="list-style-type: none"> <li>1. diary-reported symptoms (coughing rated as moderate or severe or wheezing rated as mild, moderate, or severe)</li> <li>2. rescue use of reliever medication (two or more puffs per day, or</li> <li>3. peak flows under 80% predicted</li> </ol> <p>EXCLUSION CRITERIA: corticosteroid treatment within 2 weeks (unless ingested nasally in which case at discretion of investigator; current or prior use of medications known to interact with corticosteroids; more than three hospitalizations for asthma in the past year; lung disease other than asthma; significant medical illness other than asthma; history of cataracts, glaucoma, or medical disorder associated with adverse effects related to corticosteroids; uncontrolled gastroesophageal reflux symptoms; significant asthma exacerbation within 2 weeks of Visit 1 or more than 5 courses of systemic corticosteroids in the past year; life-threatening asthma exacerbation requiring intubation, mechanical ventilation, or resulting in a hypoxic seizure in last 5 years; adverse reactions to ICS, LTRA, or LABA preparations; hyposensitization therapy other than an established maintenance regimen (continuous regimen for &gt;3 months); pregnancy or lactation; failure to practice abstinence or use of an acceptable birth control if of child-bearing potential; inability to perform study procedures; refusal to consent to a genotype evaluation; inability to ingest the study drug; evidence that the family may be unreliable or nonadherent, or may move from the clinical center area before trial completion</p> <p>SETTING: not described</p>
Interventions	<p>LTRA + ICS versus LABA + ICS (stable dose of ICS)</p> <p>DURATION: Run-in period: 2-8 weeks Intervention period: 48 weeks (3 x 16 weeks)</p> <p>INTERVENTION GROUP 1 LTRA: montelukast 5 or 10 mg once daily + fluticasone 100 µg bid via DPI</p> <p>INTERVENTION GROUP 2 LABA: salmeterol 50 µg bid, via MDI + fluticasone 100 µg bid via DPI 1 inhaler used for combination therapy</p> <p>CO-TREATMENT: not specified</p>
Outcomes	<p>INTENTION-TO-TREAT ANALYSES No (completers analysed)</p> <p>PULMONARY FUNCTION TESTS: Collected as part of a composite outcome (differential response**): FEV1</p> <p>SYMPTOM SCORES: Collected as part of a composite outcome (differential response**): symptom-free days</p> <p>EXACERBATIONS Collected as part of a composite outcome (differential response**): exacerbations requiring systemic steroids</p> <p>FUNCTIONAL STATUS</p>

Lemanske 2010 (Continued)

	Quality of life (AQLQ) INFLAMMATORY MARKERS: Collected ADVERSE EFFECTS Drug related and non-drug related WITHDRAWALS Stated (** denotes trials primary outcome)	
Notes	Full-text article Funded by National Heart, Lung, and Blood Institute (HL064307, HL064288, HL064295, HL064287, HL064305, and HL064313), the National Institute of Allergy and Infectious Diseases (T32AI007635), and the Clinical Translational Science Award program of the National Center for Research Resources (UL1-RR025011 [Wisconsin], UL1-RR025780 [Colorado], and UL1-RR024992 [St. Louis]) Confirmation of data: not obtained User-defined number: 16 weeks	
<b>Risk of bias</b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Random sequence generation (selection bias)	Low risk	Computer generated randomisation schedule: "The pattern of treatment assignment will utilize the complete set of orthogonal Latin squares..."
Allocation concealment (selection bias)	Low risk	Centralised randomisation. Investigators dialled into server requesting assignment, and received a packet number which related to a medication
Blinding (performance bias and detection bias) All outcomes	Low risk	"The drug assignments were masked with the use of placebo tablets and dummy disk devices that discharged powder without the active drug" '...investigators and the children, along with their caregivers, will not know which treatment is being received during each treatment period.'
Incomplete outcome data (attrition bias) Exacerbations	High risk	Completers analysed (crossover design)
Selective reporting (reporting bias)	Low risk	Primary outcome analysed as events
Other bias	Low risk	

**Nelson 2000**

Methods	Parallel-group study, multicentre trial (39 centres)
Participants	<p>INADEQUATELY controlled participants on inhaled glucocorticoids at baseline</p> <p>BASELINE INHALED STEROID DOSAGE:</p> <p>For the three week run-in period 100 µg twice daily FP (equivalent to 400 µg daily of beclomethasone)</p> <p>RANDOMISED: 447</p> <p>LTRA: 225</p> <p>LABA: 222</p> <p>WITHDRAWALS:</p> <p>LTRA: 30 (13%)</p> <p>LABA: 24 (11%)</p> <p>AGE in years: mean ± SD</p> <p>LTRA: 43 ± 13.7</p> <p>LABA: 40.2 ± 14.4</p> <p>GENDER (% male)</p> <p>LTRA: 40%</p> <p>LABA: 39%</p> <p>SEVERITY</p> <p>Not reported</p> <p>BASELINE FEV1 (% predicted)</p> <p>LTRA: 70.8 ± 0.05 (SEM)</p> <p>LABA: 70.0 ± 0.05</p> <p>ALLERGEN TRIGGERS</p> <p>Not reported</p> <p>ASTHMA DURATION in years: %</p> <p>Under 10 years</p> <p>LTRA: 23%</p> <p>LABA: 24%</p> <p>10 years or more</p> <p>LTRA: 77%</p> <p>LABA: 76%</p> <p>ELIGIBILITY CRITERIA: age ≥15 years; asthma ≥ 6 months; low-moderate dose of ICS for ≥ 1month CFC-BDP: 252-420 µg/day; BUD 400 µg/day; FP 176- 220 µg/day; triamcinolone 600 - 800 µg/day); 50-80% of predicted normal</p> <p>≥12 % increase in FEV1 post-200 µg albuterol;</p> <p>At randomisation: FEV1 50% to 80% of predicted; 1 additional sign of inadequate asthma control in the preceding 7 days:</p> <ol style="list-style-type: none"> <li>1. ≥ 4 puffs/day albuterol</li> <li>2. symptom score ≥2 on a scale of (0-5) for ≥ 3 days</li> <li>3. ≥3 nights waking for asthma</li> </ol> <p>EXCLUSION CRITERIA: pregnant or lactating female patients; life threatening asthma; hospitalised for asthma in the last three months; significant concurrent diseases; &lt;30 days of screening: use of theophylline, other bronchodilators, other leukotriene modifiers, cromolyn or nedocromil</p> <p>SETTING: not specified</p>
Interventions	<p>LTRA + ICS versus LABA + ICS (stable dose of ICS)</p> <p>DURATION:</p> <p>Run-in period: 3 weeks</p>



	<p>Intervention period: 12 weeks  INTERVENTION GROUP 1  LTRA: oral montelukast 10 mg once daily + ICS = FP 100 µg twice daily, via diskus  INTERVENTION GROUP 2  LABA: salmeterol 50 µg twice daily, via Diskus + ICS = FP 100 µg twice daily, via Diskus  1 inhaler used for combination therapy  CO-TREATMENT: none</p>	
Outcomes	<p>Modified INTENTION-TO-TREAT ANALYSES  Outcomes used at endpoint for exacerbations and withdrawals only (not available for continuous values)  PULMONARY FUNCTION TESTS  Change from baseline FEV1; change from baseline in AM PEFr; change from baseline in PM PEFr  SYMPTOM SCORES  Change from baseline OVERALL symptom scores; change from baseline in nighttime awakenings; change in symptom-free days  EXACERBATIONS  Exacerbations requiring hospital admission; exacerbations requiring systemic steroids (data provided)  FUNCTIONAL STATUS  Change from baseline in mean OVERALL use of β2-agonists (puffs/DAY); change in rescue-free days  INFLAMMATORY MARKERS  Not reported  ADVERSE EFFECTS  Included oral candidiasis, sore throat, hoarseness, headache  WITHDRAWALS  Due to adverse effects  Due to poor control  Overall  (reported)  (** denotes primary outcome)</p>	
Notes	<p>Full-text report  Received additional unpublished data provided by Karen Richardson, GSK (July 2003)  Funded by Glaxo Wellcome, study SAS40018  Confirmation of methodology and data extraction received  User-defined order: 12 weeks</p>	
<b><i>Risk of bias</i></b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Random sequence generation (selection bias)	Low risk	Computer generated randomisation schedule
Allocation concealment (selection bias)	Low risk	Numbered coded inhaler/pills supplied by pharmacy

**Nelson 2000** (Continued)

Blinding (performance bias and detection bias) All outcomes	Low risk	Double-dummy
Incomplete outcome data (attrition bias) Exacerbations	Unclear risk	'The primary population for the analyses of demographic/baseline characteristics, efficacy and safety was the Intent-to-Treat (ITT Population), which consisted of all subjects who were randomised to receive study drug.'
Selective reporting (reporting bias)	Low risk	Data available for primary outcome.
Other bias	Low risk	

**Nelson 2001**

Methods	Parallel-group, multicentre trial (54 centres)
Participants	<p>INADEQUATELY controlled adolescent and adult participants on inhaled glucocorticoids at baseline</p> <p>BASELINE INHALED STEROID DOSAGE:</p> <p>Not described</p> <p>RANDOMISED = 429</p> <p>LTRA: 215</p> <p>LABA: 214</p> <p>WITHDRAWALS:</p> <p>LTRA: 18 (8%)</p> <p>LABA: 12 (6%)</p> <p>AGE in years: mean ± SD</p> <p>LTRA: 39.3 ± 13.20</p> <p>LABA: 40.9 ± 13.17</p> <p>GENDER (% male)</p> <p>LTRA: 44%</p> <p>LABA: 44%</p> <p>SEVERITY</p> <p>Not described</p> <p>BASELINE FEV1 (% predicted)</p> <p>LTRA: 65.86 ± 0.58 (SEM)</p> <p>LABA: 66.62 ± 0.58</p> <p>ALLERGEN TRIGGERS</p> <p>Not reported</p> <p>ASTHMA DURATION in years: %</p> <p>Under 10 years</p> <p>LTRA: 24%</p> <p>LABA: 24%</p> <p>10 years or over</p> <p>LTRA: 76%</p>

	<p>LABA: 76%</p> <p>ELIGIBILITY CRITERIA: age <math>\geq</math>12 years; asthma <math>\geq</math> 6 months; FEV1 50-80% of predicted normal; <math>\geq</math>12 % increase in FEV1 post 200 <math>\mu</math>g albuterol</p> <p>Following 7-14 day run-in</p> <p>In the six days prior to randomisation one or more of the following:</p> <ol style="list-style-type: none"> <li>1. an average of 4 or more puffs/day of albuterol</li> <li>2. a symptom score of 2 or more on at least 2 days for any of the asthma symptom categories</li> <li>3. at least one night when the patient woke due to asthma</li> <li>4. two or more days where pm to am PEF variation was 20% or more</li> </ol> <p>* intake of daily inhaled steroids prior to randomisation is NOT specified as inclusion criteria*</p> <p>Patients also must have been using an oral or inhaled SABA for 6 weeks</p> <p>EXCLUSION CRITERIA: not described</p> <p>SETTING: clinical centres</p>
Interventions	<p>LTRA + ICS versus LABA + ICS (stable dose of ICS)</p> <p>DURATION:</p> <p>Run-in period: 1-2 weeks</p> <p>Intervention period: 4 weeks</p> <p>INTERVENTION GROUP 1</p> <p>LTRA: zafirlukast 20 mg twice daily + ICS: constant dose of existing ICS medication</p> <p>INTERVENTION GROUP 2</p> <p>LABA: salmeterol 42 <math>\mu</math>g, 2 puffs twice daily via MDI + ICS = constant dose of existing ICS medication</p> <p>2 inhalers used for combination therapy</p> <p>CO-TREATMENT:</p> <p>Theophylline or other medications that could potentially interact with study treatment not allowed; Albuterol inhalers provided for use on an as needed basis but all other bronchodilators not permitted; antihistamines, nasal decongestants and intranasal medications for rhinitis were permitted</p>
Outcomes	<p>INTENTION-TO-TREAT ANALYSES: outcomes used at endpoint</p> <p>PULMONARY FUNCTION TESTS</p> <p>Change from baseline FEV1; **change from baseline in am PEF; change from baseline in PM PEF; change in PEF variability</p> <p>SYMPTOM SCORES</p> <p>Change from baseline DAYTIME symptom scores; change from baseline NIGHT-TIME symptom scores; change in symptom-free days; patient satisfaction</p> <p>EXACERBATIONS</p> <p>Exacerbations requiring systemic steroids; exacerbations defined as any worsening of asthma symptoms requiring a change in the patients asthma therapy other than increased use of supplemental albuterol. Patients who experienced an exacerbation were withdrawn from the study</p> <p>FUNCTIONAL STATUS</p> <p>Change from baseline in mean DAYTIME use of B2-agonists (/DAY); change from baseline in mean NIGHT-TIME use of <math>\beta</math>2-agonists (/DAY); change in rescue-free days; change/absolute in rescue-free nights; change in quality of life; change in night-time awakenings</p>

**Nelson 2001** (Continued)

	<p>INFLAMMATORY MARKERS Not reported</p> <p>ADVERSE EFFECTS Upper respiratory tract infection, headache, nausea</p> <p>WITHDRAWALS Due to adverse effects Due to poor control</p> <p>Overall (reported) (** denotes primary outcome)</p>
--	--

Notes	<p>Full-text report Received additional unpublished data provided by Karen Richardson, GSK Funded by Glaxo Wellcome, protocols SLGA5024 &amp; SLGA5025 Confirmation of methodology and data extraction received User-defined order: 4 weeks</p>
-------	---

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	See <a href="#">Appendix 1</a>
Allocation concealment (selection bias)	Low risk	See <a href="#">Appendix 1</a>
Blinding (performance bias and detection bias) All outcomes	Low risk	Double-dummy
Incomplete outcome data (attrition bias) Exacerbations	Unclear risk	'The ITT population included all subjects who were randomized to study drug.'
Selective reporting (reporting bias)	Low risk	Data available for primary outcome
Other bias	Low risk	

**Nsouli 2001**

Methods	Unclear if parallel-group or crossover
Participants	<p>INADEQUATELY controlled participants on inhaled glucocorticoids at baseline</p> <p>BASELINE INHALED STEROID DOSAGE: FP 100-300 or CFC BDP 200-550 or BUD 200-400 or flunisolide 500-1000 or triamcinolone 400-1000</p> <p>RANDOMISED: 30 LTRA: unknown LABA: unknown</p>

**Nsouli 2001** (Continued)

	<p>WITHDRAWALS Not described AGE in years: mean ± SD Not described GENDER (% male) Not described SEVERITY Not described BASELINE FEV1 (L OR % PRED) Not described ALLERGEN TRIGGERS Not described ASTHMA DURATION in years: mean ± SD Not described ELIGIBILITY CRITERIA Not described EXCLUSION CRITERIA Not described SETTING Not described</p>
Interventions	<p>LTRA + ICS versus LABA + ICS (stable dose of ICS) DURATION: Run-in period: not described Intervention period: 8 weeks INTERVENTION GROUP 1 LTRA: montelukast 10 mg QD pm + ICS (low dose ICS) INTERVENTION GROUP 2 LABA: salmeterol 50 µg BID + ICS (low dose ICS) 2 inhalers used for combination therapy CO-TREATMENT Not reported</p>
Outcomes	<p>ANALYSES: not reported PULMONARY FUNCTION TESTS FEV1 and FEF25-75 SYMPTOM SCORES None described EXACERBATIONS Not described FUNCTIONAL STATUS Quality of life INFLAMMATORY MARKERS Not described ADVERSE EFFECTS Not described WITHDRAWALS Not described</p>

**Nsouli 2001** (Continued)

Notes	Abstract Funding of study unknown Confirmation of methodology and data extraction not obtained User-defined order: 8 weeks	
<b>Risk of bias</b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Random sequence generation (selection bias)	Unclear risk	Described as randomised; other information not available
Allocation concealment (selection bias)	Unclear risk	Information not available
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Information not available
Incomplete outcome data (attrition bias) Exacerbations	Unclear risk	Information not available
Selective reporting (reporting bias)	Unclear risk	Cannot establish this reliably
Other bias	Unclear risk	Cannot establish this reliably

**Pavord 2007**

Methods	Parallel-group, multicentre study in the UK
Participants	<p>BASELINE INHALED STEROID DOSE: up to 400 µg (which BDP or HFA) BDP equivalent            N SCREENED: 132            N RANDOMISED: 66            N COMPLETED: 54            M = 34            F = 32            MEAN AGE: 35            BASELINE DETAILS: PEF 417 L/min; FEV1 predicted 76%            INCLUSION CRITERIA: 18 to 50 years, non-smokers, receiving a stable dose of up to 400 µg of beclomethasone dipropionate (presumed CFC-BDP equivalent) a day or equivalent ICS, requiring further therapy; likelihood of compliance with the protocol requirements and ability to use an Accuhaler and mini-Wright peak flow meter. Post-run in: baseline FEV1 61 to 85% predicted; PC20 &lt; 8 mg/ml with methacholine challenge; at least one of: diary card recording of symptoms on &gt; 4 of the last seven days of the run-in period; recorded use of relief medication on &gt;2 different days during the last seven days of the run-in period; period variation in PEF of &gt;10% over last seven days of run in            EXCLUSION: additional medication other than ICS, SABA or OCS in previous 3</p>

**Pavord 2007** (Continued)

	months; acute respiratory infection/exacerbation of asthma within 4 weeks of screening; recent or significant smoking history; pregnancy/lactation; inadequate contraceptive methods in women of child-bearing age	
Interventions	1. Combination fluticasone/salmeterol 100/50 µg B.I.D 2. Fluticasone 100mcg B.I.D. plus montelukast 10mg O.D. RUN-IN PERIOD: 2 weeks TREATMENT PERIOD: 12 weeks	
Outcomes	INTENTION TO TREAT ANALYSES: no PULMONARY FUNCTION TEST: FEV1; am PEF; pm PEF SYMPTOMS: Percentages of symptom-free days and nights FUNCTIONAL STATUS: Rescue medication use INFLAMMATORY MARKERS: Neutrophils, eosinophils, macrophages, lymphocytes	
Notes		
<b><i>Risk of bias</i></b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Random sequence generation (selection bias)	Low risk	'...consecutively randomised according to a pre-defined randomisation list...'
Allocation concealment (selection bias)	Low risk	'Treatment allocation was concealed from the subject, pharmacist, and investigator.'
Blinding (performance bias and detection bias) All outcomes	Low risk	Double-dummy design employed
Incomplete outcome data (attrition bias) Exacerbations	Unclear risk	'All summaries and analyses are for the intention-to-treat population (all subjects receiving at least one dose of the study drug) . No imputations were performed for missing data. Therefore if data were missing for either baseline or one of the time points, it was not possible to calculate a change from baseline. However, all available data have been used for relevant summaries.' Some imbalance between the treatment groups in terms of withdrawal, although denominators for lung function outcomes show N randomised

**Pavord 2007** (Continued)

Selective reporting (reporting bias)	Low risk	The outcomes identified as being those of interest were presented in the article. Data on exacerbations were not identified as being an outcome of interest to the investigators
Other bias	Low risk	

**Ringdal 2003**

Methods	Parallel-group, multicentre trial (114 centres in 19 countries)
Participants	<p>INADEQUATELY controlled participants on 'moderate or high doses' of inhaled glucocorticoids at baseline</p> <p>BASELINE INHALED STEROID DOSAGE: 800 µg or more of beclomethasone-equivalent/day (moderate or high dose)</p> <p>RANDOMISED: 806, 81 excluded due to not meeting eligibility criteria for randomisation</p> <p>LTRA: 369 LABA: 356</p> <p>WITHDRAWALS: LTRA: 37 (10%) LABA: 19 (5%)</p> <p>AGE in years: mean ± SD LTRA: 43 (14-79) LABA: 43 (15-75)</p> <p>GENDER (% male) LTRA: 45% LABA: 46%</p> <p>SEVERITY: MODERATE PERSISTENT asthma</p> <p>BASELINE FEV1 (% PRED) LTRA: 74.3 ± 16.1 LABA: 75.8 ± 15.3</p> <p>ALLERGEN TRIGGERS Not described</p> <p>ASTHMA DURATION in years: mean ± SD Not described</p> <p>ELIGIBILITY CRITERIA: age ≥15 years; moderate persistent asthma as per the ATS and NAEP Report 2; using inhaled corticosteroids at moderate or high dose ( 400-1000 µg/day of CFC-BDP, BUD or flunisolide; or 200-500 µg/day of FP) for at least 4 weeks; history of reversible airway obstruction; ≥15% change in FEV1 after 800 µg of salbutamol;</p> <p>At end of run-in: Mean PEF of 50% to &lt; 85% of value in clinic after 400 µg of salbutamol; cumulative symptom score of ≥8 in past 7 days or ≥4 of the last 7 days of run-in</p> <p>EXCLUSION CRITERIA: Recent change in asthma medication; respiratory tract infection or admission for asthma in &lt; 4 weeks; intake of oral, depot, or parenteral corticosteroids in &lt; 4 weeks or ≥2 occasions in past 12 weeks; cigarette smoking ≥10 pack</p>



Ringdal 2003 (Continued)

	year; pregnancy or lactating women or those likely to become pregnant during study; FEV1 < 50%
Interventions	<p>LTRA + ICS versus LABA + ICS (stable dose of ICS)</p> <p>DURATION:</p> <p>Run-in period: 4 weeks</p> <p>Intervention period: 12 weeks plus a 2-week follow up</p> <p>INTERVENTION GROUP 1</p> <p>LTRA: montelukast 10 mg/day + ICS: FP 100 ug twice daily, via diskus</p> <p>INTERVENTION GROUP 2</p> <p>LABA: salmeterol 50 ug bid + ICS: FP 100 µg twice daily, via Diskus</p> <p>1 inhaler used for combination therapy.</p> <p>CO-TREATMENT:</p> <p>Salbutamol provided for relief of symptoms, no other SABAs permitted</p> <p>Other oral, parenteral or depot CS not allowed except where documented for treatment of exacerbations. Other existing asthma treatment allowed at constant dose</p>
Outcomes	<p>INTENTION-TO-TREAT ANALYSES: yes, but excluding those who were incorrectly randomised because they failed major inclusion criteria; outcomes used at endpoint</p> <p>PULMONARY FUNCTION TESTS</p> <p>Change from baseline in FEV1; **change from baseline in am PEFr; change from baseline in pm PEFr</p> <p>SYMPTOM SCORES</p> <p>Change in total symptom score; % change in symptom-free days and nights; patient satisfaction; physician assessment of effectiveness; compliance with study treatment</p> <p>EXACERBATIONS</p> <p>Exacerbations requiring systemic steroids; exacerbations requiring hospital admission; exacerbations defined as MILD: deterioration in asthma requiring a clinically relevant increase in salbutamol use defined as more than 3 additional inhalations per 24 hour period with respect to baseline for more than 2 consecutive days. MODERATE: requiring oral CS and/or antibiotics. SEVERE: requiring hospitalisation</p> <p>FUNCTIONAL STATUS</p> <p>% rescue-free days; % change in use of rescue medication (puffs/day); % symptom-free days</p> <p>INFLAMMATORY MARKERS</p> <p>Not reported</p> <p>ADVERSE EFFECTS</p> <p>Serious adverse events, headache, oral thrush</p> <p>WITHDRAWALS</p> <p>Due to adverse effects</p> <p>Overall</p> <p>(reported)</p> <p>(** denotes primary outcome)</p>
Notes	<p>Full-text report</p> <p>Received additional unpublished data provided by Karen Richardson, GSK</p> <p>Funded by Glaxo SmithKline, study SAS40015</p> <p>Confirmation of methodology and data extraction received</p> <p>User-defined order: 12 weeks</p>

Ringdal 2003 (Continued)

<b>Risk of bias</b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Random sequence generation (selection bias)	Low risk	Computer generated randomisation schedule
Allocation concealment (selection bias)	Low risk	Numbered coded inhalers/pills supplied by pharmacy
Blinding (performance bias and detection bias) All outcomes	Low risk	Double-dummy
Incomplete outcome data (attrition bias) Exacerbations	Unclear risk	'The ITT population (SFC: 404 subjects; FP+montelukast: 401 subjects), which included all randomised subjects, was used for adverse event and concurrent medication data. The modified ITT population (SFC: 356 subjects; FP+montelukast: 369 subjects), which excluded randomised subjects who did not receive treatment as well as subjects who were incorrectly randomised, was used for efficacy, demography and baseline characteristics data.'
Selective reporting (reporting bias)	Low risk	Data available for primary outcome
Other bias	Low risk	

**SAM40030**

Methods	Parallel-group, multicentre trial
Participants	<p>INADEQUATELY controlled participants on inhaled glucocorticoids at baseline</p> <p>BASELINE INHALED STEROID DOSAGE:  <math>\leq 400 \mu\text{g}</math> of BDP/day or equivalent</p> <p>RANDOMISED: 66            LTRA: 33            LABA: 33</p> <p>WITHDRAWALS:            LTRA: 4/33 (12.12%)            LABA: 9/33 (27.27%)</p> <p>AGE in years: mean <math>\pm</math> SD            35 years</p> <p>GENDER (% male)            52%</p> <p>SEVERITY:</p>

	<p>Mild-moderate          BASELINE FEV1 (% pred)          76%          ALLERGEN TRIGGERS:          Not reported          ALLERGIC RHINITIS:          Not reported          ASTHMA DURATION in years          Not reported          ELIGIBILITY CRITERIA: age 18-50 years; confirmed diagnosis of asthma          -have received constant daily dose of up to 400 mcg of inhaled CFC-BDP or equivalent in the last 4 weeks          During run-in period: FEV1 61-85% of predicted; <math>\geq 20\%</math> fall in FEV1 on methacholine challenge; symptom score of <math>\geq 1</math> on 4/7 days; use of rescue <math>\beta_2</math>-agonists on <math>\geq 2/7</math> days; <math>\geq 10\%</math> period variation in PEFR over the last 7 days of run-in          EXCLUSION CRITERIA: intake of asthma medication other than inhaled steroids or short-acting <math>\beta_2</math>-agonists in the past 4 weeks; oral steroids in the past 3 months; respiratory infection within 4 weeks; hospital admission in past 12 months; evidence of underlying chronic lung disease; smoking history of 10 pack-years or more; pregnant or lactating women; other chronic diseases; use of LABA or LTRAs within 1 month prior to visit 1; known intolerance to study drugs or inhaled lactose          SETTING: not described</p>
Interventions	<p>LTRA + ICS versus LABA + ICS (stable dose of ICS)          DURATION:          Run-in period: not reported          Intervention period: 12 weeks          INTERVENTION GROUP 1          LTRA: montelukast 10 mg die + fluticasone (Flixotide) 100 bid via MDI          INTERVENTION GROUP 2          LABA: salmeterol 50 <math>\mu</math>g bid via MDI + fluticasone 100 <math>\mu</math>g bid          (in single MDI: Seretide 50)          1 inhaler used for combination therapy          CO-TREATMENT: not specified</p>
Outcomes	<p>Modified INTENTION-TO-TREAT ANALYSES          Outcomes used at 12 weeks or endpoint          PULMONARY FUNCTION TESTS          Change from baseline in AM PEFR (L/min); change from baseline in PM PEFR (L/min); change from baseline in FEV1 (L)          SYMPTOMS (reported as medians)          Change in symptom-free days; change in symptom-free nights          EXACERBATIONS REQUIRING SYSTEMIC STEROIDS          Not reported          FUNCTIONAL STATUS (reported as medians):          Change from baseline in mean DAYTIME use of <math>\beta_2</math>-agonists; change from baseline in mean NIGHT-TIME use of <math>\beta_2</math>-agonists; change in rescue-free days; change in night-time awakenings          INFLAMMATORY MARKERS (reported as medians):</p>

**SAM40030** (Continued)

	Sputum **eosinophils, neutrophils, total cell counts, C-LT, histamine, IL-8 ADVERSE EFFECTS Reported WITHDRAWALS Reported (** denotes primary outcome)
Notes	Unpublished data Received full disclosure of unpublished data provided by Karen Richardson, GSK (July 2003) Funded by GSK : study #40030 Confirmation with supportive documents received for methodology and data extraction obtained from Karen Richardson, GSK, UK

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computer generated randomisation schedule
Allocation concealment (selection bias)	Low risk	Opaque consecutive envelopes containing assessment
Blinding (performance bias and detection bias) All outcomes	Low risk	Identical placebo
Incomplete outcome data (attrition bias) Exacerbations	Unclear risk	'The intention-to-treat (ITT) sample was used for the efficacy and safety analyses. This consisted of all subjects randomised to and receiving at least one dose of study medication.'
Selective reporting (reporting bias)	Unclear risk	Not clear whether OCS exacerbations collected in the study
Other bias	Low risk	

**SD-004-0216**

Methods	Parallel-group study; multicentre trial (49 centres in 6 countries)
Participants	INADEQUATELY controlled participants on inhaled glucocorticoids at baseline BASELINE INHALED STEROID DOSAGE: 400-1000 µg of ICS (not specified)/day RANDOMISED: 236 LTRA: 118 LABA: 118 WITHDRAWALS:

	<p>LTRA: 19/118 (16%)  LABA: 12/118 (10%)  AGE in years: mean <math>\pm</math> SD  LTRA: 38.3 <math>\pm</math> NS  LABA: 38.1 <math>\pm</math> NS  GENDER (% male)  LTRA: 47 %  LABA: 49%  SEVERITY:  Not described  BASELINE FEV1 (% predicted)  LTRA: 72.03 <math>\pm</math> SD  LABA: 69.71 <math>\pm</math> SD  ALLERGEN TRIGGERS  Not reported  ALLERGIC RHINITIS  Not reported  ASTHMA DURATION in years  LTRA: 10.1 <math>\pm</math> SD  LABA: 12.1 <math>\pm</math> SD  ELIGIBILITY CRITERIA: Male or female outpatient; age 12-70 years; treated for at least 3 mo with 400-1000 <math>\mu</math>g of inhaled glucocorticoids (presumed CFC-BDP equivalent) ; asthma diagnosis; FEV1 50-80% predicted; <math>\geq</math>12% reversibility in FEV1 and at least 200 mL after inhalation of 1 mg of terbutaline; smoking history of <math>\leq</math>10 pack years  In the 7 days prior to randomisation one or more of the following:</p> <ol style="list-style-type: none"> <li>1. a symptom score of <math>\geq</math>1 on 4 days</li> <li>2. awakening on <math>\geq</math> 1 night due to asthma symptoms</li> <li>3. use of <math>\beta</math>2-agonists <math>\geq</math>10 puffs as weekly mean</li> </ol> <p>EXCLUSION CRITERIA: respiratory infection; clinical obstructive pulmonary disease, or pulmonary dysfunction other than asthma; pregnant or lactating women; use of LABA within 1 month prior to visit 1; previous use ever of a leukotriene antagonist; known intolerance to study drugs or inhaled lactose  SETTING: not described</p>
Interventions	<p>LTRA + ICS versus LABA + ICS (stable dose of ICS)  DURATION:  Run-in period: 10-14 days  Intervention period: 8 weeks  INTERVENTION GROUP 1  LTRA: zafirlukast 20 mg bid + budesonide 200 <math>\mu</math>g bid via turbuhaler  INTERVENTION GROUP 2  LABA: formoterol 12 <math>\mu</math>g bid, via turbuhaler + budesonide 200 <math>\mu</math>g bid via turbuhaler  2 inhalers used for combination therapy  CO-TREATMENT: not specified</p>
Outcomes	<p>Modified INTENTION-TO-TREAT ANALYSES for patients who received at least one dose of medication. Outcomes used at endpoint  PULMONARY FUNCTION TESTS  **Change from baseline in am PEFR; change from baseline in pm PEFR; change from baseline in FEV1</p>

SD-004-0216 (Continued)

	<p>SYMPTOM SCORES Change from baseline DAY-TIME symptom scores; change from baseline NIGHT-TIME symptom scores</p> <p>EXACERBATIONS Exacerbations requiring systemic steroids</p> <p>FUNCTIONAL STATUS Change from baseline in mean OVERALL use of <math>\beta</math>2-agonists (puffs/DAY); change from baseline in mean DAYTIME use of <math>\beta</math>2-agonists (puffs/DAY); change from baseline in mean NIGHT-TIME use of <math>\beta</math>2-agonists (puffs/DAY); % night-time awakenings</p> <p>INFLAMMATORY MARKERS Not reported</p> <p>ADVERSE EFFECTS Drug related and non-drug related</p> <p>WITHDRAWALS Due to adverse effects reported (** denotes primary outcome)</p>
--	---

Notes	<p>Unpublished data Received full disclosure of unpublished data provided by Roger Metcalf, AstraZeneca, July 2003 Funded by Astra Zeneca. Report #SD-004CR-0216 Confirmation with supportive documents received for methodology and data extraction User-defined number: 12 weeks</p>
-------	--

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Described as randomised; no other information presented
Allocation concealment (selection bias)	Low risk	Opaque consecutive numbered envelopes containing assignment
Blinding (performance bias and detection bias) All outcomes	Low risk	Double-dummy
Incomplete outcome data (attrition bias) Exacerbations	Unclear risk	Analysis described as modified
Selective reporting (reporting bias)	Unclear risk	Not clear whether the study collected information on exacerbations treated with OCS
Other bias	Low risk	

**Storms 2004**

Methods	Parallel-group; multicentre study (16 centres in USA)
Participants	<p>INADEQUATELY controlled participants on inhaled glucocorticoids and SABA prn with history of EIB at baseline</p> <p>BASELINE INHALED STEROID DOSAGE</p> <p>Not reported</p> <p>RANDOMISED: 78</p> <p>LTRA: 39</p> <p>LABA: 39</p> <p>WITHDRAWALS</p> <p>LTRA: 0 (0%); LABA: 2 (5%)</p> <p>AGE in years: mean:</p> <p>LTRA: 33.3</p> <p>LABA: 30</p> <p>GENDER (% male):</p> <p>LTRA: 29.2</p> <p>LABA: 41</p> <p>SEVERITY</p> <p>Not described</p> <p>BASELINE % PRED FEV1 (L)</p> <p>LTRA: 87.5</p> <p>LABA: 88.1</p> <p>ALLERGIC RHINITIS (%)</p> <p>Not reported</p> <p>ALLERGEN TRIGGERS</p> <p>Not reported</p> <p>ASTHMA DURATION in years: mean ± SD:</p> <p>LTRA: 17.4 ±11.1</p> <p>LABA: 19.7 ±12</p> <p>ELIGIBILITY CRITERIA: age 15-45 years with one year history of asthma; uncontrolled asthma on ICS for at least 2 months; treatment at randomisation with only SABA and ICS; history of EIB (15% drop in FEV1 on ICS, 20% if not on ICS); resting FEV1 ≥70% predicted; ≥12% increase in baseline FEV1 post-SABA; requirement for SABA on ≥3 days of last week of run-in period</p> <p>EXCLUSION CRITERIA: respiratory infection within last 3 weeks and emergency asthma care in previous 3 months; systemic corticosteroids in previous month; patients were required to stop an anti-asthma medication with the exception of ICS two weeks before first study visit; participants requiring oral steroids during the study were withdrawn</p>
Interventions	<p>LTRA + ICS versus LABA + ICS (stable dose of ICS)</p> <p>DURATION:</p> <p>Run-in Period: 1-2 weeks</p> <p>Intervention Period: 4 weeks</p> <p>INTERVENTION GROUP 1</p> <p>LTRA: montelukast @ 10 mg/day p.o.+ placebo salmeterol inhaler + FP 100 µg bid, via Diskus</p> <p>INTERVENTION GROUP 2</p> <p>LABA: salmeterol 50 µg bid via MDI + montelukast placebo + FP 100 µg bid, via Diskus (separate inhalers)</p>

Storms 2004 (Continued)

	CO-TREATMENT: SABA prn
Outcomes	<p>INTENTION-TO-TREAT ANALYSES - outcomes used at endpoint or 4 weeks</p> <p>PULMONARY FUNCTION TESTS</p> <p>**Challenge FEV1 % predicted; absolute FEV1 % predicted; fall in FEV1 post-exercise (%); rescue bronchodilation</p> <p>SYMPTOM SCORES</p> <p>Clinic exercise assessment score</p> <p>EXACERBATIONS</p> <p>None occurred during the study (requirement for OCS)</p> <p>FUNCTIONAL STATUS</p> <p>Not reported</p> <p>INFLAMMATORY MARKERS</p> <p>Not reported</p> <p>ADVERSE EFFECTS</p> <p>Not reported</p> <p>WITHDRAWALS</p> <p>Reported</p> <p>Due to adverse events: reported</p> <p>Due to poor control: not reported</p> <p>Overall: reported</p> <p>(** denotes primary outcome)</p>
Notes	<p>Full-text report</p> <p>Funded by Merck</p> <p>User-defined number: 4 weeks</p>

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computer-generated randomisation schedule
Allocation concealment (selection bias)	Unclear risk	Information not available
Blinding (performance bias and detection bias) All outcomes	Low risk	Double-dummy LTRA and LABA
Incomplete outcome data (attrition bias) Exacerbations	Low risk	'A modified intention-to-treat approach was used for efficacy analyses. For FEV1, all randomized patients who had challenge-rescue evaluations at baseline and during treatment were eligible for analyses. There was no imputation of missing values, and prior values were not carried forward.'



**Storms 2004** (Continued)

Selective reporting (reporting bias)	Low risk	No exacerbations occurred during the study
Other bias	Low risk	

BDP: beclomethasone; DPI: dry powder inhaler; FEV1: forced expiratory volume in one second; FP: fluticasone; GSK: GlaxoSmithKline; ICS: inhaled corticosteroids; LABA: long-acting beta-agonist; LTRA: leukotriene receptor antagonist; MDI: metered dose inhaler; PEF: peak expiratory flow; challenge FEV1 % predicted: FEV1 measured post-SABA after 6 minutes exercise on a treadmill exacerbating heart rate to 80-90% of individual's predicted maximum.

**Characteristics of excluded studies** [ordered by study ID]

Study	Reason for exclusion
Adinoff 1998	One of the interventions was not LTRA + ICS
Anon 1999	Not an RCT - Montelukast vs. zafirlukast review
Anon 2000	Not an RCT (review)
Anon 2001	Not an RCT (review)
Barnes 1997	Not an RCT (review)
Becker 2000	Not an RCT (Review of montelukast)
Bergmann 2004	One of the tested interventions was not daily LTRA as add-on to inhaled glucocorticoid
Bleecker 2006	Combined analysis of two combination therapy trials versus anti-leukotriene agent alone
Borker 2005	No ICS co-treatment in both groups
Brabson 2002	No co-intervention with ICS
Buchvald 2003	Study duration was less than 28 days.
Caffey 2005	No ICS co-treatment in both groups
Calhoun 2001	Non permitted drugs: study compared montelukast vs. placebo with both group receiving ICS and LABA
Cash 2001	Not an RCT - Commentary on a previously published trial.
Chopra 2005	Comparison between two different LABA + ICS combinations

(Continued)

Chuchalin 2002	One of the interventions was not LTRA + ICS
Currie 2002	No systematic co-treatment with ICS
Currie 2003a	Non permitted drug : salmeterol in both groups
Currie 2003b	LTRA in both groups
Currie 2003c	Duration of intervention <30 days
Davis 2001	No co-treatment with ICS and LTRA
Dekhuijzen 2002	Not an RCT but a review article
Delaronde 2005	Intervention is educational (not drug)
Dempsey 2000	Single dose intervention (not > 28 days)
Deykin 2007	Comparison of MON/SAL with FP/SAL
Dicpinigaitis 2002	No systematic co-treatment with ICS
Donohue 2001	Review of combination therapies
Dorinsky 2001	No ICS used
Dorinsky 2002	One of the interventions was not LTRA + ICS
Dorinsky 2002a	One of the tested interventions was not daily LTRA as add-on to inhaled glucocorticoid (no ICS in LTRA group)
Dorinsky 2004	One of the tested interventions was not daily LTRA as add-on to inhaled glucocorticoid (no ICS in LTRA group)
Dunn 2001	Review of zafirlukast
Edelman 2000	No co-intervention with ICS
Edin 2002	One of the interventions was not LTRA + ICS
Eliraz 2001	No co-treatment with LTRA - Compares two dry powder inhalers
Eliraz 2002	One of the interventions was not LTRA + ICS
Everden 2002	One of the interventions was not LTRA + ICS
Gabrijelcic 2004	One of the tested interventions was not daily LTRA as add-on to inhaled glucocorticoid

(Continued)

Giannini 2002	One of the interventions was not LTRA + ICS
Grzelewska 2003	One of the tested interventions was not daily LTRA as add-on to inhaled glucocorticoid
Gupta 2007	Study assessed LTRAs in addition to LABAs.
Havlucu 2005	Not an RCT
Horwitz 1998	Not an RCT (Review)
Houghton 2004	Comparison of propellants in formoterol - no ICS in both groups
Inouhe 2007	Single dose study protocol
Jarvis 1998	Not an RCT (Review of zafirlukast)
Jarvis 1999	Not an RCT but a review article on Zafirlukast.
Jenkins 2005	LTRA and LABA not compared as add on to ICS
Jonsson 2004	One of the tested interventions was not daily LTRA as add-on to inhaled glucocorticoid
Kalberg 1999	Retrospective data analysis, not an RCT
Kanniess 2002	No systematic co-treatment with ICS
Kanniess 2002b	One of the interventions was not LABA + ICS
Karaman 2007	No prior treatment with ICS.
Kardos 2001	One of the interventions was not LABA + ICS
Keith 2009	Observational study
Kemp 1998	Not an RCT (Review)
Knorr 2001	No consistent co-tx with ICS in all patients (Montelukast vs placebo)
Koenig 2008	Study compared LABA and LTRA without background ICS in either group
Kohrogi 1999	Not an RCT (before and after study)
Laviolette 1999	One of interventions is not LABA + ICS
Lazarus 2001	One of interventions is not LTRA + ICS
Lee 2004	No LTRA and No LABA

(Continued)

Lee 2005	RCT testing two types of ICS
Leflein 2002	No systematic co-treatment with ICS
Lipworth 2000	Intervention < 28 days (1 week only)
Liu 1996	No consistent co-treatment with ICS (Zileuton vs. placebo as add-on therapy to ICS)
LOCCS	Comparison of Combination therapy with LRTA alone.
Maspero 2008	Study compared LABA and ICS with LTRA alone.
McCarthy 2002	One of the interventions was not LTRA + ICS
Meltzer 2002	No co-treatment with inhaled corticosteroids
Miraglia del Giudice 2007	No prior ICS treatment.
Mitchell 2005	Intervention is educational (not drug)
Molitor 2005	One of the interventions not LTRA
Naedele-Risha 2001	Not a RCT, review of LABA+ICS therapy
Nathan 2000	Good review of add-on therapy to ICS. Not an RCT.
Nathan 2001b	Not a RCT, review of antileukotriene agents
Nathan 2005	No direct comparison between LABA and LTRA
Nelson 2004	Both treatment groups received FP and Salmeterol (LTRA tested as add-on to LABA)
O'Sullivan 2003	One of the interventions was not LABA + ICS
Ohbayashi 2009	Investigation of addition of anti-leukotriene to combination inhaled steroid and long-acting beta-agonist
Ollendorf 2000	Not an RCT, but an economic evaluation
Oppenheimer 2008	Study assessed addition of anti-leukotriene (montelukast) in addition to combination LABA and ICS in asthma
Ortega-Cisneros 1998	No leukotriene antagonists used in intervention
Paterson 1999	No systematic co-treatment with ICS
Pearlman 2002	No consistent co-tx with ICS (FP + S vs Montelukast alone)

(Continued)

Perez 2000	Not RCT - no control group, all patients treated with montelukast
Peroni 2002	Short duration < 28 days
Peroni 2005	Inadequate duration.
Petermann 2004	Review article
Plaza 2005	Intervention is educational (not drug)
Price 2003	One of the interventions was not LABA + ICS
Riccioni 2002	No systematic co-treatment with ICS
Rickard 1998	No systematic co-treatment with ICS
Rosenthal 2003	One of the interventions is not LTRA + ICS
SAS40036	LTRA administered without an ICS.
SAS40037	LTRA administered without an ICS.
SAS40066	LTRA administered without an ICS.
Serrier 2003	One of the interventions is not LTRA + ICS
Sheth 2002	Second report - cost effectiveness analyses
Sims 2003	Intervention < 28 days
Smith 1998	Not an RCT (Review)
Sorkness 2007	LTRA administered without an ICS.
Stanford 2003	LTRA administered without an ICS.
Stelmach 2001	No consistent co-intervention with ICS (RCT of ICS vs. LABA vs. LTRA )
Stelmach 2002	No consistent co-intervention with ICS (RCT of ICS vs. LABA vs. LTRA vs. nedocromil )
Stelmach 2002a	No co-intervention with ICS
Stelmach 2007	Participants were all on combination therapy ICS + LABA prior to enrollment and all controller medication was withdrawn for the 4-week run-in period. Neither before or during the run-in were the participants on ICS alone prior to randomisation
Stelmach 2008	Participants were all on combination therapy ICS with either LABA or LTRA prior to enrollment and were removed from all controller medications for the 4-week run-in period; consequently they were not on ICS alone prior to enrollment

(Continued)

Stempel 1998	Not an RCT (Review)
Stempel 2002	Not an RCT (Review)
Stevenson 2005	No LTRA or LABA given.
Terzano 2001	One of the interventions is not LTRA + ICS
Thien 2000	Not an RCT (Review)
Tolley 2002	One of the interventions was not LTRA + ICS
Vaquerizo 2003	One of the interventions was not LABA + ICS
Volovitz 1999	No consistent co-intervention with ICS in all patients (Montelukast vs. beclomethasone )
Warner 2001	Not an RCT (Review)
Wilson 1999	Only 14 days intervention (not >=28 days)
Wilson 2001	Only 14 days intervention (not >= 28 days)
Wytrychowski 2001	Not an RCT - controlled study
Yurdakul 2002	Not truly randomised as eligible patients were allocated to each treatment group according to their application month to hospital (consecutive allocation not random)
Zarkovic 1998	One of the interventions was not LTRA + ICS
Zimmerman 2002	One of the interventions was not LTRA + ICS

### Characteristics of ongoing studies [ordered by study ID]

#### Fardon 2002

Trial name or title	
Methods	
Participants	
Interventions	
Outcomes	
Starting date	

**Fardon 2002** (Continued)

Contact information	
Notes	

**Fardon 2004**

Trial name or title	
Methods	
Participants	
Interventions	
Outcomes	
Starting date	
Contact information	
Notes	

**Price 2001**

Trial name or title	
Methods	
Participants	
Interventions	
Outcomes	
Starting date	
Contact information	Professor D Price (University of East Anglia, Norwich, NR4 7TJ)
Notes	ISSN: N0254145816.

**Ruggins 2003**

Trial name or title	
Methods	
Participants	

**Ruggins 2003** (Continued)

Interventions	
Outcomes	
Starting date	
Contact information	
Notes	



## DATA AND ANALYSES

### Comparison 1. Long-acting $\beta_2$ -agonists + ICS versus leukotriene receptor antagonists + ICS

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Participants with one or more exacerbations requiring systemic corticosteroids	6	5571	Risk Ratio (M-H, Fixed, 95% CI)	0.83 [0.71, 0.97]
1.1 Montelukast 10 mg once daily versus Salmeterol 50 mcg twice daily	5	5142	Risk Ratio (M-H, Fixed, 95% CI)	0.83 [0.71, 0.97]
1.2 Zafirlukast 20 mg twice daily versus Salmeterol 50 mcg twice daily	1	429	Risk Ratio (M-H, Fixed, 95% CI)	0.86 [0.29, 2.52]
2 Morning PEF: L/min change from baseline	11		Mean Difference (Random, 95% CI)	15.36 [11.35, 19.37]
2.1 Montelukast 10 mg once daily versus Salmeterol 50 mcg twice daily	8		Mean Difference (Random, 95% CI)	15.91 [13.27, 18.55]
2.2 Zafirlukast 20 mg twice daily versus salmeterol 50 mcg or formoterol 9 mg twice daily	2		Mean Difference (Random, 95% CI)	9.66 [-1.40, 20.73]
2.3 Montelukast 10 mg once daily versus formoterol 18mg twice daily	1		Mean Difference (Random, 95% CI)	23.8 [10.89, 36.71]
3 Evening PEF: L/min change from baseline	10		Mean Difference (Random, 95% CI)	12.64 [10.11, 15.17]
3.1 Montelukast 10 mg once daily versus Salmeterol 50 mcg twice daily	7		Mean Difference (Random, 95% CI)	13.29 [10.34, 16.23]
3.2 Zafirlukast 20 mg twice daily versus salmeterol 50 mcg or formoterol 9 mg twice daily	2		Mean Difference (Random, 95% CI)	8.24 [1.99, 14.50]
3.3 Montelukast 10 mg once daily versus formoterol 18mg twice daily	1		Mean Difference (Random, 95% CI)	17.5 [10.16, 24.84]
4 FEV1: L change from baseline	10		Mean Difference (Fixed, 95% CI)	0.08 [0.06, 0.10]
4.1 Montelukast 10 mg once daily vs. Salmeterol 50 mcg twice daily	6		Mean Difference (Fixed, 95% CI)	0.08 [0.06, 0.11]
4.2 Zafirlukast 20mg twice daily vs. Salmeterol 50 mcg or Formoterol 9mcg twice daily	2		Mean Difference (Fixed, 95% CI)	0.05 [-0.02, 0.12]
4.3 Montelukast 10 mg once daily versus formoterol 18mg twice daily	2		Mean Difference (Fixed, 95% CI)	0.0 [-0.09, 0.09]
5 FEV1: L % change from baseline	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected

5.1 Montelukast 10 mg once daily vs. Salmeterol 50 mcg twice daily	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
5.2 Zafirlukast 20mg twice daily vs. Salmeterol 50 mcg or Formoterol 9mcg twice daily	0		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
6 FEV1: % predicted end of treatment	1		Mean Difference (IV, Random, 95% CI)	Totals not selected
6.1 Montelukast 10 mg once daily vs. Salmeterol 50 mcg twice daily	1		Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
6.2 Zafirlukast 20mg twice daily vs. Salmeterol 50 mcg or Formoterol 9mcg twice daily	0		Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
6.3 Montelukast 5 mg once daily versus formoterol 18mg twice daily	0		Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
7 % fall in FEV1 POST-EXERCISE	1		Mean Difference (IV, Random, 95% CI)	Totals not selected
7.1 Montelukast 10 mg once daily versus salmeterol 50 mcg twice daily	1		Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
7.2 Zafirlukast 20mg twice daily versus salmeterol 50 mcg or formoterol 9mcg twice daily	0		Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
7.3 Montelukast 5 mg once daily versus formoterol 18mg twice daily	0		Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
8 Rescue-free days: % change from baseline	5	2612	Mean Difference (IV, Random, 95% CI)	9.18 [5.39, 12.98]
8.1 Montelukast 10 mg once daily vs. Salmeterol 50 mcg twice daily	4	2183	Mean Difference (IV, Random, 95% CI)	7.33 [4.41, 10.26]
8.2 Zafirlukast 20 mg twice daily vs. Salmeterol 50 mcg twice daily	1	429	Mean Difference (IV, Random, 95% CI)	15.0 [9.43, 20.57]
9 Rescue medication use: puffs/day change from baseline	7	4055	Mean Difference (IV, Random, 95% CI)	-0.49 [-0.75, -0.24]
9.1 Montelukast 10 mg once daily vs. Salmeterol 50 mcg twice daily	4	3353	Mean Difference (IV, Random, 95% CI)	-0.37 [-0.56, -0.19]
9.2 Zafirlukast 20 mg twice daily vs. Salmeterol 50 mcg or Formoterol 9 mg twice daily	2	662	Mean Difference (IV, Random, 95% CI)	-0.36 [-0.72, 0.00]
9.3 Montelukast 10 mg once daily versus formoterol 18mg twice daily	1	40	Mean Difference (IV, Random, 95% CI)	-1.4 [-1.81, -0.99]
10 Change in Global asthma QoL AQLQ Score (higher is better) - change from baseline	3	2893	Mean Difference (IV, Fixed, 95% CI)	0.11 [0.05, 0.17]

10.1 Montelukast 10 mg once daily vs. Salmeterol 50 mcg twice daily	2	2464	Mean Difference (IV, Fixed, 95% CI)	0.09 [0.03, 0.16]
10.2 Zafirlukast 20 mg twice daily vs. Salmeterol 50 mcg twice daily	1	429	Mean Difference (IV, Fixed, 95% CI)	0.19 [0.02, 0.36]
11 Symptom free days: % change from baseline	6		Mean Difference (Fixed, 95% CI)	7.27 [4.71, 9.83]
11.1 Montelukast 10 mg once daily versus Salmeterol 50 mcg twice daily	5		Mean Difference (Fixed, 95% CI)	5.87 [2.86, 8.87]
11.2 Zafirlukast 20 mg twice daily versus Salmeterol 50 mcg twice daily	1		Mean Difference (Fixed, 95% CI)	11.0 [6.10, 15.90]
12 Day-time symptom scores (high is worse) - change from baseline	5	3823	Std. Mean Difference (IV, Fixed, 95% CI)	-0.18 [-0.25, -0.12]
12.1 Montelukast 10 mg once daily vs. Salmeterol 50 mcg twice daily	4	3394	Std. Mean Difference (IV, Fixed, 95% CI)	-0.17 [-0.24, -0.10]
12.2 Zafirlukast 20 mg twice daily vs. Salmeterol 50 mcg twice daily	1	429	Std. Mean Difference (IV, Fixed, 95% CI)	-0.29 [-0.48, -0.10]
13 Morning symptoms - change from baseline	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
13.1 Montelukast 10 mg once daily versus formoterol 18mg twice daily	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
14 Night-time symptom score (5pt scale, higher score is worse) - change from baseline	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
14.1 Zafirlukast 20 mg twice daily vs. Salmeterol 50 mcg twice daily	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
15 Change in number of night awakenings per week - change from baseline	4	4214	Mean Difference (IV, Fixed, 95% CI)	-0.12 [-0.19, -0.06]
15.1 Montelukast 10 mg once daily vs. Salmeterol 50 mcg twice daily	3	3785	Mean Difference (IV, Fixed, 95% CI)	-0.16 [-0.26, -0.05]
15.2 Zafirlukast 20 mg twice daily vs. Salmeterol 50 mcg twice daily	1	429	Mean Difference (IV, Fixed, 95% CI)	-0.1 [-0.18, -0.02]
16 Change in % of nights with no awakenings per week - change from baseline	2	673	Mean Difference (IV, Fixed, 95% CI)	6.89 [2.87, 10.91]
16.1 Montelukast 10 mg once daily vs. Salmeterol 50 mcg twice daily	1	244	Mean Difference (IV, Fixed, 95% CI)	6.60 [-1.06, 14.26]

16.2 Zafirlukast 20 mg twice daily vs. Salmeterol 50 mcg twice daily	1	429	Mean Difference (IV, Fixed, 95% CI)	7.0 [2.28, 11.72]
17 Rescue-free nights (%) - change from baseline	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
17.1 Montelukast 10 mg once daily vs. Salmeterol 50 mcg twice daily	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
17.2 Zafirlukast 20 mg twice daily vs. Salmeterol 50 mcg twice daily	0		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
18 Withdrawals for any reason	11	6291	Risk Ratio (M-H, Fixed, 95% CI)	0.84 [0.74, 0.96]
18.1 Montelukast 10mg/day vs Salmeterol 50ug twice daily	9	5626	Risk Ratio (M-H, Fixed, 95% CI)	0.86 [0.76, 0.98]
18.2 Zafirlukast 20 mg twice daily vs Salmeterol 50 mcg twice daily	2	665	Risk Ratio (M-H, Fixed, 95% CI)	0.65 [0.40, 1.06]
18.3 Montelukast 10mg/d versus Formoterol 18mcg/d	0	0	Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
19 Withdrawals due to adverse events	11	6291	Risk Ratio (M-H, Fixed, 95% CI)	1.01 [0.79, 1.29]
19.1 Montelukast 10 mg once daily versus Salmeterol 50 mcg twice daily	9	5626	Risk Ratio (M-H, Fixed, 95% CI)	1.02 [0.78, 1.32]
19.2 Zafirlukast 20 mg twice daily vs. Salmeterol 50 mcg twice daily	2	665	Risk Ratio (M-H, Fixed, 95% CI)	0.92 [0.41, 2.05]
20 Withdrawals due to poor asthma control/asthma exacerbation	8	5354	Risk Ratio (M-H, Random, 95% CI)	0.87 [0.49, 1.56]
20.1 Montelukast 10 mg once daily vs. Salmeterol 50 mcg twice daily	6	4689	Risk Ratio (M-H, Random, 95% CI)	1.02 [0.50, 2.07]
20.2 Zafirlukast 20 mg twice daily vs. Salmeterol 50 mcg twice daily	2	665	Risk Ratio (M-H, Random, 95% CI)	0.50 [0.19, 1.32]
21 Patients with one or more exacerbations requiring hospital admission	4	3993	Risk Ratio (M-H, Fixed, 95% CI)	1.31 [0.58, 2.98]
21.1 Montelukast 10 mg once daily vs. Salmeterol 50 mcg twice daily	4	3993	Risk Ratio (M-H, Fixed, 95% CI)	1.31 [0.58, 2.98]
22 Serious Adverse events	7	5658	Risk Ratio (M-H, Fixed, 95% CI)	1.35 [1.00, 1.82]
22.1 Montelukast 10 mg once daily vs. Salmeterol 50 mcg twice daily	6	5229	Risk Ratio (M-H, Fixed, 95% CI)	1.35 [1.00, 1.83]
22.2 Zafirlukast 20 mg twice daily vs. Salmeterol 50 mcg twice daily	1	429	Risk Ratio (M-H, Fixed, 95% CI)	1.00 [0.06, 15.96]
23 Death	1		Risk Ratio (M-H, Fixed, 95% CI)	Totals not selected

23.1 Montelukast 10 mg once daily vs. Salmeterol 50 mcg twice daily	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
24 Headache	10	6187	Risk Ratio (M-H, Fixed, 95% CI)	1.07 [0.90, 1.26]
24.1 Montelukast 10 mg once daily vs. Salmeterol 50 mcg twice daily	7	5482	Risk Ratio (M-H, Fixed, 95% CI)	1.09 [0.92, 1.29]
24.2 Zafirlukast 20 mg twice daily vs. Salmeterol 50 mcg twice daily	2	665	Risk Ratio (M-H, Fixed, 95% CI)	0.75 [0.36, 1.57]
24.3 Montelukast 10 mg once daily versus formoterol 18mg twice daily	1	40	Risk Ratio (M-H, Fixed, 95% CI)	1.0 [0.07, 14.90]
25 Cardiovascular events	5	5163	Risk Ratio (M-H, Fixed, 95% CI)	1.09 [0.77, 1.53]
25.1 Montelukast 10 mg once daily vs. Salmeterol 50 mcg twice daily	5	5163	Risk Ratio (M-H, Fixed, 95% CI)	1.09 [0.77, 1.53]
26 Oral moniliasis	6	5203	Risk Ratio (M-H, Fixed, 95% CI)	1.86 [1.00, 3.44]
26.1 Montelukast 10 mg once daily vs. Salmeterol 50 mcg twice daily	5	5163	Risk Ratio (M-H, Fixed, 95% CI)	1.92 [1.02, 3.61]
26.2 Montelukast 10 mg once daily versus formoterol 18mg twice daily	1	40	Risk Ratio (M-H, Fixed, 95% CI)	1.0 [0.07, 14.90]
27 Osteopenia/osteoporosis	2	2963	Risk Ratio (M-H, Fixed, 95% CI)	0.56 [0.12, 2.63]
27.1 Montelukast 10 mg once daily vs. Salmeterol 50 mcg twice daily	2	2963	Risk Ratio (M-H, Fixed, 95% CI)	0.56 [0.12, 2.63]
28 Elevated liver enzymes	1		Risk Ratio (M-H, Fixed, 95% CI)	Totals not selected
28.1 Montelukast 10 mg once daily vs. Salmeterol 50 mcg twice daily	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
29 Overall adverse events	9	5977	Risk Ratio (M-H, Fixed, 95% CI)	1.03 [0.99, 1.07]
29.1 Montelukast 10 mg once daily vs. Salmeterol 50 mcg twice daily	8	5548	Risk Ratio (M-H, Fixed, 95% CI)	1.03 [0.99, 1.07]
29.2 Zafirlukast 20 mg twice daily vs. Salmeterol 50 mcg twice daily	1	429	Risk Ratio (M-H, Fixed, 95% CI)	1.03 [0.81, 1.31]
30 Patient treatment satisfaction	3	2020	Risk Ratio (M-H, Random, 95% CI)	1.12 [1.04, 1.20]
30.1 Montelukast 10 mg once daily vs. Salmeterol 50 mcg twice daily	2	1591	Risk Ratio (M-H, Random, 95% CI)	1.09 [1.05, 1.14]
30.2 Zafirlukast 20 mg twice daily vs. Salmeterol 50 mcg twice daily	1	429	Risk Ratio (M-H, Random, 95% CI)	1.27 [1.10, 1.47]
31 Change from baseline in serum eosinophils (x 10e9/L)	2	2787	Mean Difference (IV, Fixed, 95% CI)	0.04 [0.02, 0.05]
31.1 Montelukast 10 mg once daily vs. Salmeterol 50 mcg twice daily	2	2787	Mean Difference (IV, Fixed, 95% CI)	0.04 [0.02, 0.05]

## Comparison 2. Subgroup and sensitivity analyses

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Participants with one or more exacerbations requiring systemic corticosteroids: number of inhaler devices	6		Risk Ratio (IV, Fixed, 95% CI)	Subtotals only
1.1 Single device for LABA + ICS	2	1252	Risk Ratio (IV, Fixed, 95% CI)	0.49 [0.29, 0.83]
1.2 Two devices for LABA + ICS	4	4319	Risk Ratio (IV, Fixed, 95% CI)	0.88 [0.75, 1.04]
2 Participants with one or more exacerbations requiring systemic corticosteroids: dose of ICS	6		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
2.1 Low dose of ICS	3	2742	Risk Ratio (M-H, Fixed, 95% CI)	0.80 [0.64, 1.00]
2.2 Medium dose of ICS	1	1452	Risk Ratio (M-H, Fixed, 95% CI)	0.85 [0.67, 1.08]
2.3 Mixed	1	948	Risk Ratio (M-H, Fixed, 95% CI)	0.99 [0.50, 1.96]
2.4 Unclear	1	429	Risk Ratio (M-H, Fixed, 95% CI)	0.86 [0.29, 2.52]
3 Participants with one or more exacerbations requiring systemic corticosteroids: study duration	6		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
3.1 12 weeks or less	4	2629	Risk Ratio (M-H, Fixed, 95% CI)	0.65 [0.45, 0.96]
3.2 48 weeks	2	2942	Risk Ratio (M-H, Fixed, 95% CI)	0.88 [0.74, 1.04]
4 Serious adverse effects stratified by number of inhaler devices used for LABA + ICS	7		Risk Ratio (IV, Fixed, 95% CI)	Subtotals only
4.1 Single device for LABA + ICS	3	1318	Risk Ratio (IV, Fixed, 95% CI)	0.72 [0.26, 1.99]
4.2 Two devices for LABA + ICS	4	4340	Risk Ratio (IV, Fixed, 95% CI)	1.43 [1.04, 1.97]

## Comparison 3. MD archive from previous review version


Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Morning PEF (L/min) - change from baseline	10		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
2 Evening PEF (L/min) - change from baseline	9		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
3 FEV1 (L) - change from baseline	8		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
4 Symptom free days (%) - change from baseline	5		Mean Difference (IV, Random, 95% CI)	Totals not selected

### Analysis 1.1. Comparison 1 Long-acting $\beta$ 2-agonists + ICS versus leukotriene receptor antagonists + ICS, Outcome 1 Participants with one or more exacerbations requiring systemic corticosteroids.

Review: Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma

Comparison: 1 Long-acting 2-agonists + ICS versus leukotriene receptor antagonists + ICS

Outcome: 1 Participants with one or more exacerbations requiring systemic corticosteroids




## Analysis 1.2. Comparison 1 Long-acting $\beta$ 2-agonists + ICS versus leukotriene receptor antagonists + ICS, Outcome 2 Morning PEF: L/min change from baseline.

Review: Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma

Comparison: 1 Long-acting 2-agonists + ICS versus leukotriene receptor antagonists + ICS

Outcome: 2 Morning PEF: L/min change from baseline






### Analysis 1.3. Comparison 1 Long-acting $\beta$ 2-agonists + ICS versus leukotriene receptor antagonists + ICS, Outcome 3 Evening PEF: L/min change from baseline.

Review: Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma

Comparison: 1 Long-acting 2-agonists + ICS versus leukotriene receptor antagonists + ICS

Outcome: 3 Evening PEF: L/min change from baseline




### Analysis 1.4. Comparison 1 Long-acting $\beta$ 2-agonists + ICS versus leukotriene receptor antagonists + ICS, Outcome 4 FEV1: L change from baseline.

Review: Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma

Comparison: 1 Long-acting 2-agonists + ICS versus leukotriene receptor antagonists + ICS

Outcome: 4 FEV1: L change from baseline




**Analysis 1.5. Comparison 1 Long-acting  $\beta$ 2-agonists + ICS versus leukotriene receptor antagonists + ICS, Outcome 5 FEV1: L % change from baseline.**

Review: Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma

Comparison: 1 Long-acting 2-agonists + ICS versus leukotriene receptor antagonists + ICS

Outcome: 5 FEV1: L % change from baseline




**Analysis 1.6. Comparison 1 Long-acting  $\beta$ 2-agonists + ICS versus leukotriene receptor antagonists + ICS, Outcome 6 FEV1: % predicted end of treatment.**

Review: Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma

Comparison: 1 Long-acting 2-agonists + ICS versus leukotriene receptor antagonists + ICS

Outcome: 6 FEV1: % predicted end of treatment




### Analysis 1.7. Comparison 1 Long-acting $\beta$ 2-agonists + ICS versus leukotriene receptor antagonists + ICS, Outcome 7 % fall in FEV1 POST-EXERCISE.

Review: Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma

Comparison: 1 Long-acting 2-agonists + ICS versus leukotriene receptor antagonists + ICS

Outcome: 7 % fall in FEV1 POST-EXERCISE




### Analysis 1.8. Comparison 1 Long-acting $\beta$ 2-agonists + ICS versus leukotriene receptor antagonists + ICS, Outcome 8 Rescue-free days: % change from baseline.

Review: Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma


Comparison: 1 Long-acting 2-agonists + ICS versus leukotriene receptor antagonists + ICS

Outcome: 8 Rescue-free days: % change from baseline



(Continued ...)

(... Continued)




### Analysis 1.9. Comparison 1 Long-acting β2-agonists + ICS versus leukotriene receptor antagonists + ICS, Outcome 9 Rescue medication use: puffs/day change from baseline.

Review: Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma


Comparison: 1 Long-acting 2-agonists + ICS versus leukotriene receptor antagonists + ICS

Outcome: 9 Rescue medication use: puffs/day change from baseline



(Continued ...)

(... Continued)




**Analysis 1.10. Comparison 1 Long-acting B2-agonists + ICS versus leukotriene receptor antagonists + ICS, Outcome 10 Change in Global asthma QoL AQLQ Score (higher is better) - change from baseline.**

Review: Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma

Comparison: 1 Long-acting 2-agonists + ICS versus leukotriene receptor antagonists + ICS

Outcome: 10 Change in Global asthma QoL AQLQ Score (higher is better) - change from baseline




### Analysis 1.11. Comparison 1 Long-acting $\beta_2$ -agonists + ICS versus leukotriene receptor antagonists + ICS, Outcome 11 Symptom free days: % change from baseline.

Review: Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma

Comparison: 1 Long-acting  $\beta_2$ -agonists + ICS versus leukotriene receptor antagonists + ICS

Outcome: 11 Symptom free days: % change from baseline






**Analysis 1.12. Comparison 1 Long-acting  $\beta$ 2-agonists + ICS versus leukotriene receptor antagonists + ICS, Outcome 12 Day-time symptom scores (high is worse) - change from baseline.**

Review: Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma

Comparison: 1 Long-acting 2-agonists + ICS versus leukotriene receptor antagonists + ICS

Outcome: 12 Day-time symptom scores (high is worse) - change from baseline




**Analysis 1.13. Comparison 1 Long-acting  $\beta_2$ -agonists + ICS versus leukotriene receptor antagonists + ICS, Outcome 13 Morning symptoms - change from baseline.**

Review: Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma

Comparison: 1 Long-acting 2-agonists + ICS versus leukotriene receptor antagonists + ICS

Outcome: 13 Morning symptoms - change from baseline




**Analysis 1.14. Comparison 1 Long-acting  $\beta_2$ -agonists + ICS versus leukotriene receptor antagonists + ICS, Outcome 14 Night-time symptom score (5pt scale, higher score is worse) - change from baseline.**

Review: Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma

Comparison: 1 Long-acting 2-agonists + ICS versus leukotriene receptor antagonists + ICS

Outcome: 14 Night-time symptom score (5pt scale, higher score is worse) - change from baseline




**Analysis 1.15. Comparison 1 Long-acting  $\beta$ 2-agonists + ICS versus leukotriene receptor antagonists + ICS, Outcome 15 Change in number of night awakenings per week - change from baseline.**

Review: Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma

Comparison: 1 Long-acting 2-agonists + ICS versus leukotriene receptor antagonists + ICS

Outcome: 15 Change in number of night awakenings per week - change from baseline




**Analysis 1.16. Comparison 1 Long-acting  $\beta$ 2-agonists + ICS versus leukotriene receptor antagonists + ICS, Outcome 16 Change in % of nights with no awakenings per week - change from baseline.**

Review: Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma

Comparison: 1 Long-acting 2-agonists + ICS versus leukotriene receptor antagonists + ICS

Outcome: 16 Change in % of nights with no awakenings per week - change from baseline




**Analysis I.17. Comparison I Long-acting  $\beta$ 2-agonists + ICS versus leukotriene receptor antagonists + ICS, Outcome 17 Rescue-free nights (%) - change from baseline.**

Review: Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma

Comparison: I Long-acting 2-agonists + ICS versus leukotriene receptor antagonists + ICS

Outcome: 17 Rescue-free nights (%) - change from baseline




**Analysis I.18. Comparison I Long-acting  $\beta$ 2-agonists + ICS versus leukotriene receptor antagonists + ICS, Outcome 18 Withdrawals for any reason.**


Review: Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma

Comparison: I Long-acting 2-agonists + ICS versus leukotriene receptor antagonists + ICS

Outcome: 18 Withdrawals for any reason



(Continued ...)




### Analysis 1.19. Comparison 1 Long-acting $\beta_2$ -agonists + ICS versus leukotriene receptor antagonists + ICS, Outcome 19 Withdrawals due to adverse events.

Review: Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma

Comparison: 1 Long-acting  $\beta_2$ -agonists + ICS versus leukotriene receptor antagonists + ICS

Outcome: 19 Withdrawals due to adverse events




**Analysis 1.20. Comparison 1 Long-acting  $\beta$ 2-agonists + ICS versus leukotriene receptor antagonists + ICS, Outcome 20 Withdrawals due to poor asthma control/asthma exacerbation.**

Review: Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma

Comparison: 1 Long-acting 2-agonists + ICS versus leukotriene receptor antagonists + ICS

Outcome: 20 Withdrawals due to poor asthma control/asthma exacerbation






**Analysis 1.21. Comparison 1 Long-acting  $\beta$ 2-agonists + ICS versus leukotriene receptor antagonists + ICS, Outcome 21 Patients with one or more exacerbations requiring hospital admission.**

Review: Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma

Comparison: 1 Long-acting 2-agonists + ICS versus leukotriene receptor antagonists + ICS

Outcome: 21 Patients with one or more exacerbations requiring hospital admission




## Analysis 1.22. Comparison 1 Long-acting $\beta_2$ -agonists + ICS versus leukotriene receptor antagonists + ICS, Outcome 22 Serious Adverse events.

Review: Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma

Comparison: 1 Long-acting  $\beta_2$ -agonists + ICS versus leukotriene receptor antagonists + ICS

Outcome: 22 Serious Adverse events




### Analysis 1.23. Comparison 1 Long-acting $\beta_2$ -agonists + ICS versus leukotriene receptor antagonists + ICS, Outcome 23 Death.

Review: Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma

Comparison: 1 Long-acting 2-agonists + ICS versus leukotriene receptor antagonists + ICS

Outcome: 23 Death




### Analysis 1.24. Comparison 1 Long-acting $\beta_2$ -agonists + ICS versus leukotriene receptor antagonists + ICS, Outcome 24 Headache.

Review: Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma


Comparison: 1 Long-acting 2-agonists + ICS versus leukotriene receptor antagonists + ICS

Outcome: 24 Headache



(Continued ...)

(... Continued)




**Analysis 1.25. Comparison 1 Long-acting  $\beta_2$ -agonists + ICS versus leukotriene receptor antagonists + ICS, Outcome 25 Cardiovascular events.**

Review: Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma

Comparison: 1 Long-acting  $\beta_2$ -agonists + ICS versus leukotriene receptor antagonists + ICS

Outcome: 25 Cardiovascular events




### Analysis 1.26. Comparison 1 Long-acting $\beta_2$ -agonists + ICS versus leukotriene receptor antagonists + ICS, Outcome 26 Oral moniliasis.

Review: Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma

Comparison: 1 Long-acting  $\beta_2$ -agonists + ICS versus leukotriene receptor antagonists + ICS

Outcome: 26 Oral moniliasis




**Analysis 1.27. Comparison 1 Long-acting  $\beta$ 2-agonists + ICS versus leukotriene receptor antagonists + ICS, Outcome 27 Osteopenia/osteoporosis.**

Review: Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma

Comparison: 1 Long-acting 2-agonists + ICS versus leukotriene receptor antagonists + ICS

Outcome: 27 Osteopenia/osteoporosis




**Analysis 1.28. Comparison 1 Long-acting  $\beta$ 2-agonists + ICS versus leukotriene receptor antagonists + ICS, Outcome 28 Elevated liver enzymes.**

Review: Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma

Comparison: 1 Long-acting 2-agonists + ICS versus leukotriene receptor antagonists + ICS

Outcome: 28 Elevated liver enzymes




### Analysis 1.29. Comparison 1 Long-acting $\beta_2$ -agonists + ICS versus leukotriene receptor antagonists + ICS, Outcome 29 Overall adverse events.

Review: Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma

Comparison: 1 Long-acting  $\beta_2$ -agonists + ICS versus leukotriene receptor antagonists + ICS

Outcome: 29 Overall adverse events






**Analysis 1.30. Comparison 1 Long-acting  $\beta_2$ -agonists + ICS versus leukotriene receptor antagonists + ICS, Outcome 30 Patient treatment satisfaction.**

Review: Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma

Comparison: 1 Long-acting  $\beta_2$ -agonists + ICS versus leukotriene receptor antagonists + ICS

Outcome: 30 Patient treatment satisfaction




**Analysis 1.31. Comparison 1 Long-acting  $\beta_2$ -agonists + ICS versus leukotriene receptor antagonists + ICS, Outcome 31 Change from baseline in serum eosinophils ( $\times 10^9/L$ ).**

Review: Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma

Comparison: 1 Long-acting 2-agonists + ICS versus leukotriene receptor antagonists + ICS

Outcome: 31 Change from baseline in serum eosinophils ( $\times 10^9/L$ )




## Analysis 2.1. Comparison 2 Subgroup and sensitivity analyses, Outcome 1 Participants with one or more exacerbations requiring systemic corticosteroids: number of inhaler devices.

Review: Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma

Comparison: 2 Subgroup and sensitivity analyses

Outcome: 1 Participants with one or more exacerbations requiring systemic corticosteroids: number of inhaler devices




## Analysis 2.2. Comparison 2 Subgroup and sensitivity analyses, Outcome 2 Participants with one or more exacerbations requiring systemic corticosteroids: dose of ICS.

Review: Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma

Comparison: 2 Subgroup and sensitivity analyses

Outcome: 2 Participants with one or more exacerbations requiring systemic corticosteroids: dose of ICS




### Analysis 2.3. Comparison 2 Subgroup and sensitivity analyses, Outcome 3 Participants with one or more exacerbations requiring systemic corticosteroids: study duration.

Review: Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma

Comparison: 2 Subgroup and sensitivity analyses

Outcome: 3 Participants with one or more exacerbations requiring systemic corticosteroids: study duration




## Analysis 2.4. Comparison 2 Subgroup and sensitivity analyses, Outcome 4 Serious adverse effects stratified by number of inhaler devices used for LABA + ICS.

Review: Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma

Comparison: 2 Subgroup and sensitivity analyses

Outcome: 4 Serious adverse effects stratified by number of inhaler devices used for LABA + ICS




### Analysis 3.1. Comparison 3 MD archive from previous review version, Outcome 1 Morning PEF (L/min) - change from baseline.

Review: Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma

Comparison: 3 MD archive from previous review version

Outcome: 1 Morning PEF (L/min) - change from baseline




### Analysis 3.2. Comparison 3 MD archive from previous review version, Outcome 2 Evening PEF (L/min) - change from baseline.

Review: Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma

Comparison: 3 MD archive from previous review version

Outcome: 2 Evening PEF (L/min) - change from baseline






**Analysis 3.3. Comparison 3 MD archive from previous review version, Outcome 3 FEV1 (L) - change from baseline.**

Review: Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma

Comparison: 3 MD archive from previous review version

Outcome: 3 FEV1 (L) - change from baseline




### Analysis 3.4. Comparison 3 MD archive from previous review version, Outcome 4 Symptom free days (%) - change from baseline.

Review: Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma

Comparison: 3 MD archive from previous review version

Outcome: 4 Symptom free days (%) - change from baseline



## ADDITIONAL TABLES

Table 1. Search history

Years	Detail
All years to January 2004	<p>Citations: 184 (181 from the literature search and three unpublished trials provided by pharmaceutical companies for a total of 184 citations)</p> <p>Citations excluded: 172: (1) duplicate citations (N=29), (2) abstracts of considered full-text publications or secondary analyses of the same study (N = 18), (3) not a randomised controlled trial (N = 72), (4) protocol of ongoing trial (N=1), (5) no consistent co-treatment with inhaled glucocorticoids (N = 21), (6) one of the tested interventions was not daily LTRA (N = 18), (7) one of the tested interventions was not daily LABA (N= 5), (8) interventions were administered for less than 4 weeks (N = 6), and (9) use of prohibited co-interventions such as LABA in both groups (N=2).</p> <p>Studies meeting the entry criteria of the review: 12 (six full-text publications (Bjermer 2003; Fish 2001; Ilowite 2004; Nelson 2000; Nelson 2001; Ringdal 2003), two unpublished full-text reports (Hultquist 2000; McCarthy 2003) and four abstracts (Gold (abs) 2001; Green (abs) 2002; Leibman (abs) 2002; Nsouli 2001)). The abstracts did not provide data in sufficient detail to contribute to the meta-analyses</p>
January 2004 to January 2006	<p>Citations: 60.</p> <p>Citations excluded: 55: the study was a duplicate (i.e. identical citation of one trial report, or a subsequent report of a trial) (N = 22); the study was not randomised (N = 2); the study was ongoing (N = 5); the administration of either LTRA or LABA was not standardised across treatment groups (N = 3); there was no consistent co-treatment with inhaled glucocorticoids (N = 8); one</p>

**Table 1. Search history** (Continued)

	of the tested interventions was not daily LTRA as add-on to inhaled glucocorticoids (N = 9); one of the tested interventions was not daily LABA as add-on to inhaled glucocorticoids (N = 2); the tested interventions were administered for less than 4 weeks (N = 1); the study used prohibited co-intervention (i.e., maintenance oral steroids, theophylline, non-steroidal anti-inflammatory drugs, anticholinergics) (N = 3)
--	--

**Table 2. ICS at CFC-BDP equivalent dose ( $\mu\text{g}/\text{day}$ )**

Study	Actual dose of ICS (total per day)	CFC- BDP equivalent / day	Population	Low/medium/high
<a href="#">Bjermer 2003</a>	200mcg fluticasone	400mcg	Adults	Low
<a href="#">Ceylan 2004</a>	400mcg budesonide	400mcg	Adults	Low
<a href="#">Fish 2001</a>	Range of doses between 175 to 1700mcg	560 $\mu\text{g}$ (range 175-1700)	Adults	Mixed
<a href="#">Gold 2001</a>	100mcg fluticasone	200mcg	Adults	Low
<a href="#">Green 2006</a>	200mcg budesonide	200mcg	Adults	Low
<a href="#">Grosclaude 2003</a>	1000mcg CFC BDP and fluticasone 500mcg	1000mcg	Adults	High
<a href="#">Hendeles 2004</a>	250mcg fluticasone	500mcg	Adults	Medium
<a href="#">Howite 2004</a>	250mcg fluticasone	500mcg	Adults	Medium
<a href="#">Lemanske 2010</a>	200mcg fluticasone	400mcg	Children	Low
<a href="#">Nelson 2000</a>	200mcg fluticasone	400mcg	Adults	Low
<a href="#">Nelson 2001</a>	not specified	requested from author 08/03	Adults	Unclear
<a href="#">Nsouli 2001</a>	Unclear	500mcg	Adults	Unclear
<a href="#">Pavord 2007</a>	200mcg fluticasone	400mcg	Adults	Low
<a href="#">Ringdal 2003</a>	200mcg fluticasone	400mcg	Adults	Low
<a href="#">SAM40030</a>	200mcg fluticasone	400mcg	Adults	Low
<a href="#">SD-004-0216</a>	400mcg budesonide	400mcg	Adults	Low
<a href="#">ELEVATE</a>	Unclear	Unclear	Adults	Unclear

**Table 2. ICS at CFC-BDP equivalent dose ( $\mu\text{g}/\text{day}$ )** (Continued)

Storms 2004	200mcg fluticasone	400mcg	Adults	Low
-------------	--------------------	--------	--------	-----

## APPENDICES

### Appendix I. GSK randomisation procedures

The procedures for randomising GSK sponsored studies has been detailed in correspondence between Richard Follows and TL, the details of which are given below:

The randomisation software is a computer-generated, centralised programme (RandAll). After verification that the randomisation sequence is suitable for the study design (crossover, block or stratification), Clinical Supplies then package the treatments according the randomisation list generated. Concealment of allocation is maintained by a third party, since the sites phone in and are allocated treatments on that basis. Alternatively a third party may dispense the drug at the sites. Unblinding of data for interim analyses can only be done through RandAll, and are restricted so that only those reviewing the data are unblinded to treatment group allocation.

## WHAT'S NEW

Last assessed as up-to-date: 16 March 2010.

Date	Event	Description
5 July 2011	Amended	Clarification made to abstract regarding subgroup analysis.

## HISTORY

Protocol first published: Issue 3, 2003

Review first published: Issue 1, 2005

Date	Event	Description
2 February 2011	New citation required and conclusions have changed	Full risk of bias assessment has been incorporated into the review Data on secondary outcomes were provided by the new studies. Serious adverse events are more common with LABA and ICS than LTRA and ICS. This result is not definitive and could be influenced by separate administration of LABA and ICS

(Continued)

17 March 2010	New search has been performed	Literature search re-run. Three new studies were included (Lemanske 2010; Pavord 2007; ELEVATE). One previously included study was excluded (Stelmach 2008); this study had not contributed data to the primary outcome
4 August 2008	Amended	Converted to new review format.
20 June 2006	New citation required and conclusions have changed	Five new studies met the entry criteria of the review (Ceylan 2004; Grosclaude 2003; Hendeles 2004; Stelmach 2008a; Storms 2004). Of these, two studies contributed data to this updated review. The additional data did not alter the conclusions of the review

## CONTRIBUTIONS OF AUTHORS

Francine M Ducharme reviewed the protocol design; supervised the literature search; reviewed all citations; participated in the selection of trials, methodology assessment, and data extraction; corresponded with authors and pharmaceutical companies to identify other relevant trials, verify methodology and data extraction, and request additional information; analysed and interpreted results of the meta-analysis; and edited the final review.

Toby Lasserson (update 2006, 2010) assessed studies for inclusion or exclusion, extracted and entered data, revised results and discussion sections, and solicited additional data from authors.

Christopher Cates edited the review, checked the methodology, and contributed to writing up the final review.

Felix Ram participated in the initial version of the review (2005): protocol design, identified and reviewed the full-text publication of all citations of potential or potentially eligible RCTs, extracted the methodology and data, analysed and interpreted results of the meta-analysis, and wrote the first draft of the review.

## DECLARATIONS OF INTEREST

Francine M Ducharme has received travel support for meeting attendance, research funds, fees for speaking and consulting fees from Merck Frosst Inc (producer of montelukast), GlaxoSmithKline (producer of fluticasone, beclomethasone, salmeterol), Novartis (producer of formoterol) and Nycomed (producer of combination of mometasone and formoterol). No conflict was reported by Toby Lasserson or Christopher Cates.

## SOURCES OF SUPPORT

## Internal sources

- No sources of support supplied

## External sources

- Nederlands Astma Fonds, Netherlands.
- Francine M. Ducharme, Canada.
- NHS Research and Development, UK.

## DIFFERENCES BETWEEN PROTOCOL AND REVIEW

1. In the protocol published in April 2001, we had planned to examine the impact of the inhaled glucocorticoids (subgroups 3) and of baseline severity (subgroups 5) as sensitivity analyses but changed to subgroup analyses because this enhanced the clarity of interpretation. The last two subgroup analyses (6 & 7), not initially considered in 2001, were added to the list subsequently as recent data indicated that the number of inhaler devices to deliver LABA + ICS might be an important effect modifier (Nelson 2003), and a peer reviewer suggested that differences might not be the same over 12 and 48 weeks.

2. Due to recent concerns over the association between LABAs and serious adverse events, we included a subgroup analysis of the data by the number of inhaler devices.

3. Study assessment was amended to reflect changes in the recommended approach to risk of bias evaluation. In the original protocol and first version of the review we assessed studies with the Jadad scale, and by grading concealment of allocation. For the 2010 update we have used a tool for assessing the degree of protection offered by the study design against systematic error. This is outlined in the section: [Assessment of risk of bias in included studies](#).

## INDEX TERMS

### Medical Subject Headings (MeSH)

Adrenal Cortex Hormones [\*therapeutic use]; Adrenergic beta-2 Receptor Agonists [\*therapeutic use]; Anti-Asthmatic Agents [\*therapeutic use]; Asthma [\*drug therapy]; Chronic Disease; Drug Therapy, Combination; Leukotriene Antagonists [\*therapeutic use]; Randomized Controlled Trials as Topic

### MeSH check words

Adolescent; Adult; Child; Humans